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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal motor neuron
disease, characterized by loss of motor neurons in the cortex, brainstem and spinal cord. Clinical
management is plagued by a lack of biomarkers and effective treatment. In spite of numerous
scientific advancements, molecular mechanisms involved in its initiation and progression remain
an enigma. At the mechanistic level, ALS is considered multifactorial. Extracellular signals may
modulate nuclear events with a possible consequence being the reactivation of cell cycle-related
genes and protein alterations in the terminally differentiated motor neurons.
In the first specific aim, we hypothesized that re-entry of post-mitotic motor neurons into
the cell cycle, concurrent with altered activity or distribution of transcription factors will result in
apoptosis of motor neurons during ALS. To address this hypothesis, we utilized archived human
autopsy material from the cortical and spinal cord regions of ALS and age-matched control
cases. We conclude that surviving ALS motor neurons in these regions exhibited increased levels
of G1 to S phase regulators (Cyclin D1, CDK4, hyperphosphorylated -pRb and E2F-1). It also
revealed two intriguing results: (i) E2F-1, a transcription factor, was cytoplasmic and (ii)
increased nuclear p53 was noted in spinal motor neurons but absent in neurons of the motor
vcortex. In addition there was increased protein levels of apoptotic death markers (BAX, FAS,
Caspases) and DNA fragmentation. Therefore we have identified a potential role for cell cycle
proteins in an apoptotic mode of motor neuron death in ALS.
In the second specific aim we hypothesized that a mass spectrometry-based proteomics
approach will identify diagnostic biomarkers and molecular targets for drug discoveries. We
used cerebrospinal fluid (CSF) from ALS and control subjects to identify and validate a
biomarker panel specific to ALS. Furthermore, utilizing peptide map fingerprinting and tandem
mass-spectrometry, we have identified three of the protein peaks to be a carboxyl-terminal
fragment of neurosecretory chaperone protein 7B2 (3.44kDa), Cystatin C (13.3kDa) and
monomer of transthyretin (13.78kDa).
Taken together, this body of work furthers the understanding of both the mechanisms
leading to selective motor neuron loss in ALS and paves the way for diagnostics and
therapeutics.
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11. INTRODUCTION
1.1.  Neurons, Glia and Synapse
The nervous system is one of the most complex and intriguing circuitry that controls and
integrates all body activities. It is primarily organized into the central (brain and spinal cord) and
the peripheral (connecting the central nervous system (CNS) to rest of the body) nervous
systems. Principally the nervous system comprises of two types of cells: Nerve cells or Neurons
and Neuroglial cells or Glia. Dr. Cajal suggested neurons to be the structural and functional units
of the nervous system in the “Neuron Doctrine” [1-3]. Neurons can be classified based on their
functions (motor, sensory), shape (pyramidal, stellate), size (small sized granule cells or large
motor neurons) number of processes found on the cell body (uni-, bi-, or multipolar), or named
after scientists (Purkinje, Betz) (Fig 1).
Neuroglial cells, which literally mean “Nerve Glue”, function as ancillary cells in the
nervous tissue. There are four types of neuroglial cells in the CNS: Astrocytes, Microglia,
Oligodendrocytes, and Ependymocytes. In addition to providing structural support, astrocytes
possess glutamate transporters that aid in uptake of the excitatory neurotransmitter glutamic acid.
Astrocytes and microglial cells have the ability to undergo rapid mitosis leading to tumor
formation, inflammation in response to injury or neurodegenerative diseases [4-7]. “Reactive
astrocytes” stain positive for glial acidic fibrillary protein (GFAP), a cytoskeletal intermediate
filament protein universally considered as a marker of activated astrocytes and phenotypically
appears with a number of processes. Microglia act as delegates of the immune system in the
2brain and are considered macrophages of the nervous system. Upon injury, microglia
dramatically increase in number due to additional infiltration of blood monocytes via blood
vessels, which in turn mature into macrophages. Oligodendrocytes (ODC) form myelin sheath
around axons of CNS neurons analogous to Schwann cells in the peripheral nervous system
(PNS). The ependymal cells form the lining of cerebral cavities or brain ventricles and the
central canal of the spinal cord. Their ciliated form aids in the flow of the cerebrospinal fluid
(CSF) that fills these spaces.
Figure 1 Schematic Representation of a Motor Neuron
Motor neurons are characterized by a large cell body (Soma) with a distinct nucleus and a long
myelinated axon. Dendritic arborization, which receive impulses and spines are evident. The
axon innervates the muscle fibers forming the motor end plate. Modified from
www.macalester.edu/~psych/whathap/UBNRP/dreaming/images/neuron.jpg
Communications between neurons occur through the synapse of one neuron (pre-
synaptic) to another (post-synaptic) with a resultant extracellular space in between the two cells
termed the synaptic cleft. The release of neurotransmitters from the pre-synaptic membrane
depolarizes the post-synaptic membrane (for instance, motor neurons) and results in an influx of
Ca2+ into the post-synaptic neuron [2, 8]. Ongoing research in this area also focuses on the
3involvement of these proteins during synaptic loss during neurodegenerative diseases such as
Alzheimer’s disease [9-11]. In order for optimal neurotransmission without excessive
neurotransmitters present in the synaptic milieu, proper functioning of the support cells or
neuroglia is critical (Fig 2).
Figure 2 Neuronal Synapse
The dendritic spines of the pre-synaptic neuron communicate with the post-synaptic neuron and
transduce nerve impulses (direction of the pink arrow) thus de-polarizing the post-synaptic
membrane. Vesicles containing glutamate (blue circles) are transported with the help of
cytoskeletal proteins such as microtubules and released into the synaptic cleft. This initiates a
signaling cascade with an influx of calcium (brown circles) into the post-synaptic neuron and a
concentration of proteins at the post-synaptic membrane termed the post-synaptic density (PSD).
Glutamate is efficiently recycled via astrocytic and neuronal transporters. Excess glutamate or
inefficient removal of glutamate has been implicated in neurodegenerative diseases such as ALS.
41.2.  The Central Nervous System
The CNS comprised of the cortex, brainstem and spinal cord is a functionally well-
organized conglomeration of cells that continually receives / transmits and perceives information
along the neuronal highway (Fig 3). The motor neurons in the CNS are affected during
amyotrophic lateral sclerosis (ALS).
Figure 3   Central Nervous System (CNS)
The brain, brainstem and the spinal cord form
the CNS. The brain is comprised amongst
other regions the cerebral cortex, thalamus,
and the cerebellum. The brainstem consists of
the midbrain, pons and the medulla, which
continues into the spinal cord.
Modified from Functional Neuroanatomy: An
Interactive Text and Manual, Jeffrey T. Joseph
and David L. Cardozo, Copyright © (2004, John
Wiley and Sons, Inc.). Reprinted with permission of John Wiley & Sons, Inc.
1.2.1.  Brain and Brainstem
The average normal male and female brain weighs approximately 1350g and 1250g,
respectively. In old age and during neurodegenerative diseases such as in Alzheimer’s disease,
there is reduction in brain weight due to atrophy [12]. The brain analyzes sensory input and then
appropriate motor signals are transmitted back to the target muscles via the spinal cord. Three
5layers of connective tissue, termed the dura mater, arachnoid and pia mater cover the brain and
the spinal cord. Cerebrospinal fluid (CSF) secreted by the choroid plexus into the brain ventricles
and the central canal of the spinal cord fills the subarachnoid space in the cranium.
Figure 4 Regions of the Brain and Brainstem
In panel A, the gross anatomy of the cortical region is shown. The central sulcus demarcates the
pre-central gyrus (motor cortex / highlighted strip) and the post-central gyrus (sensory cortex).
Panel B is a sagittal section through the cortex with the boxed region (brainstem) magnified in
C. The rightmost panel depicts the different regions that constitute the brainstem. Modified from
Functional Neuroanatomy: An Interactive Text and Manual, Jeffrey T. Joseph and David L. Cardozo,
Copyright © (2004, John Wiley and Sons, Inc.). Reprinted with permission of John Wiley & Sons, Inc.
The medulla, pons and midbrain together comprise the brain stem of the CNS and are
present deep within the brain continuous with the spinal cord containing motor and sensory
nuclei (group of nerve cell bodies). Some of the functions the brainstem controls include
6breathing, swallowing, heart rate, ability to sleep and probably laughing. Nerve fibers in the
brain stem typically do not regenerate and hence injury may result in permanent loss of function
(Fig 4).
Figure 5 Spinal Cord – Gross anatomy and histology
(A) Gross anatomical representation of spinal cord. The spinal roots and cauda equina (the
collection of the nerve fibers) are evident. (B) Fresh cord at the level of the lumbar region. The
distinct “butterfly” shaped gray matter is seen with an enlarged ventral horn that houses the
motor neurons. (C) Transverse section through a cord stained with luxol fast blue and
haematoxylin / eosin.   Modified from Functional Neuroanatomy: An Interactive Text and Manual,
Jeffrey T. Joseph and David L. Cardozo, Copyright © (2004, John Wiley and Sons, Inc.). Reprinted with
permission of John Wiley & Sons, Inc.
71.2.2.  Spinal cord
The spinal cord is covered by the bony vertebral column and is a cylindrical structure
slightly flattened dorsoventrally (Fig 5A, B). The cord is divided into five different levels
[cervical (8 pairs of nerves), thoracic (12 pairs), lumbar (5 pairs), sacral (5 pairs), coccygeal (1
pair)] depending on the regions of the human body that the spinal “mixed” nerves innervate.
These are "mixed" nerves because each contains both sensory and motor axons. In a transverse
section of the spinal cord, the gray matter is butterfly shaped in the form of the letter “H” with
the white matter at the surface (Fig 5C). The dorsal / posterior horn comprises of the sensory
neuronal cell bodies while the ventral / anterior horn possesses the large cell bodies of the motor
neurons.
1.3.  The Motor System
The muscle fibers and the motor neurons that innervate them, together, are termed the
“motor unit”. The size of these motor units vary depending on the range of functions that a
particular muscle mass performs. Usually the motor neurons are influenced by dorsal root
afferents for spinal reflexes with the intervention of interneurons and by several descending
tracts for the control of motor activity by the brain. The more complex forms of motor
movements are governed in part by the lower motor neurons (LMN) in the spinal cord, and the
upper motor neurons (UMN), which include all the nuclei in the brain stem and motor cortex.
Much of the motor system is organized in a hierarchical fashion with successive levels for motor
control. In the 19th century, it was discovered that the most excitable area for generating
movements is a cortical area anterior to the central gyrus, designated also as the motor cortex or
the precentral gyrus or the gyrus of Rolandi [2, 13]. The motor innervation of the entire human
8body is shown as a distorted human figure frequently referred to as the “Homunculus” with an
orderly progression of focal areas (Fig 6A). The motor cortical regions that have been utilized in
this study (chapters 2 and 3) include the mid- (regions #2 - #5 in Fig 6B) and the superior-motor
cortical regions (regions 6 and 7 in Fig 6B).
Figure 6 Homunculus and the tracts
(A) The upper motor neurons residing in the pre-central gyrus are arranged in a stereotypical
fashion, which is graphically represented in the form of a distorted human figure called the
“Homunculus”. The size of the face and mouth as well as the limbs is depicted large because
many motor nerve fibers innervate these parts of human body.
(B) The axons originating from the motor cortex form a bundle of fibers and traverse through the
cerebral peduncle in the midbrain. The axons that innervate the face are present medially in the
lower medulla and form the corticobulbar tract (CBT) terminating in the brainstem / cranial
9motor nuclei. The axons innervating the lower limbs are laterally present in the peduncles and
form the lateral corticospinal tracts (LCST) aggregating to form the pyramids in the lower
medulla. About 80-90% of these tracts then crossover to the other side of the lower medulla
(pyramidal decussation). The anterior CST does not decussate and continues in an ipsilateral
manner. These axons then synapse on the lower motor neurons situated in the ventral horn of the
spinal cord. During ALS, the CBT and the CST degenerate resulting in loss of connectivity
between the upper motor centers and the brainstem nuclei or the spinal cord (red underlines).
Modified from (A) http://faculty.etsu.edu/currie/images/homunculus1.JPG
and (B) http://diagnosis.hallym.ac.kr/multimedia/img/sin_563p.gif
1.4.  The Tracts
The a- and g-motor neurons in the spinal cord are controlled by the axons originating in
the precentral gyrus, thus forming the corticospinal tract, also known as the pyramidal tract. At
the level of the medulla, 85% of the fibers cross over to the opposite side (pyramidal
decussation) and form the lateral corticospinal tract (LCST) (Fig 6B). The LCST fibers synapse
on the lateral motor nuclei of the ventral horn. Axons, which do not cross (15%) continue as the
anterior or ventral corticospinal tract (A/VCST) and preferentially innervate the axial / trunk
muscle groups. The ACST axons synapse on the medial motor nuclei of the ventral horn. Some
of the pyramidal tract fibers can terminate in the bulbar (medulla) cranial motor nuclei forming
the corticobulbar tract (CBT), which controls facial muscles (Fig 6B). Giant neurons called Betz
cells in cortical layer V give rise to about 3% of the corticospinal tract fibers [13]. The
corticospinal and corticobulbar fibers regarded, as the pathways of voluntary movements are
both affected in some motor neuron diseases such as ALS.
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1.5.  Motor Neuron Diseases
The term “motor neuron diseases (MND)” is used in plural to designate the entire
spectrum of diseases of the anterior horn cells and the motor system. However, the term MND is
used in the United Kingdom synonymously to ALS, with the latter being preferred by the United
States. Clinico-pathologically, the spectrum of MND presents with loss of upper and/or lower
motor neurons (UMN/LMN) resulting in muscle wasting or atrophy (Table 1). Parkinson’s
disease (PD) and Huntington’s disease (HD) fall into the class of neuromuscular diseases and are
not conventionally classified as MND with their involvement of the extra-pyramidal motor
system. In some disorders (such as ALS), the axons from the motor cortex to the brain stem
(corticobulbar tracts) or spinal cord (corticospinal tracts) are involved; in others (such as bulbar
palsies), motor nuclei in the brain stem (bulbar nuclei) are selectively affected [14-16].
Injuries to the UMN in the cortex or their axons before they enter the pyramidal
decussation result in contralateral spastic paralysis. Injuries to the pyramidal tract below the
decussation or to the LMN cause ipsilateral paralysis. The neuromuscular junction or the muscle
fibers can also be affected as in myasthenia gravis, or myopathies [14, 17]. However, it is
intriguing to note that in some MND such as ALS there is selective sparing of motor neuronal
populations. While the somatic motor neurons that control eye movements (extraocular muscles)
remain unaffected, those that control bladder/bowel function (Onufrowitz’s nucleus) show
inclusions but they are affected to lesser degree than other motor neurons during ALS [18-20]. 
Historically, it was Aran in 1850 who introduced the term progressive muscular atrophy
(PMA) to a muscle disorder that was first described by Duchenne in 1849. The term glosso-
labio-laryngeal paralysis was described by Duchenne in 1858 but was later changed to
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progressive bulbar palsy (PBP) by Wachsmuth in 1859. Charcot (1874) who studied the
pathological features observed earlier by Luys and Clarke (1860), and noted the involvement of
the corticospinal tracts, suggested the term ALS. It was Déjerine a French neurologist in 1882
who established the relationship of PBP to ALS [14, 21-23].
In a much more rare form, Betz cells in the motor cortex and corticospinal tracts are
principally affected with rare involvement of the lower motor neurons. Spiller (1904) defined the
lack of muscular atrophy with myelopathic weakness and the spinobulbar spasticity associated
with this disease to be primary lateral sclerosis (PLS). In PLS, there is rarely evidence of the
degeneration of spinal motor neurons or muscle wasting (amyotrophy) that occurs in ALS, which
it resembles. However, PLS is considered to present with predominantly, but not exclusive motor
neuron involvement. The disease, which scientists believe is not hereditary, progresses gradually
over a number of years, or even decades [23-26]. Onset of PLS usually occurs after the age of
50. Symptoms include spasticity with slight weakness in the lower limbs and eventually speech
with emotional problems. Sometimes PLS can be misdiagnosed to be ALS but if there is a
continued lack of LMN involvement, then ALS is ruled out [23-26].
About a century after Charcot proposed the term ALS, Brain (1962) introduced the term
motor neuron disease (MND) in recognition of the relationship between ALS, PBP and PMA,
depending on the topography of motor neuron cell loss. PMA involves only LMNs, progressive
bulbar palsy involves LMNs of the face and throat muscles and Pseudobulbar Palsy affects the
UMNs of the face and throat muscles [16, 27]. The spectrum of motor neuron diseases includes
the inherited spinal muscular atrophies (SMA) that affect infants and adults. These disorders
affect only LMNs and are slowly progressive in adults. Kennedy's Disease or X-linked
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Spinobulbar Muscular Atrophy (SBMA) that affects only males (expanded polyglutamine
repeats in the gene for androgen receptor) is marked by proximal weakness in the limbs, facial
muscles, decreased fertility, and enlarged breasts [28-30]. This disease does not shorten life
expectancy but may result in mild to moderate disability and may mimic ALS [28].
Motor Neuron Diseases Affected CNS Regions Associated Cause
Spinobulbar Muscular
Atrophy (SBMA)
BS and SC (adult onset) CAG repeats in Androgen
Receptor gene
Spinal Muscular Atrophy
(SMA)
SC (No UMN)
(Infant/Juvenile)
Survivor of motor neuron
(SMN) gene
Primary Lateral Sclerosis
(PLS)
UMN and CST (no LMN) I d i o p a t h i c  ( S l o w
progression)
Progressive Bulbar Palsy
(PBP)
Mainly BS Idiopathic
Progressive Muscular
Atrophy (PMA)
LMN (no UMN) Idiopathic
Sporadic Amyotrophic
Lateral Sclerosis (SALS)
MC, BS, SC Idiopathic / Multifactorial
Familial Amyotrophic
Lateral Sclerosis (FALS)
MC, BS, SC SOD1 (21q22.1), ALS2
(2q33), NF-H
ALS of Guam M C ,  B S ,  S C ,
Extrapyramidal system
Aluminum, Cycad Nuts
ALS with Parkinsonism M C ,  B S ,  S C ,
Extrapyramidal system
Tau (17q21)
ALS with Frontotemporal
Dementia (FTD)
M C ,  B S ,  S C ,
Extrapyramidal system
9q21-22
Lathyrism UMN BOAA, Dietary cyanide
(India)
Konzo UMN BOAA, Dietary cyanide
(Central Africa)
Table 1 Spectrum of Motor Neuron Diseases
The wide gamut of MND can vary in the CNS regions affected. The causative agents for some
sporadic MND (ALS of Guam) or familial MND (SMA, SBMA) are known but most others
remain idiopathic. CAG – codon for the amino acid, glutamine; BS – brainstem; SC – spinal
cord; UMN - upper motor neurons; CST - corticospinal tract; LMN - lower motor neurons; MC -
motor cortex;  BOAA - b-N-oxalylamino-L-alanine.
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1.6.  Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is also known as Maladie de Charcot or Lou
Gehrig’s disease. Jean-Martin Charcot was the French neurologist who first coined the term in
circa. 1874. He studied a case of muscle wasting (“amyotrophy”) caused by the hardening of the
lateral columns of the spinal cord due to gliosis of the corticospinal tracts (“lateral sclerosis”).
The disease spread to the bulbar and spinal cord motor neurons [22, 23]. Thus the clinical aspects
of both the gray matter and white matter were defined. Lou Gehrig was the famous New York
Yankee baseball player who had earned the name “iron horse” (for his 2130 consecutive games)
before succumbing to this rapidly progressive motor neuron disease. This latter reason is why the
name Lou Gehrig’s disease is more common to the general population in the United States.
ALS affects the corticomotoneuronal system, selectively the large pyramidal Betz cells in
the motor cortex and motor neurons in brain stem and spinal cord. When voluntary muscles fail
to receive impulses from the motor neurons, they weaken and waste away (atrophy) leading to
spasticity [14, 31, 32]. The process of neuronal loss can induce proximal and distal axonopathy
in related nerve fiber projections leading to a “dying back” degeneration [14, 33]. There are
multiple forms of ALS, which will be discussed later, but the predominant form is sporadic
(SALS). As discussed later, the lack of biomarkers and multifactorial nature of the disease have
deterred early diagnosis and impeded discovery of effective treatments. Patients who suffer from
this debilitating disease rely mainly on palliative care and sound clinical care management.
1.6.1. Epidemiology
ALS affects persons regardless of race, creed or the socioeconomic stature. Geographically,
there is no preference in the disease prevalence with a few regional exceptions. There is a high
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prevalence of ALS and its variants (see section 1.3.5) in certain populations of the western
Pacific islands (Guam and Rota), two areas of the Japanese Kii peninsula, off the western coast
of Indonesia (Irian Jaya), and an isolated tribe in the gulf of Carpentaria (Northern Australia)
[34, 35]. According the National Institute of Health, about 5000 new cases are diagnosed every
year with a prevalence of approximately 1 in 13,600 individuals in the United States. Globally
there is an incidence of 4-6 cases in every 100,000 people [32, 34, 36]. Statistically, the
incidence rate might increase with improved understanding of disease mechanisms and better
diagnostics but the prevalence should decrease which is the target for efficient health care
specialists. Indeed studies have documented an increase in mortality rates, which could be due to
an artifact of increased diagnosis of the disease [32, 36].
Although this disease can inflict anyone at anytime, typical disease onset ranges from 40 to
70 years with an average age of 55 years [31, 37]. With age the prevalence of ALS increases by
an order of magnitude [38]. Also, depending on the age and site of onset, the rate of disease
progression from diagnosis is rapid, ranging from 1-5 years with a median survival of about 3
years [32, 37]. Usually subjects with initial bulbar dysfunction will tend to have a more rapid
disease progression and shorter survival than cases with limb onset. In familial cases, the average
age at disease onset is about 45 years, about 10 years earlier than in sporadic cases and can
sometimes have longer disease duration [39]. It is interesting to note that men are more likely to
be affected by the MND than women (1.5 to 2:1) [31, 34]. However, this imbalance evens out
with increasing age and post-menopause, suggesting the possible role of estrogens in disease
initiation / progression [38, 40]. Indeed in vitro studies using rat spinal motor neurons have
attributed a neuroprotective for estrogens from excitotoxic insults [41]. These population
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parameters are important from the perspective of designing clinical trials and an unbiased
interpretation of primary trial outcomes.
An interesting epidemiological study revealed the prevalence of ALS in young (aged 20-40
yrs) gulf war veterans [42-44]. The relatively young age for SALS with the patients having no
familial history suggest that environmental exposures as a result of war could have triggered the
disease pathogenesis in the genetically susceptible veterans. Warfare could induce undue
increases in levels of chemical nerve agents (G-type compounds such as sarin) or heavy metals
(such as Aluminum, depleted uranium, mercury) [42]. Such studies directly stress the importance
of epidemiology and underscore the strong effects that the environment can have on the disease
progression.
1.6.2.  Clinical Features
Due to the heterogeneity of the disease with respect to the site of onset (motor cortex /
bulbar / spinal cord), direct and indirect symptoms for ALS can vary from one individual to
another. Typically, one would experience asymmetric weakness of hands often manifesting itself
by unusual and repeated dropping of objects, abnormal fatigue in the arms and difficulty
performing motor tasks [31, 32]. The disease usually initiates unilaterally and then proceeds to
become bilateral, making it difficult to perform simple tasks. If the disease affects the
musculature of the lower limbs (25%) for instance, a simple task like walking will become
difficult with a tendency to trip frequently. Bulbar (brainstem) involvement (25%) is
characterized by difficulty in chewing, swallowing (dysphagia), coughing and speech
(dysarthria). A clinical examination would reveal other symptoms such as drooping of the palate,
a depressed gag reflex, pooling of saliva, tongue atrophy and muscle twitches. The patient is
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commonly paralyzed in a few years from diagnosis. Eventually the diaphragm and respiratory
muscles are afflicted which leads to death from an inability to breathe (dysapnea). Most often,
patients in their end-stage have to be on an artificial respirator.
It is however very interesting to note that patients do not lose their ability to sense things.
In addition, the patient’s ocular muscles, bladder function and erectile function remain
unaffected. Unlike in AD, cognition is typically unaffected. About 50% of the patients present
with pseudobulbar characteristics such as pathological laughing or crying.
1.6.3.  Diagnosis
The World Federation of Neurology has established widely accepted criteria for the
diagnosis of ALS [45, 46]. The El Escorial criteria depend on the level of certainty of the
diagnosis that can vary from definite ALS to suspected ALS. There is no simple and rapid
diagnostic test available for ALS. Routine clinical laboratory tests are obtained to exclude
diseases that can mimic ALS. Such tests include a complete blood count and chemical analysis,
thyroid function tests, serum protein electrophoresis, creatine kinase levels, erythrocyte
sedimentation rate, antinuclear antibody, rheumatoid factor and when clinically indicated,
hexosaminidase A and paraneoplastic antibodies [47-49]. Some of these tests however are
performed to eliminate other disorders such as thyroid-related rather than to diagnose ALS. Anti-
GM1 ganglioside antibody testing was considered a possible diagnostic tool, but it was soon
found to yield false positives. Low titers of serum anti-GM1 antibodies are often found in the
normal population and too rarely in significantly elevated amounts in ALS patients, making it
impractical to use it for diagnostics [47, 50-52].
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Electrophysiological tests are also conducted with repetitive stimulation and
electromyography (EMG) to confirm LMN disorders and exclude disorders of the neuromuscular
junction and peripheral nerves [53-56]. Findings of EMG indicative of denervation include
fibrillations, positive sharp waves and complex repetitive discharge. Simultaneously reduced
numbers and increased amplitude of motor unit potentials indicate reinnervations [53].
Neurologists also use muscle biopsies and neuroimaging techniques such as magnetic resonance
imaging (MRI) and computed tomography (CT) scans to establish a profile when diagnosing
ALS [32, 33, 57, 58]. Frequently, MRI scans of the brain or spine help to rule out tumors or
degenerative spine disease [33, 59]. Muscle biopsies, though usually not required, typically show
grouped atrophy consisting of shrunken and angulated muscle fibers amidst groups of uniform
fiber types [60, 61]. Such detailed clinical analyses help in eliminating the possibilities of other
neurological disorders.
There is a chance for misdiagnosis in about 15% of cases and post-mortem neuropathologic
examination can confirm the clinical diagnosis of ALS [62-64]. Misdiagnosis include a wide
array of diagnoses such as cervical spondylosis, monomelic amyotrophy of upper extremities,
inflammatory neuropathy, myopathy, multiple sclerosis, parkinsonism, arsenical myopathy and
lumbar spinal stenosis [47, 63, 65]. Other MND including Kennedy’s disease or SBMA, PLS,
PMA, PBP and multifocal motor neuropathy with conduction block (an autoimmune disorder
that is responsive to immunosuppressive therapy) can be misdiagnosed as ALS. ALS diagnosis
requires the presence of UMN degeneration by clinical examination, LMN degeneration by
clinical, electrophysiological and neuropathological examinations and progressive spread of
symptoms along with the absence of electrophysiological and neuroimaging evidence of other
diseases or syndromes [31, 46].
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1.6.4.  Neuropathology
At the gross level, unlike an AD brain, which atrophies, the brain in an ALS patient
typically appears normal in spite of some amount of atrophy in the pre-central gyrus as evident in
post-mortem analysis. There is however no apparent reduction in size and weight. However, it is
common to observe marked atrophy all along the spinal cord and in the anterior roots (Fig 7A).
There is also corticospinal tract pallor in myelin stains indicative of axonal loss [32, 66-68] (Fig
7B). Microscopically, ALS manifests itself by a reduction in the number and size of the upper
and lower motor neurons including the motor nuclei in the brain stem. The disease is classically
associated with astrocytosis and microgliosis (increased proliferation and activation of astrocytes
and microglia, respectively) [69-71].
Figure 7 Spinal Degeneration in ALS
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The pathological hallmark of an individual with ALS is atrophy along the spinal cord the axons
due to loss of the LMN. Panel A shows distinct atrophy of the ventral roots that traverse from the
LMN. Compare it to the healthy looking dorsal roots that arise from the sensory neurons, which
remain unaffected during the disease process. Panel B is transverse section stained with Kluver-
Berarra stain clearly indicating the pallor in the lateral corticospinal tract and the ventral horn
again due to the selective degeneration of the motor neurons and the fibers that lead into and out
of them.
(B) Modified from Brain Pathol. 13(1):10
Figure 8 Ubiquitin Positive Inclusion Bodies in Lower Motor Neurons
Paraffin embedded section from human ALS spinal cord was immunostained for ubiquitin by 3-
amino-9-ethylcarbazole (AEC) followed by counterstaining with hematoxylin. The motor neuron
on the left with a process and another with somatodendritic attrition (on the right) reveal dark
brown ubiquitin positive intranuclear aggregates (arrows). The arrowheads indicate the nuclei.
A number of cytoplasmic inclusions or protein aggregates are often found in affected
neurons during ALS. Bunina bodies are small, round eosinophilic neuronal cytoplasmic
inclusions and hyaline inclusions have been described in both upper and lower motor neurons.
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These inclusions sometimes stain positive for ubiquitin and/or cystatin C, a small cysteine
proteinase inhibitor [67, 68, 72-74] (Fig 8).
In addition, neurofilamentous swellings (spheroids) have been identified in ALS motor
neuron bodies and proximal axons [75, 76]. This suggests an involvement of neurofilament, an
intermediate cytoskeletal protein, in ALS pathogenesis. Lewy bodies are eosinophilic and found
in the cytoplasm of cortical and brain stem neurons in Parkinson’s disease (PD), some forms of
dementia and occasionally ALS [77-79]. In PD, they are abundantly immunoreactive to 3
proteins: a-synuclein, neurofilament and ubiquitin. However, the MND inclusions in ALS
associated with parkinsonism are negative for a-synuclein and tau [80-82]. Ubiquitin positive
intraneuronal MND inclusions are observed in both the cytoplasm and nucleus of affected
neurons and may be correlated to cognitive abnormalities in ALS patients referred to as ALS-
Dementia or ALS-D [80, 82]. The neuronal Lewy body-like hyaline inclusion (LBHI) is a
characteristic neuropathological marker of mutant SOD1-linked FALS with posterior column
involvement (FALS-PCI) [83]. These SOD1 positive inclusions similar to the neuronal LBHIs
have been discovered in astrocytes in certain patients with FALS exhibiting SOD1 gene
mutations [83]. Thus the presence of protein aggregates during ALS in regions not pertaining to
the motor system suggests variants of the disease to be more widespread and may be defined as
being a multi-system disease.
1.6.5.  “ALS –Plus”: A Multisystem Disorder?
According to El Escorial criteria, any rare combination of ALS with extra-motor
neurological disorders such as dementia or “parkinsonism” is termed as “ALS-plus” [84].
Parkinsonism is a term used to describe symptoms as seen in PD, such as rigidity, loss of
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balance, certain tremors or bent postures. In general ALS affects the populous independent of
race or geographical location barring one exception. It occurs with higher than expected
frequency among the indigenous population (Chamorros) on the Marianas Islands of Guam,
where this disorder is very commonly associated with parkinsonism and dementia [35, 82, 85,
86]. This discovery led to the coining of the ALS variant ALS-Parkinsonism Dementia Complex
(ALS-PDC). The incidence and prevalence of the Guam ALS-PDC has been estimated to be an
order of magnitude higher than the worldwide average for ALS. It was recognized subsequently
in two villages in the Kii Peninsula of Japan and among the Auyu and Jakai people of Irian Jaya
(Western New Guinea), resulting in a total of three Western Pacific variants of ALS [35, 87].
Neuropathological analysis of ALS-PDC revealed fronto-temporal atrophy of the cortex
associated with neuronal loss. Hyperphosporylated tau protein, a microtubule-associated
cytoskeletal protein, forms neurofibrillary tangles (NFTs). These are aberrations commonly
associated with AD. However, these are also observed in ALS-PDC of both Guam and Kii
peninsula [87, 88]. The phosphorylated epitopes are identical to those evident in AD [87].
However this variant of ALS differs from AD in that it lacks senile plaques, the NFTs are present
in layers II and III as opposed to V and VI in AD, and these cytoskeletal abnormalities are
observed in basal ganglia and brain stem in addition to neocortex and hippocampus [87]. These
studies indeed suggest that the neurodegenerative process in ALS may provide us with more
variants involving extra-motor neuronal system or the extra-pyramidal system, including the
fronto-temporal region of the cortex, basal ganglia and the limbic system. The FTD-ALS patients
whose behavioral deficits (similar to AD or Pick’s disease) precede the MND symptoms exhibit
behavioral and cognitive deficits such as emotional disinhibition, impairment of cognition and
judgement, memory loss, reduced capacity for social conduct and behavior, personality change
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amongst others [89]. Microscopically, ALS-FTD is defined by the presence of intraneuronal
ubiquitin positive inclusion bodies in the fronto-temporal lobes. Thus ALS is growing from one
that was restricted to the motor nuclei to a spectrum of ALS with variants that involve extra-
motor systems.
1.6.6.  Genetics of ALS
The etiology of about 5-10% of the ALS patients is considered to be genetic and these
comprise both recessive and dominant inheritance patterns. Mutations in genes encoding for
cytoplasmic Cu/Zn superoxide dismutase (SOD1), Alsin (ALS2), the 150kD subunit of dynactin
(DCTN1) and Senataxin gene (ALS4) have been identified and have a direct effect on motor
neuron degeneration [90-95].
Genetic studies in families with ALS revealed autosomal dominant mutations in the gene
encoding SOD1 located on chromosome 21q22.1 [90]. Approximately 20% of familial disease
(FALS) has been linked to 113 (100 substitutions, 4 deletions, 3 insertions, 5 polymorphisms and
1 compound) different mutations in the gene encoding SOD1. This major breakthrough in 1993
has enabled researchers to develop in vitro and transgenic experimental models to further dissect
the molecular pathogenesis of ALS. This ubiquitously expressed 153-amino acid protein acts as a
homodimer in scavenging and converting superoxide radicals into hydrogen peroxide, which is
then converted to water by the action of catalase or glutathione peroxidase (Fig 9 A & B).
It remains unclear as to how and why this mutant protein causes selective motor neuron
degeneration in spite of its ubiquitous expression. A number of these mutations result in loss of
the dismutase activity to a variable degree [96-99]. Some mutations such as the G93A and D90A
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result in ALS without any or negligible loss in enzymatic activity [97, 100, 101]. Furthermore, it
was demonstrated that SOD1-/- mice were normal with no motor deficits and mice over-
expressing mutant SOD1 protein developed MND with overt ALS-like symptoms, despite
normal or elevated levels of the dismutase activity [102, 103]. These findings reveal that the
SOD1 mutations do not result in a loss of function or enzymatic activity but due to “gain of a
novel toxic function”. Studies with these mice have greatly helped in making inroads into the
understanding of disease mechanisms and development of therapeutic strategies.
Figure 9 Normal Function for Cu/Zn cytoplasmic SOD  – A schema
The copper chaperone for SOD1 (CCS) is a protein necessary to load copper ions (A; black
circles) into the catalytic site for normal dismutase function of SOD1 (B). Zinc ions are
represented by black triangles.
Genetic studies have revealed a variation in disease progression, dependent on the
mutation causing the disease. Patients with the most common form of the mutation, A4V have
rapid progression with reduced survival (1.5 years) [104]. There are other mutations (E21G,
G37R, H46R, D90A, G93C, I104F, I151T) that are slower in their progression with patients
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exhibiting longer survival times (10 years or longer). The G37R and L38V mutations predicted
an earlier age at onset. Such variations in part might be due to differential effects of these
mutations on the newly acquired cytotoxic function of SOD1.
In addition to SOD1, other genes have been implicated in adult and juvenile FALS
variants. Even though the majority of the inheritance is autosomal dominant, recessive and X-
linked variants have been reported [32]. Two loci for a juvenile form of autosomal recessive
cases (Juvenile onset AR-FALS) have been identified, on chromosome 2q33-q35 and on
chromosome 15q15-21 [105, 106]. The disease-causing gene on chromosome 2q33-q35 has been
identified to be ALSIN / ALS2 [91, 107]. These FALS cases have been predominantly reported
in populations of North Africa and the Middle East. Disease onset in these cases is prior to 25
years of age and they also have a slower disease progression. ALSIN has a full-length 184 kD
protein comprising 1657 amino acids as well as a smaller alternatively spliced variant with 396
amino acids (44 kD). Tunisian families with a severe disease phenotype have exhibited single-
base pair (bp) deletions in exon 3 and patients with a milder form of ALS have deletions in exons
5 and 9. ALSIN contains multiple motifs with homology in the N-terminus to the regulator of
chromosome condensation (RCC1), guanine exchange factor (GEF) domains (activating
GTPases), pleckstrin domain (potential membrane attachment), two membrane occupation and
recognition motifs (MORN). RCC1 acts on RAN, a protein involved in nuclear export and
import. The C-terminus of ALSIN includes a vacuolar protein sorting-9 (VSP9) domain. Thus
ALSIN might have a role in a variety of critical cellular functions such as signaling, membrane
transport, modulating cytoskeletal assembly, and nuclear transport [91, 107, 108]. All of these
important cellular functions are dysregulated during ALS. However, recent experiments with
ALSIN transgenics have failed to mimic ALS. In spite of this being a setback, it probably points
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to other modifying factors that might act in concert with ALSIN in causing the juvenile form of
AR-FALS. Another gene associated with a rare form of juvenile-onset form of ALS has recently
been identified to be senataxin [94, 109, 110]. Mutations in this gene lead to slower progression
and longer life span than normal ALS. This study involved four unrelated families with members
affected with the slowly progressing MND with minimal or no sensory nerve damage.
Abnormalities in this protein are hypothesized to cause RNA processing defects, a defect that
causes other MND such as SMA.
Other genetic alterations have been identified in FALS cases. Although a dominant form
of ALS has been linked to chromosome Xp11-q12, the disease-causing gene is yet to be
reported. Amyotrophy has been observed in cases with autosomal dominant mutations in the tau
gene on chromosome 17q21-22 that are associated with frontotemporal dementia (FTD) and
parkinsonism. These reports have been supported by the identification of ALS cases with
involvement of the extra-pyramidal pathway and also by the observations that transgenics with
mutated tau gene develop motor axonopathy and amyotrophy [111]. Additionally, a novel locus
for autosomal dominant ALS has been identified at 18q21 [112].
In addition to these rare forms of FALS, a genetic basis for the occurrence of SALS has
been implicated. In 5 unrelated SALS patients, rare heterozygous mutations (1%) in the heavy
subunit of neurofilaments (NF-H) have been identified [113, 114]. The KSP repeat domains in
the C-terminal region of the protein, where these mutations are localized, are important for NF
assembly, crosslinking and phosphorylation. Recently other genes have been identified as
modifiers such as the one encoding vascular endothelial growth factor (VEGF) implicating it as a
risk factor for the disease. Animal studies involving G93A SOD1 transgenics have indicated
levels of VEGF to directly correlate to the disease state [115]. In recent studies involving the
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delivery of VEGF using a lentiviral system, disease onset was delayed with increased survival
[116, 117]. There are other genes considered to be risk factors for SALS including those
encoding apolipoprotein allele e4 (apoe4), survivor of motor neuron (SMN), neuronal apoptosis
inhibitory protein (NAIP) and leukocyte inhibitory factor (LIF) [34]. However, given the genetic
heterogeneity of ALS, it is important to identify other candidate / modifier genes that might act
with the environment or lifestyle of individuals.
Mechanistically, it remains unknown as to if motor neurons are affected by all these
mutations through a common trigger. It is possible that protein aggregation (impairing protein or
organelle transport), mitochondrial dysfunction (altering cellular energetics) and alteration at the
nucleus may act as common trigger points for selective motor neuron death during ALS.
1.6.7. Pathogenic Mechanisms of SALS
ALS is a progressive neurodegenerative disorder involving both the UMN and LMN.
Since 90-95% of ALS cases are sporadic, it is essential to understand factors implicated in its
pathogenesis. Potential molecular mechanisms include oxidative stress, excitotoxicity,
mitochondrial dysfunction, abnormalities in the cytoskeleton and proteasomal machinery,
autoimmunity, and DNA damage [118] (Fig 10). One common mechanism leading to neuronal
death in ALS is through apoptosis mediated by altered gene expression of both pro- / anti-
apoptotic genes and cell cycle genes [119-122].
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Figure 10 ALS Pathogenesis: Do all roads lead to motor neuron death ?
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The pre-synaptic neuron membrane (PSN1) that transmits an impulse and the de-polarized post-
synaptic membrane (PSN2) are schematically represented by the lipid bilayer (brown circles
with hydrophobic tails). The membrane potential of the PSN2 is maintained by K+ (red circles)
and Na+ (blue circles) channels. Glutamate (pink ovals) is released from the PSN1 vesicles serve
as ligands for the NMDA/AMPA glutamate receptors. In ALS, mutations in SOD1 or other
sporadic agents can cause alterations in the astrocytic (Ast.) glutamate transporters (EAAT2)
resulting in inefficient re-uptake of glutamate. The excess glutamate in the cleft (excitotoxicity)
due to decreased re-uptake and decreased amounts of Ca2+ binding proteins in the MN results in
an increased influx of Ca2+ (green circles) through the voltage-gated Ca2+ channels (VGCC).
This increase in intracellular Ca2+ can activate proteases with a concomitant generation of
reactive oxygen species (ROS). Mutant SOD1 (mtSOD1) can also result in ROS and oxidative
stress. Both excitotoxicity induced oxidative injury and direct oxidative stress can result in DNA
damage. ROS via mtSOD1 causes mitochondrial vacuolation and dysfunction (MD), which in
turn can account for increased ROS. MD results in cytochrome c release (orange triangles) and
a caspase-dependent apoptosis of MN. In addition to mitochondrial vacuolation, mtSOD1 also
results in the fragmentation of the golgi cisternae (pink stacks / GF)). GF, endoplasmic reticular
stress / reduced chaperone proteins (not shown), inhibition of the proteosomal machinery
(cylinder / PI) and mutations / hyperphosphorylation of neurofilaments can all lead to improper
protein folding and aggregate formation (Agg.). protein aggregates can block axonal transport
with consequent damaging effects on the MN. MN can also be affected by decreased trophic
factor support from the target muscle fibers. In addition, bystander effects via the release of
cytokines and chemokines by activated microglia (Mgl.) can directly or indirectly through death
receptor-mediated death cascades effect MND.
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1.6.7.1.  Oxidative Stress and SOD1-mediated toxicity
Several findings point to oxidative stress as one mediator of motor neuron injury. Due to
a motor neuron’s high-energy demands, these large cells with long axonal processes may be
subjected to a higher degree of metabolic stress. Cu++/Zn++ superoxide dismutase 1 is an
abundant and ubiquitously expressed protein that normally scavenges free radicals thus reducing
oxidative damage. As discussed above, mutations in SOD1 induce an adverse gain of cytotoxic
function by the mutant protein. Over-expression (up to 6-fold) of wild type human SOD1 in
G85R mice failed to affect disease onset, progression or pathology [123]. This and other studies
(enumerated in section 1.3.6) led to the “gain of toxic function” hypothesis that these dominant
mutations confer wherein disease is caused due to one or more aberrant properties of the mutant
subunits[124]. The hypothesized mechanisms for SOD1-mediated toxicity include: i)
conformational changes and zinc-deficient SOD1 that could enable peroxide or peroxynitrite to
act as aberrant substrates resulting in increased free radicals, ii) Ineffective buffering of Cu++
resulting in increased copper-mediated toxicity, iii) aberrant SOD1 protein aggregation [37, 125].
Common to all SOD1 transgenic models of ALS, the downstream effects include the execution
of caspase-mediated apoptotic cell death [125-128].
Mutant SOD1 accumulate in conditions of low Zn++ levels and have a lower affinity for
Zn++ mainly due to the weakening of the backbone of SOD1 resulting in increased levels of
superoxide [129, 130](Fig 11A). There are mutations such as L67R found in the Zn-binding loop
of SOD1 [131]. Such substitutions of large amino acid with a positively charged amino acid can
alter the conformation of the protein and open it for aberrant reactions with toxic substrates.
Another line of investigation has pertained to metallothioneins (MT), the expression of which is
elevated in the spinal cord of ALS patients and transgenic mice [132, 133]. While the expression
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patterns of two of the isoforms (MT-I and MT-II) are glial, MT-III is expressed neuronally. The
SOD1 G93A mice that are deficient in all three isoforms develop disease consistent with zinc
depletion as a factor in SOD1-mediated toxicity [133, 134]. Production of superoxide that can
react quickly with nitric oxide (NO) can result in peroxynitrite (ONOO-), which can then impair
tyrosine receptors of growth factors by nitrosylating them or inhibit parts of the mitochondrial
transport chain (Fig 11B). It has been reported that peroxynitrite treatment of astrocytes caused
changes to their phenotype and activated them analogous to astrogliosis that is prevalent in ALS
patients [135, 136]. When embryonic motor neurons were grown on top of these activated
astrocytes, it resulted in apoptosis of the neurons, which was subsequently blocked by using
inhibitors to inducible form of nitric oxide synthase (iNOS) or by using peroxynitrite scavengers
[136]. In addition, in transgenics and human ALS spinal cord, there is an increase in free
nitrotyrosine but no increase in protein-bound nitrotyrosine [137, 138]. However, there are
conflicting reports to question the credence of a central role for peroxynitrite-mediated SOD1
toxicity. Levels of free nitro-tyrosine have not been found in ALS patients and in another study
when wild type human SOD1 was over-expressed in G85R mice, it did not alleviate toxicity but
actually exacerbated the disease state. Another aberrant substrate used by superoxides is
hydrogen peroxide resulting in a very toxic hydroxyl radical (Fig 11C). Protein carbonyl
formation and lipid peroxidation are significantly increased in the spinal cord in patients with
SALS and SOD1 transgenics, respectively [139]. In addition oxidative damage to DNA have
been demonstrated by immunocytochemical and biochemical assays [140]. These results
strongly suggest that SOD1-mediated toxicity does not strongly depend on superoxides reacting
with substrates such as peroxynitrite or hydrogen peroxide.
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Figure 11 Hypothesized Mechanisms for the “Gain of Toxic Function” in Mt SOD1
(A) Zn-deficient (lack of black triangles) SOD1 rapidly results in reduced form of the protein
that can subsequently react with oxygen to increase levels of superoxide. Also, NF can act as
sink for binding Zn leading to increased Zn-deficient SOD1.
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(B) “Peroxynitrite hypothesis” relates to the generation of peroxynitrite (ONOO-), a highly
reactive free radical formed through the reaction of superoxide with the highly diffusible small
molecule, NO. ONOO- can then act as an aberrant substrate for mtSOD1 resulting in nitration
of proteins such as tyrosine receptors.
(C) “Peroxidase hypothesis” suggests that hydrogen peroxide could act as an aberrant
substrate for the mutant form of the protein generating very toxic and highly reactive hydroxyl
radicals. These free radicals can cause oxidative damage to DNA, lipids and proteins.
(D) Copper chaperone for SOD1 is required for proper loading of copper onto the catalytic
site of the protein.
(E) Crossbreeding studies using CCS knock-out (inefficient copper loading) and 3 mutant
SOD1 transgenics failed to alleviate the motor neuron pathology.
(F) Mutant SOD1 might not bind copper and zinc tightly thus leading to free metal toxicity.
Free copper might catalyze harmful reactions resulting in cellular damage.
(G) Mutant SOD1 may elevate the propensity to protein misfolding and hence aggregate
formation. Aggregates could either play a role in enhancing the disease pathology or
alternatively be protective.
Copper chaperone for SOD1 (CCS) is a carrier protein that aids in incorporating copper
into the catalytic site of SOD1 (Fig 11D). The copper ion but not zinc is important for the
electron transfers that direct SOD1-mediated oxidative reactions. The production of both the
toxic hydroxyl free radical and peroxynitrite depends on the proper binding of copper to SOD1.
Amongst the four histidine residues involved in Cu-binding, two of them are mutated in ALS
(H46R, H48R/H48Q). The levels of copper incorporation and SOD1 activity in CCS-/- mice are
greatly reduced but the mice are viable [141] (Fig 11E). The CCS-/- / SOD1 mutant mice (G93A,
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G37R and G85R) did not exhibit any change in protein levels of SOD1 and motor neurons were
affected much like in SOD1 mutant mice [141]. Strikingly, the CCS-/- / SOD1 mutant mice
exhibited no change in disease onset and progression. They also exhibited neuropathology
similar to those observed in the SOD1 mutant mice. Thus this study negates a role for copper in
SOD1-mediated toxicity.
However, the research group did not consider key issues. Low levels of free residual
copper or its incomplete incorporation into SOD1 may not be sufficient for its complete
enzymatic activity but may be enough to cause pathogenic oxidative mechanisms resulting in
free copper mediated-toxicity (Fig 11F). This might explain the lack of amelioration of the
disease phenotype in their study. In fact copper chelators that bind free copper alleviates the
disease process in in vitro studies increasing motor neuron survival and enhancing neurite
outgrowth [142]. In conclusion, although there is evidence against copper mediated toxicity, it
cannot be excluded.
Furthermore, structural changes in SOD1 due to mutations can result in aberrant
aggregates (Fig 11G). Aggregation is common to neurodegenerative diseases such as AD, PD,
and a spectrum of poylglutamine diseases [143, 144]. In fact, SOD1 transgenics do exhibit
aggregates that stain positive for SOD1, ubiquitin and neurofilaments. However, the mechanism
by which aggregation can damage motor neurons is unknown. The recruitment of other proteins
by the aggregates could lead to a loss of function such as those of transcription factors and
chaperone proteins. It is documented that the proteasomal machinery and axonal transport
systems are dysfunctional during ALS and this might also be the case in the SOD1 transgenics
leading to aggregation [145, 146].
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1.6.7.2.  Excitotoxicity
Glutamate-mediated excitotoxicity represents another potential mechanism of
neurodegeneration in ALS. Glutamate is derived from the reductive deamination of a-
ketoglutarate by glutamate dehydrogenase (GDH) or through the action of aminotransferases on
amino acids [147]. In a normal state, glutamate is released from the pre-synaptic terminals upon
depolarization, crosses the cleft and activates the post-synaptic neuron via the glutamate
receptors. These receptors can either be ionotropic (N-methyl-D-aspartate (NMDA), a-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and Kainate) or metabotropic (mGluR1-
8). Amongst the major glutamatergic pathways are the corticobulbar and corticospinal tracts
innervating the motor neurons. The primary mechanism for the inactivation of glutamate is
simply its removal from extracellular space via a Na+ / K+-dependent transport system in
astrocytes (EAAT1/GLAST and EAAT2/GLT-1) and neurons (EAAT3/EAAC1, EAAT4 and
EAAT5).
Over-activation of synaptic glutamate receptors can lead to increased intracellular
calcium (Ca++i) resulting in oxidative stress-mediated synapse degeneration and cell death
[148]. In addition to primary excitotoxicity such as in acute neurodegenerative diseases,
secondary forms of glutamate toxicity can result in chronic forms of neuronal death. This occurs
for instance through a drop in the energy levels of neurons resulting in a loss of membrane
potential and activation of NMDA receptors.
Several lines of data support the excitotoxicity hypothesis in ALS. There is an increased
concentration of glutamate and aspartate in CSF of ALS patients [149]. In organotypic spinal
slices, neuronal toxicity by chronic levels of glutamate was selectively prevented by non-NMDA
glutamate receptor antagonists and glutamate synthesis or release inhibitors, but not by NMDA
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receptor antagonists [150]. The GluR2 subunits of pentameric AMPA receptors are normally
calcium impermeable. In ALS motor neurons, the mRNA and protein levels of these subunits
have been shown to be reduced resulting in increased calcium permeability [151, 152]. Increased
levels of intracellular calcium are exacerbated by the relative lack of calcium buffering proteins
such as calbindin, calretinin and parvalbumin leading to elevated levels of intracellular calcium
[153, 154]. Additionally, RT-PCR studies of the disease-specific tissues, revealed two aberrant
mRNA species of EAAT2, one that retains the 7th intron resulting in a truncated protein and
another with exon-9 skipping [155]. This led to the speculation that aberrant mRNAs were the
cause of the earlier reports of decreased expression of EAAT2 in ALS [156, 157]. Furthermore,
EAAT2 knockout and knockdown mice have motor neuron degeneration. EAAT2 expression is
also decreased in SOD-1 mice suggesting a link between oxidative damage to EAAT-2 and
subsequent glutamate accumulation thus increasing susceptibility to excitotoxicity. The idea of
aberrant splicing mechanisms of EAAT2 however has since been challenged because it has not
been reproduced efficiently and also found to be a mechanism not exclusive to ALS [158-160].
In addition to these, environmental toxins such as b-N-oxalyl-amino-L-alanine (BOAA)
(in chickling peas) and b-N-methylamino-L-alanine (BMAA) (in the seed of false sago palm)
can cause only motor or sensorimotor pathology such as lathyrism and ALS-PDC (see section
1.3.5). Further the finding that Riluzole, a FDA approved drug that is the only current therapy
diminishes pre-synaptic glutamate release provides added support to this theory. There seems to
be a strong interplay between excitotoxicity, oxidative stress mechanisms and lack of
mitochondrial efficacy all of which can result in increased levels of intracellular calcium. This is
not only seen in ALS but also in many other neurodegenerative diseases.
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1.6.7.3.  Mitochondrial dysfunction
In an elegant study using low copy G93A mutant mice, behavioral and muscle strength
assays delineated four stages during disease progression – pre-muscle weakness (PMW), rapid
decline of muscle strength (RD), slow decline (SD) and paralysis (Para) or end-stage [161]. The
rapid decline stage was considered as the time of disease onset, which correlated to pathological
changes without any death of motor neurons. The chief pathological change at the RD stage was
mitochondrial vacuolation with a concomitant loss in muscle strength [161]. Another study also
reported mitochondria to form vacuoles in a transgenic mouse model [162]. Electron
microscopic studies have further demonstrated a process of inter-membrane space expansion
(MVISE) resulting in these vacuoles and that these vacuoles contain peroxisomes in addition to
SOD1 aggregates but not lysosomal proteins discounting a mechanism of autophagy [163].
Another group has recently corroborated prior ideas that mutant SOD1 is recruited
specifically to the spinal cord mitochondria through the action of spinal cord specific factors
[164]. Dysfunctional mitochondria can lead to improper release of pro-death molecules causing
apoptotic death. It is interesting to note that mutations in the mitochondrial isoform of SOD
(Mn++ SOD or SOD2) do not have any effect on motor neurons but the overexpression of SOD2
in the transgenic line over-expressing G37R mutant SOD1 blocks motor neuron death [165].
These studies place mitochondria, which is present in close proximity to another calcium store
(endoplasmic reticulum) in a central position to ALS pathogenesis.
1.6.7.4.  Cytoskeletal Abnormalities
 Proper retention of neuronal energy status (mitochondria) and morphology along with the
function of protein transport (cytoskeletal proteins) seem to be important in many
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neurodegenerative diseases such as AD, PD, ALS and HD [166, 167].  Given that the axons of
motor neurons extend a long distance, it is imperative for the structural integrity of the neuron
and axon to be retained for efficient protein transport. Cellular protein and organelle trafficking
depends on the integrity of endoplasmic reticulum (ER) and the golgi complex.
Imuunocytochemical evidence from human autopsy studies and ALS transgenics point towards
an increase in fragmentation of golgi apparatus much like seen during the depolymerization of
microtubules [168-171]. In the transgenic mouse model, golgi fragmentation was identified two
months before onset of paralysis placing the event as an early mediator of ALS [172].
Another cytoskeletal protein abnormality that has led to many transgenic studies is the
intermediate heteropolymers that are specific to neurons localized in axons and plays an
important role in axonal transport. Neurofilaments (NF) are comprised of the light (NF-L),
medium (NF-M) and high (NF-H) molecular weight subunits. The frequent neurofilamentous
aggregates that co-localize with nitrotyrosine and SOD1 in different models of the disease have
implicated these major intermediate filaments in ALS pathogenesis [118, 173, 174]. These could
either be a result of the pathogenic process or the cause of ALS. Evidence discounting aggregate
formation as the primary or only cause for the disease phenotype is from a study utilizing the
G85R mutants. In these mutants, other defects such as slowing of axonal transport mostly due to
defects in neurofilaments arose several months prior to aggregate formations [175]. The light
chain of neurofilaments (NF-L) is required for cytoskeletal assembly and its deletion in the
G85R mice delayed disease onset and resulted in fewer aggregates [175]. These results suggest
that mitigating SOD1 aggregates is insufficient at disease amelioration.
Mice over-expressing mouse NF-L, human NF-H or mouse peripherin develop symptoms
akin to ALS patients or the SOD1 transgenics [176, 177]. Also, transgenic mice with a point
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mutation in NF-L subunit developed neurofilamentous aggregates in cell bodies and proximal
axons causing selective degeneration of motor neurons [178]. Reduced slow axonal transport as
seen in over-expressors of NF-H can result in aberrant accumulation of proteins. If NF-L is also
over-expressed in these motor neurons, the transport defect and pathology can be reversed [179].
It has also been shown that NF transport in 3 different lines of mutant SOD1 mice is defective.
Genetic studies in families of ALS patients have revealed polymorphisms in the KSP
repeats of NF-H and a recent study indicated mutations in genes encoding the dynein / dynactin
protein complex [92, 93, 114]. The dynactin complex is important for transporting NF
bidirectionally. The KSP repeats of NF-H and NF-M has been hypothesized to be
phosphorylated by activated kinases such as the members of the mitogen activated protein kinase
(MAPK) family and cyclin dependent kinase5 (CDK5), resulting in accumulation of NF in the
SOD1 transgenics [180, 181]. Post-translational modifications can modulate axonal growth and
transport of NF. Thus from all these studies, it is evident that cytoskeletal integrity is important
for protein, organelle transport and normal functioning of the motor neurons.
1.6.7.5.  Astrogliosis
Excessive proliferation and hypertrophy of the glial component is a neuropathological
hallmark of the disease [182]. This event is termed astrogliosis wherein the astrocytes and
microglial cells get activated, which may result in inflammatory cytokine / chemokine –
mediated responses. These may then have a bystander effect on the adjacent motor neurons thus
signaling the importance of the astroglial component of the CNS. A recent study in the
transgenics has demonstrated that overexpression of mutant (G37R) human SOD1 driven by
neuron-specific promoter did not result in motor neuron deficit, suggesting the importance of
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glial interactions [183]. In another interesting study utilizing chimeric mice, it was demonstrated
that the presence of SOD1 mutations in motor neurons is solely not sufficient in the disease
pathogenesis [184]. Non-neuronal cells are also required to express the mutant SOD1 protein.
Strikingly, they report that astroglial cells expressing wild-type SOD1 can delay motor neuron
death and also extend survival of the affected motor neurons. Albeit this study used state of the
art transgenic technology, the results did not shed any new light on ALS pathogenesis. It was
convincingly demonstrated that the state of the glial cells (i.e., local environment) plays an
equally important role in ALS. These studies provide important insight and guidance for any
cell-based therapeutic approaches for ALS.
1.6.7.6.  Autoimmunity
Autoimmunity has been hypothesized as a mechanism for SALS. Sera from SALS
patients have exhibited levels of antibodies against voltage-gated calcium channels (VGCC),
which could alter calcium channel function [185, 186]. Support for this hypothesis also stems
from various studies that describe increase in microglial activation and inflammatory cytokines
accompanying cell death in AD, PD and ALS. Activated microglia can act as antigen presenting
cells (APC) and mount an autoimmune response as noticed in cases of multiple sclerosis and
demyelinating inflammatory neuropathies. In fact a recent publication has documented increased
expression of mature dendritic cell markers, microglia and chemokines in ALS spinal cord and
CSF [187]. Microglial activation is an early response in ALS and it increases over time in
transgenic mice models. Support for the role of immune response in ALS also comes from the
fact that a cyclo-oxygenase 2 (COX2) inhibitor, minocycline has been demonstrated to extend
lifespan of transgenic mice [188, 189].
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1.6.7.7.  Other mechanisms (DNA Damage, Growth Factors, Viruses)
Lipid peroxidation of proteins or other markers of oxidative damage are well documented
for not only ALS but also for other neurodegenerative diseases [190-194]. Thus oxidative
damage to proteins and DNA can be a common pathogenic mechanism for neurodegeneration.
DNA damage can occur in glial or neuronal cells. Damage to mitochondrial DNA, activation of
p53 and PARP have been reported in spinal motor neurons of both transgenic mice and post-
mortem ALS tissues [195-200]. Antioxidant and DNA repair enzymes can counteract harmful
effects of oxidative injury. Base excision repair (BER), which corrects the loss of single bases
(AP sites) via the action of the apurinic / apyrimidinic endonuclease (APE) is one of the repair
pathways. One group identified APE mutations in 8 of the 11 SALS and FALS patients [201].
While two groups reported reduced DNA repair activity in ALS patients, one other study did not
show evidence for reduced enzymatic activity [202, 203]. Although inconclusive, these results
suggest that DNA repair activity is compromised in disease states thus making cells susceptible
to death via DNA damage. Another study suggested increased APE-1 activity in the surviving
upper motor neurons and the astrocytes in the spinal cord of ALS patients [203]. Although this
study does not directly corroborate the previous reports, it does support the DNA damage theory
by suggesting that DNA repair activity is increased in an effort to compensate for the damage.
Other factors that may be involved in disease pathogenesis include target-derived trophic
factor deprivation. Trophic factors or growth factors is a more viable hypothesis simply because
their signaling is important for the survival of neurons and glia. It is likely that if there is a target-
derived deprivation of these growth factors to the neurons, the death might be one of retrograde
also termed the “dying back” phenomenon. This indeed is true in some ALS cases [14, 33]. Also,
there have been a number of clinical trials involving the genetic manipulations of various growth
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factors such as brain derived growth factor (BDNF), glial derived growth factor (GDNF), ciliary
neurotrophic factor (CNTF), insulin-like growth factor-1 (IGF-1) and hepatocyte growth factor
(HGF) amongst others [204-209]. Although most have proved unsuccessful in human trials, it
nevertheless remains as a viable option to be explored in combinatorial therapeutic approach.
Although the viral hypothesis initially gained strength it has been mostly discounted.
There have been contradictory reports suggesting the presence of enteroviruses [210-212]. A
recent study has negated an earlier study by reporting the absence of echoviral RNA [213, 214].
Given the viral pathogenesis of poliomyelitis and the closeness in clinical symptoms between
polio victims and ALS patients, cannot be entirely excluded without further investigations.
1.7.  Cell Cycle and Cell death
The cell cycle plays a pivotal role in determining the decision to proliferate or to
withdraw from the cycle and enter a quiescent state. Thus, there is a distinct possibility that the
molecular mechanisms that control cell division and cell death are interrelated. During cell
division, there are transient and reversible changes that occur involving chromatin condensation,
cell rounding and cytoskeletal rearrangements. However, in cell death these changes occur
irreversibly and with destructive consequences [215-217].
Progression of the cell cycle through the four phases (G1, S, G2 and M) in eukaryotic
cells is associated with the phase-specific expression of defined sets of genes and their regulation
by transcriptional repressors and/or activators. Additionally, there are elaborate feedback
mechanisms called checkpoints that regulate the transition of a cell through the cell cycle [218].
If irreparable damages to DNA or the mitotic apparatus itself are detected, cell death ensues. The
p53 protein is an example of such an S-phase checkpoint controller that links cell cycle and cell
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death mechanisms. Early G1 events are dependent on the binding of extracellular mitogens to
cell surface receptors. There is a point in this phase termed the “restriction point” when cell cycle
progression becomes independent of growth factors [217]. This point is characterized by the
activation of the G1 cyclin dependent kinases (CDK), which are a family of cytosolic serine /
threonine protein kinases and the subsequent inactivation of the tumor suppressor retinoblastoma
protein (pRb), followed by increased DNA synthesis through transcriptional activation of S
phase genes [219]. These kinases are tightly controlled by their regulatory subunits, the cyclins.
Figure 12 Hypothesis: Aberrant re-activation of G1 to S phase Regulators
Phosphorylation of pRb by G1 cyclin (D1) - cyclin-dependent kinase 4/6 inhibits the ability of
pRb to bind the E2F family of transcription factors. When released from inactive,
hyperphosphorylated pRb, free and active E2F-1 in a dimeric complex with DP1 protein
enhances DNA binding activity, which activates transcription of S phase genes to induce
proliferation or apoptosis. Proliferation is not likely to occur in post-mitotic neurons. Apoptosis
could be dependent or independent of p53. Alternatively, E2F-1 in cytoplasm could initiate other
death cascades.
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One of the substrates for Cyclin D1 / CDK4 (G1 phase) is pRb (p105) that normally
exists in a hypophosphorylated form [220, 221]. It represses E2F/DP, a family of heterodimeric
transcription factors important for regulating cell cycle genes [222-225]. pRb binds to the
transactivating domain of E2F-1 acting as a transcriptional repressor. The overlying hypothesis
for aberrant re-entry of post-mitotic motor neurons into cell cycle is depicted in Figure 12.
Certain cellular signals such as glutamate and hydrogen peroxide can induce the kinase activity
of CDK4 or CDK6 resulting in hyper-phosphorylating pRb (ppRb), which results in the release
and de-repression of E2F-1 [220, 221]. Once E2F-1 is de-repressed, a number of genes related to
cell cycle progression such as the p53 family of tumor suppressor genes, and genes encoding
CDK inhibitors are transactivated.
The tumor suppressor protein, p53 is a sequence-specific DNA-binding protein that can
regulate transcription. When wild-type p53 is over-expressed, it can suppress cell growth [226,
227] and promote cell death by apoptosis [228, 229]. It inhibits cell cycle progression through
the activation of CDK inhibitors (CDKi) that blocks the activity of CDK/cyclin complexes. The
existence of p53 knockout mouse indicates that functional p53 is not required during early
development [230]. Co-expression of the wild-type p53 protein and E2F-1 in mouse embryo
fibroblasts resulted in a rapid loss of cell viability through a process of apoptosis triggered by
conflicting signals (growth arrest vs S phase entry). This E2F-1 mediated apoptosis may be
dependent or independent of p53 [231-233]. These studies thus link the G1 to S phase regulators
to p53 and apoptosis. In addition to the well-studied areas of development and cancer biology,
the role for cell cycle during neurodegeneration and brain injury is emerging.
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1.7.1.  Cell cycle Regulators and Neurological disorders
Although neuronal apoptosis is an important component of brain development, a growing
body of evidence suggests that it also participates in the progression of neuropathological
conditions such as stroke and neurodegenerative diseases [234-237]. Animal studies using
sympathetic and cortical neuron cultures implicate cell cycle elements such as CDK4/6,
pRb/p107, E2F-DP1 complex, and p53 in neuronal death evoked by DNA damage and b-
amyloid [238-243]. In a study using a ALS mouse model expressing mutant human G37R SOD1,
activity and levels of the G1 to S phase regulators such as CDK4, cyclin D1 and
hyperphosphorylated Rb were elevated. However there was no change in the levels of CDK2 or
CDK6 [244]. Thus, emergence from a post-mitotic state of selectively vulnerable populations of
neurons and their subsequent “re-entry” into cell cycle such as in AD, PD, ALS and SIVE have
been well documented [121, 242, 245-250]. There has been one report using fluorescent in-situ
hybridization (FISH) suggesting ploidy in these post-mitotic neurons of AD brains [251].
However, these results have not been successfully reproduced. Thus the overlying hypothesis for
the role of cell cycle proteins in post-mitotic adult neurons during neurodegeneration is one of
“abortive re-entry leading to neuronal death via multiple pathways”.
1.8.  Types of Cell Death during Neurodegeneration
Depending on the kind of insult and the toxicity levels, different pathways can lead to
neuronal cell death. In spite of the fact that most kinds of cell death is programmed, there are
variations in the involvement of subcellular organelles and mechanisms. Neurons can degenerate
via different types of death processes including apoptosis, necrosis, paraptosis and/or autophagy.
In spite of a number of reports implicating caspases and classical apoptosis in acute and chronic
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neurodegeneration, the lack of morphologically convincing apoptotic neurons has blunted a clear
understanding of the relationship between neurodegenerative processes and apoptosis. In
addition, in some studies the use of caspase inhibitors has either not had a significant effect on
delaying onset or increasing survival while in others, it has been effective [252, 253]. This
conundrum is probably due to the fact that it is very likely that many interrelated or independent
pathways may regulate cell death. In fact, in several models of neuronal cell death such as after
stroke or ischemia, the explosive necrotic death and the energy driven apoptotic type of death are
considered to represent a continuum [254].
A variation of apoptosis termed “Paraptosis” has been defined and is hypothesized as an
alternative form of neuronal cell death studies [255]. This form of death is characterized by the
formation of empty spaces called vacuoles in the cell cytoplasm derived predominantly from the
endoplasmic reticulum and later from the mitochondria. The process reveals mitochondrial
swelling and a general lack of caspases except caspase-9.
An emerging concept in neurodegeneration is the role for autophagy, a catabolic process
wherein the cytoplasm and other cellular organelles are phagocytosed by vacuoles and degraded
in the lysosomes [256]. In a lurcher mouse model for ataxia, glutamate receptor-induced
autophagy was evident in the Purkinje neurons [257]. In a PD model of methaphetamine-induced
dopaminergic loss and in lewy bodies of post-mortem PD cases, autophagy has been documented
[258, 259]. Furthermore trophic factor deprivation of in vitro cerebellar Purkinje neurons
resulted in increased autophagosomes in a p75 low affinity NGF receptor dependent manner
[260]. Thus it is fair to note that neuronal cell death can occur through more than one kind of
mechanism.
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1.8.1.  Apoptosis during Neurodegeneration
While multiple modes of cell death may contribute to ALS, apoptosis is the commonly
proposed mechanism. Apoptosis (etymologically from Greek apo- from, detached, separate and
ptosis- falling) is believed to function in molding the nervous system’s cellular structure and
function during brain development. Apoptotic events include DNA fragmentation, chromatin
condensation, membrane blebbing, and cell shrinkage [261]. While it is favorable to have
apoptosis to maintain cell number during neurodevelopment, if a cell sustains irreparable internal
damage and initiates a death cascade when it should not, it becomes detrimental to the nervous
system leading to, for instance, neuronal loss in ALS. Adult neurons aberrantly re-capture the
ability to exhibit apoptosis during the process of aging, ischemia or stroke and neurodegeneration
such as in ALS, AD, PD, and HD [119, 126, 262-272]. In a cortical injury model, it has been
demonstrated that neuronal apoptosis in the thalamus is dependent on p53 and its downstream
pro-apoptotic target, Bax [273, 274].
Cell disassembly is caused by the action of initiator proteases and effector proteases [275].
Proteases involved in programmed cell death have been termed “caspases”. These are
synthesized as cytoplasmic, inactive pro-caspases that are activated during apoptosis by the
initiation of a cascade of proteolytic cleavage. Activation of an initiator caspase, in turn,
activates effector caspases, resulting in cellular attrition. Different initiator caspases mediate
distinct sets of signals. For instance, while caspase-8 is associated with apoptosis involving death
receptors [276], caspase-9 is involved in death induced by cytotoxic agents [277]. Proapoptotic
signals can cause mitochondrial membrane changes that induce the release of mitochondrial
cytochrome c oxidase. This enzyme acts as a cofactor on the inactive Apaf-1 (Apoptosis
promoting associated factor)/pro-caspase-9 complex and results in the formation of cytoplasmic
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active caspase-9 [278]. This active caspase-9 through other intermediate proteases activates
effector caspases such as caspase-3 and -7. A proteolytic cascade thus activated acts on various
cellular substrates. A factor, DFF-45, is an inhibitor of the nuclease (CAD, caspase-activated
deoxyribonuclease) responsible for DNA fragmentation, a hallmark of apoptosis [279, 280].
During apoptosis, caspase-3 cleaves DFF-45, thus de-suppressing CAD and results in DNA
fragmentation [281]. Given the complexity of the system, it is conceivable that there could be
redundancy in the activity of these different caspases in mediating death response through
multiple signaling pathways.
Involvement of tumor necrosis factor (TNF-a) receptors and FAS in conjunction with
adaptor proteins containing death domains in apoptosis has also been extensively reported in
various systems. Fas receptor and its downstream apoptotic signaling via caspases-8 and -3 have
been implicated during neurogenesis and also in a model of transient spinal cord ischemia [282,
283]. TNF-a and FAS-ligand (FAS-L) can be released in response to inflammatory reactions by
glial cells or by developing neurons, which would then activate caspases leading to neuronal
death. In fact, the involvement of the Fas and its ligand (FasL) in p53-mediated neuronal
apoptosis has been documented [284].
There are also reports of caspase-independent death mechanisms of such as in PD and
stroke wherein DNA damage or oxidative stress can lead to the activation of poly (ADP-ribose)
polymerase (PARP). PARP in turn leads to altered nuclear localization of apoptosis inducing
factor (AIF) that can then trigger DNA fragmentation [285]. In fact evidence for AIF’s in
neuronal cell death also come from the “harlequin” mouse model, which has a mutation in the
AIF gene [286, 287]. The cerebellar and retinal neurons in these mice are susceptible to
oxidative stress, which then causes them to duplicate their DNA as they “re-enter the cell cycle”.
48
Neuronal death via apoptosis in these mice in spite of reduced expression of AIF is suggestive of
an antioxidant function of AIF. Thus in addition to causing apoptosis by nuclear translocation
from the mitochondria, it is likely to scavenge free radicals that may arise through oxidative
stress. This is a finding that directly connects oxidative stress to abortive re-entry into cell cycle.
1.8.2.  Apoptotic Pathways in ALS
Morphological and biochemical apoptotic characteristics have been observed in lower
and upper motor neurons in ALS. It has been reported that there is enhanced chromatolysis,
somatodendritic attrition, increased levels of DFF-45 and internucleosomal cleavage in spinal
cord and motor cortex of ALS cases [288]. Also there is an increased level of cytosolic anti-
apoptotic proteins (Bcl-2) in ALS cases, which reduces the chances of blocking cell death.
Recent evidences from transgenic mice have establishes that mutant SOD1 selectively induce
apoptosis in motor neurons [126, 289-291]. Many studies using caspase inhibitors or ablation of
genes encoding caspases have not yielded expected results such as delay in disease onset and
progression. It could be due to the fact that neuronal apoptosis is just one pathway of cell death
and there would be the prevalence of caspase-independent pathways. To this effect there are
reports in ALS transgenic mice of cell death mechanisms that are morphologically similar to
paraptosis [103, 292].
1.9.  Current Therapeutics and Clinical Trials
Identifying therapeutic targets and developing an approach to stem the relentless loss of
motor neurons is essential from a clinical perspective. The disease lacks diagnostic biomarkers
and any long-term drug interventions [293]. Currently there is only one FDA approved drug,
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riluzole/rilutek that increases lifespan by 2-3 months. Although the exact mechanism of its action
is unknown, riluzole is thought to act through partially being an antagonist for glutamate release
[294]. With ALS being heterogeneous simultaneous targeting of several pathways will probably
be the most effective way to impede disease progression.
Antioxidant (Vitamin E and N-acetlycysteine), energy supplements (Creatine) and
intrathecal / subcutaneous injections of neurotrophic factor (BDNF, CNTF and GDNF) were
ineffective in drug trials [295]. Specifically, a double blind, placebo controlled human BDNF
study failed to improve survival and was aborted. Although, some of these were very effective in
animal studies, human trials failed. Another ongoing clinical trial uses minocycline (tetracycline-
derivative with anti-inflammatory properties). It crosses the blood-brain barrier and has been
effective in many paradigms such as PD, NMDA-mediated toxicity, and cerebral ischemia [296-
299]. Its effects are possibly through inhibiting caspase activation / cytochrome c release,
microglial activation and iNOS activity [298-301]
In recent animal studies (G93A mutant SOD1) a combination of creatine (supplement
that improves mitochondrial function) and minocycline delayed disease onset and increased
survival by 25% [302]. Another group used a cocktail of minocycline, riluzole and nimodipine
(VGCC blocker) demonstrating delay in onset, slowed the loss of muscle strength and increase
survival by about 6 weeks [303]. A recent gene therapy approach in SOD1 transgenics using
IGF1 (myotrophin) delayed disease onset by 31 days and increased survival by 37 days when
administered pre-symptomatically [206]. These mice also exhibited reduced pathology. IGF1 by
far seems to be the most ideal candidate amongst growth factors. Caspase inhibitors (caspase-1
and -3) and over-expression of anti-apoptotic proteins (Bcl-2) in mutant SOD1 mice prolong
their lifespan by upto 15% [290, 304, 305]. Furthermore, ongoing in vitro and animal studies
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modulating the proteasome (ritonavir) increase survival and a molecule (Ceftriaxone) that
increases glutamate transporter expression slows disease progression. Preliminary drug screening
of G1 to S phase inhibitors (Eflorinthine and Olumucine) that confer neuroprotection provides
credence for cell cycle in ALS.
Numerous studies that are conducted in a laboratory fail to succeed in clinical trials due
to a variety of reasons. Positive results from animal studies might be difficult to replicate in
human studies because the time of disease course at which drugs are administered, mode of
delivery, differences in drug metabolism and the fact that the transgenic animal models
represents a very small fraction of ALS population. However, efficient early diagnosis, multi-
system approach to disease marker discovery and drug intervention involving pharmacological,
genetic and cell-based methodologies may be an efficient way to battle ALS.
1.10.  Drug design and therapy – The “Omics” approach
Drug discovery and therapeutics relies on understanding molecular mechanisms,
identification of drug targets and efficient utilization of novel approaches. Combinatorial
approaches include high-throughput screening assays, genomics, proteomics and metabolomics.
Over the past decade genomics has been used extensively to study the expression patterns of
various genes. However mRNA does not directly correlate to levels of its product / protein
mainly due to the prevalence of various post-transcriptional modifications and is a limitation to
genomic studies. Thus the study of the entire set of proteins (“Proteome”) expressed by a
genome, defined as “Proteomics” or the study of all the metabolites in a cell, also known as
“Metabolomics” could result in successful drug discovery, design and better clinical
management [306].
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1.10.1.  Clinical Proteomics
The dynamic nature of the proteome of a cell or tissue is a strong reason to study disease at
the proteomic level. Proteomics using complex systems such as cells, tissues, or body fluids
(serum, plasma or CSF) provides the tool for identifying clinical biomarkers that extends the
understanding of molecular mechanisms to drug discovery [307-310]. Biomarkers can be defined
as any molecule that can be specifically associated with a biological process. Clinically a
diagnostic biomarker can be utilized to correctly distinguish between a patient and a normal
individual. Ideally one would like a validated diagnostic marker to predict at an early stage of the
disease. It is thus important to understand the biology of the disease and stratify patients based
on age, clinical symptoms, and drug regimen. Proteomics however has its disadvantages in that it
has to deal with complex mixtures arising from alternative splicing and post-translational
modifications. In addition, proteins found in low abundance cannot be amplified unlike low
abundant DNA or RNA. Sometimes, high abundance proteins such as albumin present in
elevated levels in serum and other body fluids may mask other proteins. These aspects
necessitate the use of albumin depleting protocols, enrichment and fractionation methods
coupled to sensitive techniques such as mass spectrometry (MS). Proteomic profiling can be
performed either using a 2D-GE coupled to MS for protein identification or using protein chip-
based tandem MS such as matrix-assisted laser desorption / ionization time of flight (MALDI-
TOF), surface-enhanced laser desorption / ionization-TOF (SELDI) and electrospray ionization
(ESI) [311]. While both 2D-GE and MS approaches have their advantages and disadvantages, in
this study we have chosen the latter approach because of the following reasons: (i) MS-based
proteomics is more rapid and sensitive; (ii) Protein chips require smaller amounts of sample; (iii)
Proteins less than 10kDa can be better identified by MS but not 2D-GE; (iv) It is possible to
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perform direct amino acid sequencing from the protein chips; (v) MS-based approach is better
suited to identify post-translational modifications than 2D-GE.
1.10.2.  Two Dimensional Gel Electrophoresis (2D-GE)
2D-GE has been extensively used for proteomics but it presents certain caveats such as
limited automation, difficulty in reproducing results and quantification. The latter two aspects
were however solved by the fluorescence difference GE (DIGE) reducing the number of gels and
increasing the efficacy of spot picking. This approach uses mass and charge-matched spectrally
resolvable fluorescent dyes (Cy3 and Cy5) to label different protein samples in vitro before
subjecting them to 2D electrophoresis [312]. In addition to providing a means to quantify protein
differences, the DIGE technology can also identify any post-translational modifications.
However the caveat to this technology is that the labeling step has to be optimized
stoichiometrically. Once differentially expressed spots are picked from the 2D-GE they can be
sequenced and validated by molecular techniques.
A combination of 2D-GE, Western immunoblotting and MS has been utilized in studying
the proteomic patterns in the CSF and brain tissues of neurodegenerative and neuropsychiatric
patients [313-318]. Studies have indicated oxidative damage to proteins involved in the neuronal
proteasome machinery (ubiquitin carboxy-terminal hydrolase-L1, UHC-L1), oxidatively
modified or nitrated protein differences in AD and PD brain samples [316, 317, 319-322]. In fact
a recent study was published using a mouse model of HD and post-mortem samples from HD
patients, wherein differences in serine protease inhibitors and chaperone proteins were reported
[323, 324]. Other studies have involved Down’s syndrome and Schizophrenic patients [318, 325,
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326]. 2D-GE has thus yielded insights to disease-specific differences in the “neurome” (nervous
system-specific proteome) and it can be handily coupled to the sensitivity of MS.
1.10.3.  Mass Spectrometry
The use of MS in biomedical sciences is a highly sensitive and analytical tool that bridges
basic and clinical science. MS-based proteomics can detect signals with low amounts of clinical
samples and aid in defining disease-specific “biosignatures”. All MS contain three parts: ionizer,
analyzer, and detector. These instruments are based on the principle of desorbing and ionizing
protein samples for analysis followed by their detection based on mass to charge (m/z) ratios.
The detector provides a pattern of spectral peaks, which discriminates disease from normal
condition.
In the late 1980s, two new protein ionization techniques led to the discovery of matrix-
assisted laser desorption / ionization (MALDI) and electrospray ionization (ESI) mass
spectrometric instruments [327-329]. In MALDI, the sample of interest when mixed with an
energy-absorbing matrix (EAM) forms a crystal and this is applied on a reusable metal plate with
spots available for a number of different samples. When the samples are pulsed with laser, they
are ionized accepting protons from the EAM and are desorbed from the plate in the gas phase
being ejected into the mass analyzer. The mass analyzer helps in the separation of ions according
to their m/z ratios prior to their detection. The mass analyzers can be of different kinds such as
time-of-flight (TOF), quadrupole (Q), ion trap or a combination of these such as (TOF-TOF, Q-
TOF). In a TOF analyzer, the mass is directly proportional to the speed at which the ions travel.
The beam is focused by a reflector and directed towards a detector. Ions with a lower m/z ratio
travel faster and are therefore quicker to be detected. In quadrupole analyzers, ions pass through
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two pairs of oppositely charged parallel metal rods and are filtered based on the applied voltage
prior to detection. Hybrids of these mass analyzers (TOF-TOF or Q-TOF) make for higher
sensitivity to low abundance ions and also coupling the discovery phase of MS-based proteomics
to the identification phase. MS however cannot be used for quantitative purposes much like 2D-
GE. Nevertheless, similar to the DIGE system, a modification of MS termed isotope coded
affinity tags (ICAT) has made it a quantifiable technique. In this approach, the samples are
linked to isotopes and thus differences in the peak sizes isotope-labeled proteins / ions (heavy vs
light) determine relative quantities.
Currently, a modified version of MALDI-TOF is used, termed surface-enhanced laser
desorption / ionization-time of flight (SELDI-TOF) [330]. In SELDI, the samples are applied to
spots on protein chip arrays that are biochemically modified with an active surface chemistry
such as cation / anion exchange properties, hydrophobicity or metal affinity. All these
approaches are closely associated with the use of bioinformatics, which provide the algorithmic
tool for efficient data mining and interpretation [331]. They aid in determining discriminatory
patterns of m/z values. Machine learning and classification tree based algorithms are used to
discern differences [332-334]. Potential predictors of the disease can then be enriched and
sequenced through MALDI based tandem MS/MS. The availability of such databases and the use
of statistical methods emphasize the important role played by bioinformatics in proteomics.
1.10.4.  MS-Based Proteomics
In a landmark “proof-of-principle study in 2002, this approach was published by a group
from the National Cancer Institute using a training set of 100 serum samples from normal and
ovarian cancer patients [335]. The model was then tested on a sample set of 116 of which 50
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were diagnosed with cancer. They reported very high predictive value (95% specificity and
100% sensitivity) and biomarkers were utilized to develop commercial diagnostic tests. Re-
analysis of this data by other groups revealed experimental artifacts generated by the limitations
imposed by the Ciphergen-based SELDI-TOF machine and experimental protocol utilized to
process the samples that questioned the credibility of the ovarian cancer study [336]. The
SELDI-TOF does not provide high-resolution spectral data for proteins with high molecular
weight (> 50 kDa). Usually researchers do not analyze m/z values less than 2kDa as they might
present the matrix-related peaks and other experimental artifacts. Mass inaccuracy and spectral
patterns that differ from machine to machine may also pose problems for interpretation. In spite
of its limitations, MALDI / SELDI-TOF has been increasingly used in clinical research studies
for identification of diagnostic biomarkers for diseases such as glioblastomas, breast, prostate,
non-small cell lung carcinomas, renal cell carcinoma, cardiovascular diseases, allergies and
neurological disorders such as AD, HIV-1 associated dementia [308, 316, 320, 337-345]. In an
elegant study, clinical samples from HIV-1 infected individuals were analyzed for the identity of
the soluble factor from CD8+ T lymphocytes that has been reported to inhibit HIV-1 replication.
Using a immuno-SELDI-TOF-MS approach, this factor was identified to be a-defensin 1, 2, and
3 [346]. This is further validation for the use of MS-based proteomics on clinical samples and
identification of putative disease markers. Hence, although MS-based proteomics is in its
infancy, it nevertheless provides an exciting prospect at identifying disease specific diagnostic
markers and extending therapeutics even for such heterogeneous and fatal neurodegenerative
diseases as ALS.
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1.11.  Statement of Problem
It is evident that the molecular mechanisms in chronic and fatal degeneration of motor
neurons during ALS are far from being delineated. This relentless disease is devoid of early
diagnostic biomarkers and therapeutic targets / drugs for long-term intervention. This study was
undertaken so as to bridge two aspects that are lacking in the world of ALS. The role for cell
cycle proteins and apoptosis has been reported in other neurodegenerative diseases but not ALS.
We hypothesized that aberrant re-activation of cell cycle proteins could lead to an apoptotic
mode of motor neuron death furthering the understanding of disease mechanisms. In addition we
hypothesized that a sensitive mass-spectrometry-based proteomic approach would not only yield
ALS specific disease markers but also provide additional targets for drug design.
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2. Abortive Re-entry of Motor Neurons into Cell Cycle
2.1.  Abstract
The mechanisms that regulate the initiation and/or progression of selective motor neuron
loss during amyotrophic lateral sclerosis (ALS) remain enigmatic. Cell cycle events that occur
during development and studied extensively during pathological states of tumorigenesis can be
aberrantly recapitulated during neurodegeneration. Indeed recent data has implicated increased
expression and activation of various cell cycle proteins in neuronal cell death. We have
examined the expression and subcellular distribution of G1 to S phase cell cycle regulators in the
spinal cord, motor cortex, and sensory cortex from clinically and neuropathologically diagnosed
sporadic ALS cases and age-matched controls. Our results indicate hyperphosphorylation of the
retinoblastoma protein in motor neurons during ALS, concurrent with increased levels of cyclin
D, cyclin dependent kinase 4 (CDK4) and re-distribution of E2F-1 into the cytoplasm of motor
neurons and glia. Furthermore, the cell cycle checkpoint, p53 co-localizes with
hyperphosphorylated retinoblastoma and E2F-1 in spinal motor neurons. These results suggest
that re-sensitization of cells to G1 to S phase activation occurs during ALS and may participate
in molecular mechanisms regulating motor neuron death.
58
2.2.  Introduction
The etiology of ALS is thought to be multifactorial with a number of different
hypothesized factors as enumerated in chapter 1 (Fig 10). Signaling from the cell surface to the
nucleus modulates chromatin structure and the activity of transcription factors, resulting in
altered gene expression. In fact it is known that alteration in levels of pro- and anti-apoptotic
genes can tilt the balance towards motor neuronal death [119]. Another potential cell death
mechanism is the inappropriate expression or activation of cell cycle proteins [234]. Cell cycle is
associated with the phase-specific expression or modification of defined sets of cell cycle genes
that regulate cellular proliferation, differentiation or entry into a quiescent state [347]. However
re-entry of quiescent, terminally differentiated neurons, into the cell cycle may result in a
“mitotic catastrophe” and cell death [234, 235, 348]. For entry into the cell cycle, quiescent
neurons of the adult brain must first exit G0 and enter the G1 phase of the cell cycle. Multiple
cell cycle proteins regulate progression through G1, the most important being the products of
retinoblastoma (pRb) tumor suppressor and E2F gene families [220]. In quiescent cells, the
retinoblastoma protein (pRb) remains in a hypophosphorylated state and sequesters members of
the E2F gene family of transcription factors, which suppresses cell cycle progression. The
hyperphosphorylation of pRb (ppRb) releases and de-represses E2F-1 [219, 349].
Numerous lines of investigation have implicated pRb and E2F-1 in neuronal cell death
[215, 239-242, 245-247, 350-352]. Studies using transgenic mouse models revealed that
neuronal death in pRb knockouts was rescued by concurrent mutations in E2F-1, suggesting a
role for E2F-1 in neuronal death [353, 354]. In vitro studies in PC12 cells or primary neuronal
cultures suggest a role for pRb and E2F-1 in response to insults such as b-amyloid toxicity, over-
expression of a-synuclein, UV irradiation, DNA damaging agents, trophic factor withdrawal,
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and depolarizing conditions [242, 352, 355-358]. The functional role for these proteins has been
established in mouse and rat cortical cultures using pharmacological inhibitors of CDK,
dominant-negative and antisense constructs of CDK and/or E2F-1/DP-1 [240, 352, 359-361].
Human and animal post-mortem studies in AD, PD and SIV-E also suggest a plausible role for
these regulators in selective neuronal death [121, 245, 248, 355, 358, 362]. There is one report in
ALS wherein the G37R mutant SOD1 mouse model demonstrates increased levels of
CDK4/cyclin D1 and ppRb [244]. This model does not reveal any changes in levels of CDK2 or
CDK6 and the authors have not reported protein alterations downstream of ppRb.
Evidence from studies on non-neuronal cells suggests that E2F-1 induces cell death via
apoptosis and can be either p53-dependent or independent [231, 232]. The role for p53 and E2F-
1 in cortical neuronal cell death and DNA damage paradigms are well established [234, 363].
However, a role for these other cell cycle proteins in neurodegeneration during ALS is unknown.
We hypothesize that activation of G1 to S phase cell cycle transcriptional regulators in motor
neurons during ALS leads to altered gene expression and regulates cell death.
In this study, we report enhanced nuclear accumulation of hyperphosphorylated pRb
(ppRb) and altered localization of E2F-1 in both lower and upper motor neurons in ALS patients.
In addition, we show the co-localization of p53 with ppRb and E2F-1 in spinal cord motor
neurons. These results suggest that, similar to in vitro models of neuronal cell death, motor
neurons are induced to enter the G1 phase of the cell cycle, suggesting that hyperphosphorylation
of pRb (ppRb) and altered localization of E2F-1 participates in motor neuron cell death during
ALS.
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2.3.  Materials and Methods
2.3.1.  Source of Tissue Samples
The lumbar spinal cord (see Fig 5A) and pre/post-central gyrus (motor/sensory cortex,
see Fig 4A) region from eighteen cases of clinically diagnosed SALS, and nine non-ALS age-
matched controls, were utilized to examine protein expression and distribution. All tissues were
obtained from the University of Pittsburgh ALS tissue bank and approved for use by the
University of Pittsburgh Institutional Review Board. The average age at death was 60.05 ± 12.22
yrs for ALS cases (40-76 yrs) and was not significantly different from control cases (65.33 ±
15.37 yrs; 51-95 yrs; p = 0.34). The average post-mortem interval times for ALS and control
cases were 6.02 ± 3.35 (2.5-14 hrs) and 9.88 ± 5.68 hrs (5-20 hrs), respectively. The difference in
the post-mortem interval time was statistically significant  (p = 0.039).  Some of the controls and
ALS cases (indicated with an asterisk in Table 1) were neuropathologically diagnosed as cases
with possible AD (Braak II or III / VI). For immunohistochemistry, all tissues were fixed in 10%
buffered formalin for 1 week and 8-mm paraffin-embedded sections were examined.
2.3.2.  Antibodies
A list of antibodies and their dilutions used for experiments in Chapters 2 and 3 are
shown in Table 3. Monoclonal antibodies were used to detect hypophosphorylated pRb
(Pharmingen, La Jolla, CA), E2F-1 (Santa Cruz Biotechnologies, Santa Cruz, CA), Cyclin D1
(Santa Cruz Biotechnologies, Santa Cruz, CA) and CD68 (DAKO, Carpinteria, CA). Polyclonal
antibodies were utilized to detect hyperphosphorylated pRb (ser-795, NEN biolabs), active form
of CDK4 (Santa Cruz Biotechnologies, Santa Cruz, CA), Actin (Chemicon, Temecula, CA) and
GFAP (DAKO, Carpinteria, CA). Westerns were probed at dilutions of 1:750 (pRb, ppRb, E2F-
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1), 1:200 (Cyclin D1, CDK4) or 1:10000 (Actin). For light microscopy, antibodies were utilized
at dilutions of 1:150 (pRb, ppRb, E2F-1), 1:200 (CDK4, Cyclin D1) and for confocal laser
scanning microscopy at 1:80 (ppRb, p53), 1:60 (E2F1), 1:100 (GFAP), and 1:30,000 (CD68).
Cases Age /
Sex
PMI
(hrs)
Neuropathology
Spinal Cord
Neuropathology
Motor Cortex
Ctl 1 53 / F 7 No LMN loss or gliosis No UMN loss or gliosis
Ctl 2 54 / M 6 No LMN loss or gliosis No UMN loss or gliosis
Ctl 3 62 / M 5 No LMN loss or gliosis No UMN loss or gliosis
Ctl 4 58 / F 5 No LMN loss or gliosis No UMN loss or gliosis
Ctl 5* 82 / F 5 No LMN loss or gliosis No UMN loss or gliosis
Ctl 6* 76 / M 13 No LMN loss or gliosis No UMN loss or gliosis
Ctl 7 57 / F 11 No LMN loss or gliosis No UMN loss or gliosis
Ctl 8 95 / M 20
No LMN loss or gliosis
No UMN loss or gliosis
Ctl 9 51 / F 17 No LMN loss or gliosis No UMN loss or gliosis
ALS 1 71 / F 5 Severe LMN loss and gliosis Moderate UMN loss and gliosis
ALS 2 71 / M 3 Severe LMN loss and gliosis Moderate UMN and axonal loss
ALS 3 75 / M 2.5 Severe loss of LMN and gliosis Moderate loss of UMN and gliosis
ALS 4 43 / M 4 Severe LMN loss, and gliosis Severe UMN loss and gliosis
ALS 5 51 / F 5 Severe LMN loss, moderate gliosis Severe UMN loss and gliosis
ALS 6 67 / M 4 Severe LMN loss and gliosis Severe UMN loss and gliosis,
Severe loss of axons
ALS 7 51 / M 5 Severe LMN loss, axonal loss, and
Gliosis
Moderate UMN loss and mild
gliosis, mild axonal loss
ALS 8 40 / M 6 Severe LMN and axonal loss, gliosis Moderate UMN loss, mild gliosis
ALS 9 70 / F 3 Severe loss of LMN and gliosis Moderate UMN loss and gliosis
ALS 10* 49 / M 14 Severe loss of LMN and gliosis Moderate UMN loss and gliosis
ALS 11 44 / M 3 Severe loss of LMN, axonal loss
and gliosis
Severe UMN loss, moderate
gliosis, mild axonal loss
ALS 12 54 / F 6 Severe loss of LMN and gliosis Moderate loss of UMN and gliosis
ALS 13 57 / M 3 Severe LMN loss, moderate gliosis No loss of UMN and mild gliosis
ALS 14 73 / F 13 Moderate LMN loss and gliosis No loss of UMN and mild gliosis
ALS 15 53 / M 10 Severe loss of LMN and gliosis Moderate loss of UMN and gliosis
ALS 16 73 / F 11 Severe loss of LMN and gliosis Mild loss of UMN and gliosis
ALS 17* 76 / F 6 Severe loss of LMN and moderate
gliosis
Moderate loss of UMN and gliosis
ALS 18* 63 / F 5 Severe loss of LMN and gliosis Moderate loss of UMN and gliosis
Table 2 List of the cases utilized in this study
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The post-mortem interval (PMI) and age in hours (average control, 9.88 hrs; ALS, 6.02 hrs) are
indicated for the ALS (average age of 65.33 yrs) and age-matched controls (Ctls; 60.05 yrs),
respectively. MN, motor neurons; UMN, Upper motor neurons; LMN, Lower motor neurons;
asterisk next to cases indicates possible Alzheimer’s disease.  Reprinted from Am J Pathol 2003,
162:823-835 with permission from the American Society for Investigative Pathology.
Protein Antibody WB L-IHC C-IHC  Vendor
pRb mAb 1:750 1:150 ------ Pharmingen
ppRb pAb 1:750 1:150 1:80 NEN Biolabs
E2F-1 mAb (KH95) 1:750 1:150 1:60 Santa Cruz
E2F-1 mAb (C-20) ------ 1:150 ------ Santa Cruz
Cyclin D1 pAb 1:200 1:200 ------ Santa Cruz
CDK4 pAb 1:200 1:100 ------ Santa Cruz
Actin pAb 1:1500 ------ ------ Zymed
GFAP pAb ------ 1:200 1:150 DAKO
CD68 mAb ------ ------ 1:30,000 DAKO
p53 mAb 1:750 1:150 1:80 Santa Cruz
p73 pAb 1:750 1:150 ------ Santa Cruz
BAX pAb 1:1000 1:200 ------ Pharmingen
Caspase-3 pAb 1:700 1:150 1:80 NEN Biolabs
Caspase-8 pAb 1:600 1:100 1:80 Stressgen
Table 3 List of Antibodies
The table illustrates all the antibodies with the respective dilutions they were used at for
detection through Western immunoblotting (WB), immunohistochemistry at the light microscopic
level (L-IHC) and laser scanning confocal microscopy (C-IHC). mAb and pAb indicate the type
of antibody (monoclonal or polyclonal). Abbreviations of proteins are explained in the text. N/A
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represents either that the antibody was not used or that the detection of the protein by that
particular technique was not performed. Also provided is the information regarding the vendor
and the specific catalog number of the antibody utilized in these studies.
Reprinted from Am J Pathol 2003, 162:823-835 with permission from the American Society for Investigative
Pathology.
2.3.3.  Immunohistochemistry – Light and Confocal Microscopy
Paraffin-embedded tissue sections from lumbar or cervical spinal cord and mid-motor
cortical regions (regions # 2 through #5 in Fig 6B) were microwave treated for 4 min at full
power followed by 7 min at 40% power in 1X citra antigen retrieval (Biogenex, San Ramon,
CA), cooled to room temperature for 90 min, and then incubated in 3% H2O2 and 0.25% Triton
X-100 in PBS (phosphate-buffered saline) for 30 min. The sections were then blocked in 5%
milk/PBS for 1 hour. Primary antibodies at dilutions (see 2.3.2) were added in 1X PBS and
incubated overnight at 4oC. After four 15-minute washes in PBS, sections were incubated in
biotinylated goat anti-rabbit or anti-mouse IgG secondary antibody (1:1000; dilution Southern
Biotechnology Labs, Birmingham, AL) for 1.5 hours. The signal was further amplified using
biotinylated tyramide according to the manufacturer’s protocol (TSA Biotin system, NEN
Biolabs). On washing, the sections were incubated in streptavidin-Horseradish Peroxidase (HRP,
1:1000 dilution) for 1 hour and the reaction product visualized using 3-amino-9-ethylcarbazole
(AEC for 3-5 mins) (Biogenex, San Ramon, CA). This reaction results in a red end product and
all sections were then counterstained with hematoxylin. The study was conducted in a blinded
fashion using 18 ALS and 10 age-matched control cases.
For laser scanning confocal microscopy, tissues were processed as for light microscopy
with the following modifications. Primary antibodies were used at a higher concentration than
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for light microscopy (Table 3) and the slides incubated overnight at 4oC. After incubations with
biotinylated secondary antibodies, the signal was further amplified using the tyramide
amplification kit as per manufacturer’s protocol. The sections were finally incubated with a
1:500 dilution of streptavidin-Alexa Green  (green) or streptavidin-Cy5 / Cy3 (red) at a dilution
of 1:500. Co-localization was determined by the presence of yellow color (combination of green
and red dyes). The sections were analyzed on a laser scanning confocal microscope (Zeiss). A
total of 70-80 and 20-30 motor neurons in the spinal cord and cortex were counted, respectively
at 400X magnfication. The study was conducted in a blinded fashion using 11 ALS and 6 age-
matched control cases. Post-mortem tissues are susceptible to auto-flourescence through the
presence of lipoproteinaceous deposits (lipofuscin). Single labeling and other control
experiments were performed to determine optimal concentrations of primary and fluorescently
labeled secondary antibodies. Omission of the primary antibody resulted in absence of
fluorescent signal. Crossover control experiments were also performed to determine the
specificity of the secondary antibody.
2.3.4.  Protein Extraction
Lumbar spinal cord and motor cortical (mid- and superior-motor cortical regions, #2 - #7
in Fig 6B) frozen tissue from controls and ALS cases (Table 2) were utilized for immunoblotting
and DNA binding assays. For total cell lysates, tissue samples were homogenized using polytron
homogenizer (PGC Scientific, Gaithersburg, MD) set at 15000 rpm for 45 seconds. It was carried
out in lysis buffer containing 25mmol/L HEPES (pH 7.4), 50mmol/L NaCl, protease inhibitor
cocktail II (SIGMA), and 1% triton-X 100. The homogenized product was spun at 14000 rpm in
a cold microfuge and the supernatant saved as the total cell lysate. Nuclear and post-nuclear
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extracts were extracted as described previously [121]. Briefly, protein extracts were prepared by
detergent lysis on ice (0.1% Nonidet P-40, 10 mmol/L Tris (pH 8.0), 10 mmol/L MgCl2, 15
mmol/L NaCl, 0.5 mM phenylmethylsulfonyl fluoride, 2 µg/ml pepstatin A, and 1 µg/ml
leupeptin). The nuclei were collected by low speed centrifugation at 800x g for 5 min. The
supernatant was saved as the post-nuclear supernatant and the pellet containing the nuclei was
further extracted with high salt buffer (0.42 mol/L NaCl, 20 mmol/L HEPES (pH 7.9), 20%
glycerol, 0.5 mmol/L phenylmethylsulfonyl fluoride, 2 µg/ml pepstatin A, and 1 µg/ml
leupeptin) on ice for 10 min. Residual insoluble material was removed by centrifugation at
14,000 x g for 5 min. The resulting supernatant fraction was collected and termed the "nuclear
extract." Protein concentrations were determined by Bio-Rad assay (Bio-Rad, Richmond, CA).
2.3.5.  Immunoblotting
Total cell lysates, nuclear extracts and post-nuclear supernatants were fractionated by
electrophoresis on an 8, 10 or 12% sodium dodecyl sulfate-polyacrylamide gels. The proteins
were transferred to polyvinylidene difluoride nylon membranes (NEN Biolabs) and blocked in
5% nonfat milk / 1X PBS or 0.5% BSA / 0.15% glycine in 1X PBS overnight at 4°C. The blots
were probed individually with the antibodies and concentrations overnight at 4°C in 0.5%
milk/PBS (Table 3). The blots were washed three times in PBS / 0.1% Tween-20 for 15 min.
Isotype-specific horseradish peroxidase-conjugated secondary antibodies (Chemicon) specific for
each primary antibody were added for 2 hrs at room temperature. The secondary antibodies were
washed extensively in PBS / 0.1% Tween-20 (three times for 20 min). The final reaction
products were visualized using enhanced chemiluminescence (ECL; Pierce) and the band
intensities were within the linear range of detection. Actin was used to normalize protein levels
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within each sample. The density of bands was measured using the NIH Image software version
1.58 (National Institutes of Health, USA).
2.3.6.  Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts (20-25µg) were preincubated with salmon sperm DNA (120ng) as a
nonspecific competitor in 12-15µl EMSA buffer (20% glycerol, 150mmol/L KCl) prior to
addition of 32P-labeled oligo to reduce nonspecific DNA-protein interactions. Wild type (WT
E2F-1 5’-ATTTAAGTTTCGC G CCCTTTCTCAA-3’) and mutant (MT E2F-1 5’-
ATTTAAGTTTCGATCCCTTTCTCAA-3’) oligonucleotides were synthesized and gel purified
(Oligos ETC.). For competition reactions, unlabeled E2F-1 (3, 30, and 100ng) or unlabeled
unrelated (5’-GATCATTCAGGTCATGACCTGA-3’; 100, and 300ng) competitor oligos were
preincubated with the protein for 5 min on ice prior to addition of labeled probe. For positive
controls of E2F1 DNA binding activity, nuclear extracts were prepared from NIH3T3 cells. The
reaction mixture was loaded onto a 6% nondenaturing polyacrylamide gel and electrophoresed at
100 V in 1X Tris-borate-tetraethylenediaminetetraacetic acid. The gel was removed from the
apparatus, dried, and exposed to autoradiography film. The density of the complexes was
measured using the NIH Image software 1.58 (National Institutes of Health, USA).
2.3.7.  Statistical Analysis
Comparisons between any two groups of data were done using the single-factorial
analysis of variance (ANOVA). A p-value of £ 0.05 was considered statistically significant.
Numerical data were expressed as means ± the standard deviation with “n” signifying the
number of experiments or cases.
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2.4.  Results
Based on the reported activation of cell cycle proteins in neurodegenerative diseases such
as Alzheimer disease [121, 242, 246, 251], we investigated the expression and distribution of G1
to S phase cell cycle proteins in human post-mortem tissues from ALS and age-matched control
cases. The G1 to S phase cell cycle transition is necessary for cell cycle progression and
regulated by the activation of cyclin/cyclin-dependent kinases that hyperphosphorylate pRb, thus
de-repressing the transactivational ability of E2F (Fig 12; [220, 223, 225, 347]). Therefore, the
cell cycle proteins analyzed in this study include cyclin D1, CDK4, ppRb, and E2F-1. Co-
localization studies involving these regulators and p53 were also performed. Since ALS affects
the lower motor neurons in the spinal cord and upper motor neurons (Betz cells) in the cortex, we
utilized tissue samples from both CNS regions to determine subcellular localization of cell cycle
proteins by immunohistochemistry. Regions primarily unaffected during ALS, namely the dorsal
horn of the cord (see Fig 5C) and the sensory cortex (see Fig 4A), were used as internal controls.
2.4.1.  Increased immunoreactivity of G1 to S phase cell cycle proteins in ALS
spinal cord motor neurons
Sections of lumbar spinal cord and pre/post-central gyri were immunostained using
commercially available antibodies (Table 3). For light microscopy, the antigen-antibody complex
was visualized with 3-amino-9 ethylcarbazole (AEC) and counterstained with haematoxylin (see
Materials and Methods). Cyclin D1, a D-type cyclin functional in the hyperphosphorylation of
pRb and G1 to S phase transition of the cell cycle, exhibited increased cytoplasmic distribution
in the spinal motor neurons of ALS patients (Fig 13, A and B). Sections were also stained for the
active form of CDK4. Although active CDK4 immunoreactivity was primarily negligible in the
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ventral horn of control cases (Fig 13D), increased and punctate CDK4 immunoreactivity was
apparent in the cytoplasm and occasionally in the nucleus of ventral horn motor neurons of ALS
patients (Fig 13E). CDK4 and cyclin D1 immunoreactivity were negligible in the dorsal horn
sensory neurons and surrounding glia in the ALS patients (Fig13, C and F).
One downstream target of active cyclin D/CDK4 complex is the retinoblastoma protein
(pRb), with cyclin D specific phosphorylation of serine at position 795. Therefore, we examined
the phosphorylation state of pRb in ALS using a phospho-specific anti-pRb antibody to serine
795 that has been shown to detect increased pRb phosphorylation in AD [121, 242, 355]. We
detected abundant nuclear and punctate cytoplasmic staining of Ser-795 phosphorylated pRb
(ppRb) in the motor neurons of ALS spinal cord but not in the age-matched control tissues (Fig
13, G and H). When morphologically distinct motor neurons from multiple lumbar spinal cord
sections of 18 ALS cases and 10 control cases were counted (total of 450 motor neurons /
condition) the number of ppRb-positive lower motor neurons in ALS (85.5%) was significantly
greater than controls (2.8%). The retinoblastoma protein regulates the transactivation ability of
E2F family of transcription factors. We noted punctate E2F-1 immunoreactivity specific to the
cytoplasm of ALS spinal motor neurons but not control motor neurons (Fig 13, J and K). The
number of E2F-1 positive motor neurons in ALS cases was significantly greater (80.8%) than in
control cases (4.5%). There were negligible levels of nuclear E2F-1 irrespective of the disease
state. These results were reproduced using a second E2F-1 antibody that recognizes a distinct
epitope not encompassing the pRb-binding domain (data not shown). In contrast to the motor
neurons, the ALS sensory neurons were ppRb and E2F-1 negative (Fig 13, I and L).
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Figure 13 Immunohistochemical analysis of G1 to S phase regulators in human spinal
cord tissues
Lumbar spinal cord sections from 18 ALS and 9 non-neurological disease controls were
immunostained for cyclin D1 (A-C), CDK4 (D-F), hyperphosphorylated Rb (ppRb, G-I), and
E2F-1 (J-L). AEC was used to stain the antigens of interest (red) and each section was
counterstained with hematoxylin. In relation to Table 2, panels represent cases C 2 (A, J), C 1
(D, G), ALS 4 (B, C), ALS 11 (E, F), ALS 5 (H, I) and ALS 8 (K, L). All insets are of the same
cases as the lower magnification. Original magnifications: X200 (A to L); X400 (all insets).
Reprinted from Am J Pathol 2003, 162:823-835 with permission from the American Society for Investigative
Pathology.
2.4.2.  Cellular distribution of cell cycle proteins in motor cortex
We next examined the expression patterns of cell cycle proteins in the motor and sensory
cortex (pre- and post-central gyrus) of control and ALS patients. All ALS cases except one (ALS
10, Table 2) exhibited substantial loss of Betz cells and the presence of gliosis were used to
identify the motor cortex when all Betz cells were absent. While cyclin D1 expression was
largely cytoplasmic in any remaining large pyramidal neurons (Betz cells) of the motor cortex of
ALS patients (Fig 14, A and B), CDK4 immunoreactivity was both nuclear and cytoplasmic in
these neurons (Fig 14, D and E). There was variation in the level of CDK4 immunoreactivity
within the motor cortex of ALS patients, though this did not correlate to any reported clinical
information for the patients. The cortical neurons in the post-central gyrus of these patients
exhibited little immunoreactivity for cyclin D1 or active CDK4 (Fig 14, C and F).
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Figure 14 Immunohistochemical analysis of G1 to S phase regulators in human motor
cortex
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Precentral and post-central gyrus from 18 ALS and 9 non-neurological controls were
immunostained for cyclin D1 (A-C), CDK4 (D-F), hyperphosphorylated Rb (ppRb, G-I), and
E2F-1 (J-L). AEC was used to stain the antigens of interest (red) and sections were
counterstained with hematoxylin. In relation to Table 2, panels represent cases C 1 (A, D, G, J),
ALS 1 (B, C, H, I), ALS 4 (E, F, K, L). All insets are of the same cases as the lower
magnification. Original magnifications: X200 (A to L); X400 (all insets). Reprinted from Am J Pathol
2003, 162:823-835 with permission from the American Society for Investigative Pathology.
Hyperphosphorylated pRb (ppRb) was detected predominantly in the nucleus of many
cortical neurons in the pre-central gyrus of ALS patients but not in control cases (Fig 14, G and
H). The reactivity of ppRb in the cortical sensory neurons was low or negligible (Fig 14 I). E2F1
immunoreactivity was observed in the cytoplasm of neurons in the ALS motor cortex with no
protein detected within control tissues (Fig 14, J and K). E2F-1 immunoreactivity was absent in
the post-central gyrus (Fig 14 L). It is interesting to note that one ALS case lacking loss of upper
motor neurons (ALS case #13, Table 2) exhibited little immunoreactivity for these G1 to S phase
cell cycle regulators.
2.4.3. Distribution of cell cycle proteins in white matter of ALS spinal cord and
motor cortex
Subsequently we investigated the presence of these proteins in cells with a glial
morphology. We observed moderate immunoreactivity for cyclin D1 and CDK4 in cells with
astrocytic morphology in the white matter of ALS lumbar spinal cord (data not shown). ppRb
immunoreactivity appeared nuclear in the spinal cord white matter cells of ALS patients but not
in control cases (Fig 15A). Furthermore, glial cells with morphology of activated astrocytes in
the ALS lumbar spinal cord tissues were E2F-1 immunoreactive (Fig 15B). In the motor cortex,
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ppRb was cytoplasmic in cells of the ALS white matter but not in control cases (Fig 15C). In
consecutive sections, GFAP positive astrocytes were ppRB and E2F-1 positive (asterisk in
Fig15, C-E). Some GFAP labeled astrocytes were E2F-1 positive but ppRb negative (arrowheads
in Fig15, D-E).
                 
Figure 15 Immunohistochemical analysis of ppRb and E2F-1 in glia in the white matter
of ALS spinal cord and motor cortex
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Hyperphosphorylated Rb (ppRb) was in the nucleus of cells in the white matter of ventral horn of
ALS spinal cord (A), while E2F-1 was cytoplasmic in cells that have an astrocytic morphology in
ALS ventral horn white matter (B). However, both ppRb and E2F-1 appeared in the cytoplasm of
cells in the motor cortex of ALS patients (C, D). Panels C, D and E represent ppRb, E2F-1 and
glial fibrillary acidic protein (GFAP) staining in consecutive sections, with the arrow marking a
blood vessel as landmark. The asterisk indicates a ppRb+GFAP+E2F-1+ cell, and arrowheads
indicate E2F-1+GFAP+ cells. AEC was used to stain the antigens of interest (red) and each
section counterstained with haematoxylin. Each panel is at a X200 magnification with the insets
at X400. In relation to Table 2, panels represent cases ALS 8 (A), ALS 9 (B), ALS 4 (C, D, E).
Reprinted from Am J Pathol 2003, 162:823-835 with permission from the American Society for Investigative
Pathology.
2.4.4.  Co-localization of ppRb, E2F-1 and p53 in ALS motor neurons using laser
scanning confocal microscopy
E2F-1 can transactivate tumor suppressor proteins such as p53 and p73, expressed in
response to DNA damage. A more detailed analysis of p53 in human post-mortem ALS tissues
will be presented in Chapter 3. To determine if ppRb, E2F-1 and p53 co-localize in the
remaining motor neurons in the spinal cord and motor cortex, confocal microscopy was utilized.
ALS spinal cord motor neurons that exhibited increased ppRb also demonstrated increased E2F-
1 (68.5% of the motor neurons) and p53 (61%) (Fig 16, A and B). A total of 61 ALS motor
neurons were counted. Abundant nuclear co-localization was specific in diseased lower motor
neurons but not in control cases. In these studies, E2F-1 immunoreactivity was also present in
the nucleus, contrasting the results from light microscopy or Western immunoblotting. While
ppRb co-localized with E2F-1 in the remaining neurons (63.3% of 30 counted) in the ALS motor
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cortex, there was no immunoreactivity of p53 detected in the motor neurons that expressed ppRb
and E2F-1 (Fig 16, C and D).
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Figure 16 Immunohistochemical co-localization analysis of ppRb, E2F-1 and p53 in
motor neurons of ALS spinal cord (A, B) and motor cortex (C, D)
Each of the panels are spilt into 4 quadrants with the top left representing antigen stained with a
secondary antibody conjugated to a red dye (Cy5/Cy3) and the top right the antigen stained with
a secondary antibody conjugated to a green dye (Alexa green), the bottom left represents the
merged image with regions of protein co-localization appearing yellow and the bottom right
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remaining empty. The left and right sides represent control and ALS sections stained for the
proteins pairs, respectively. All figures are at X400 magnification.
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Figure 17 Immunohistochemical co-localization analysis of ppRb, E2F-1 and p53 in
activated astrocytes of ALS spinal cord (A-C) and motor cortex (D-F)
GFAP is labeled with alexa green and the G1 to S phase regulators with Cy5 (red). (A-C) The
merge panel shows GFAP(+) astrocytes that are  ppRb+ (A), E2F-1+ (B), and p53+ (C).
Arrows indicate astrocytes and arrowheads in merge panel (grey matter, GM) indicate motor
neurons.
(D to F) GFAP(+) astrocytes in the motor cortex that are also positive for ppRb (nuclear, D),
E2F-1 (cytoplasmic, E) and p53 (nuclear, F). All figures are at a magnification X400.
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Figure 18 Immunohistochemical co-localization analysis of ppRb, E2F-1 and p53 in
activated microglia of ALS spinal cord (A-C)
Activated microglia have been labeled with alexa green with the G1 to S phase regulators
labeled with Cy5 (red). Control panels are largely negative for all proteins. The merge panel
shows CD68 (+) microglia that are  ppRb+ (A), E2F-1+ (B), and p53+ (C). In the merge (grey
matter, GM) panel, the ALS spinal cord motor neurons are CD68(-) but positive for ppRb
(nuclear, A), E2F-1 (cytoplasmic, B), and p53 (nuclear, C).
2.4.5. Co-localization of ppRb, E2F-1 and p53 in the white matter of ALS spinal
cord and motor cortex using laser scanning confocal microscopy
To corroborate the white matter staining at the level of light microscopy, the expression
of these proteins in activated astrocytes and microglia of the spinal cord was analyzed using anti-
GFAP and anti-CD68 antibodies, respectively. In the spinal cord, while ppRb and p53 appeared
nuclear in GFAP positive activated astrocytes (Fig 17, A and C), E2F-1 localized in the
cytoplasm and proteoplasmic processes of activated astrocytes (Fig 17B). In the motor cortex,
ppRb and p53 were nuclear and E2F-1 was cytoplasmic in the activated astrocytes (Fig 17 D, F
and E). Both ppRb and p53 appeared diffused in activated microglia (Fig 18, A and C). E2F-1
immunoreactivity in the cytoplasm and the processes of activated microglia (Fig 18B).
2.4.6. Analysis of protein levels by Western immunoblotting
To determine if altered immunostaining correlates to increased protein levels in control
and ALS spinal cords, we performed immunoblot analysis using total cell lysates from lumbar
spinal cord tissues for 18 ALS and 9 control cases. We show representative data from ten ALS
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and six control cases (Fig 19). The level of ppRb was significantly increased in the spinal cord of
ALS patients, though the predominant pRb family member phosphorylated is p130 (Fig 19A &
B). There was also an increase in phosphorylated Rb in nuclear extracts while it was undetected
in post-nuclear supernatants (data not shown). We failed to detect altered levels of total pRb in
nuclear extracts from control or ALS spinal cord, suggesting that phospho-pRb results from
phosphorylation of pre-existing pRb (data not shown). Cyclin D1, CDK4 and E2F-1 expression
exhibited increased levels in the total cell lysates (Fig 19A & B). Increased levels of Cyclin D1,
ppRb and E2F-1in ALS extracts were statistically significant (p ≤ 0.05). E2F-1 was increased
specifically in soluble post-nuclear supernatants but undetectable in the nuclear fraction from
spinal cord of ALS patients (data not shown). All protein levels were normalized to levels of
actin and quantitated to demonstrate statistical significance of these findings (Fig 19).
We further examined protein expression in the motor cortex by immunoblot analysis.
There was a decrease in levels of cyclin D1, CDK4, and E2F-1 in total cellular extracts (Fig
19C). This decrease was statistically significant for cyclin D1 (p ≤ 0.05). Hyperphosphorylated
pRb (ppRb) was undetectable in the total cell extracts. However, we did notice a significant
accumulation of ppRb in nuclear extracts of ALS patients but not in the post-nuclear
supernatants (data not shown). Also, Increased levels of cyclin D1 and E2F-1 were present in
post-nuclear supernatants (data not shown). There was a significant 2-fold increase in the levels
of active CDK4 in the nuclear fraction by immunoblot correlating with nuclear CDK4
immunoreactivity as noticed in many of the ALS cases (data not shown).
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Figure 19 Protein levels in total cell extracts from human spinal cord and motor cortex
Protein extracts from lumbar spinal cord (A) and motor cortex (B) tissues of ten ALS (ALS 4 to
7, 13 to 18; Table 1) and six non-neurologic age-matched controls (C1, C4 to C7, C9; Table 1)
were prepared as described in the Material and Methods. 150mg of protein from each extract
were loaded on SDS-PAGE and the resulting blots probed with antibodies specific to each
protein. Immunoblots were repeated twice and all data quantified using NIH 1.58 software
densitometry normalized to levels of actin in each sample. (A) Immunoblots of lumbar spinal
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cord total cellular extracts with the following lane assignments: P – Positive control (ppRb),
Lanes 1-6 – Control cases, Lanes 7-16 – ALS cases; (B) and (C) are densitometric quantified
representation of total cellular extracts from spinal cord and motor cortex, respectively with the
bars denoting mean ± standard deviation. Black bars are control cases (n = 6) and the gray bars
are ALS cases (n = 10). ND indicates non-detectable levels. Statistical analysis was performed
using single-factor ANOVA and asterisks indicate p £ 0.05. In 19B, the p value for Cyclin D1,
ppRb and E2F-1 was 0.046, 0.034 and 0.044, respectively. In 19C, the p value for Cyclin D1 was
0.04. Reprinted from Am J Pathol 2003, 162:823-835 with permission from the American Society
for Investigative Pathology.
2.4.7. DNA-binding activity of E2F-1
We next examined the DNA-binding activity of E2F-1 in control and ALS patients as a
measure of E2F-1 functional activity. To evaluate DNA binding activity, gel mobility shift
assays (EMSA) were performed using nuclear extracts from spinal cord and motor cortex, with
extracts from proliferating NIH3T3 cells as positive control (see section 2.3.6). We first
demonstrated that the very sensitive EMSA could detect nuclear E2F-1 that was below the limits
of detection by immunoblot. The spinal and cortical nuclear extracts contained E2F-1 protein
that bound the recognized E2F-1 binding element with specificity as demonstrated by
competition with excess wild type cold oligos but not with excess mutant or unrelated oligos (Fig
20A). In Figure 20A, the slowest migrating complex is competed away by excess unlabelled
oligos but not by mutant or unrelated and were interpreted to contain E2F-1. We next used
nuclear extracts from proliferative 3T3 cell nuclear extracts as positive control (lane 2 in left
panel of 20B) and competed the E2F-1 complex with increasing levels of excess cold oligo (Fig
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20B, lanes 3 and 4). We next examined nuclear extracts of control and ALS spinal cord and
motor cortex for E2F-1 DNA binding activity (Fig 20B). Densitometric measurement of the
protein:DNA complex indicates no significant change in the intensity of DNA binding in spinal
cord (p = 0.189) or motor cortex (p = 0.724) of ALS patients when compared to age-matched
controls (Fig 20B&C).
Figure 20 E2F-1 DNA binding activity is unaltered in ALS
Nuclear extracts from spinal cord and motor cortex tissues of six ALS (case # 3-5, 9, 12 and 13,
Table 2) and three non-neurologic age-matched controls (case # 1,2,3, Table 2) were used for
electrophoretic gel mobility shift assay (EMSA). (A) is a competition EMSA using radiolabeled
E2F-1 oligo and spinal cord nuclear extracts (25mg) indicating a concentration dependent
competition (lanes 3 – 5) when excess cold oligos were used in the binding reaction. The
complexes remain unaltered when excess mutant oligos (lanes 6 – 8) were utilized in the binding
reactions. Lane assignments were as follows: Lane 1: Free probe, Lane 2: Hot probe, Lanes 3 –
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5: Excess cold oligos (3ng, 30ng, and 100ng, respectively), Lanes 6 – 8: Excess mutant oligos
(30ng, 100ng, and 300ng, respectively). (B) is an EMSA using radiolabeled E2F-1 oligo and
spinal cord nuclear extracts. Spinal cord gel lane assignments: 1: Free probe alone, 2: Positive
control (3T3 cells), 3: Positive control with 3 ng cold oligo, 4: Positive control with 100 ng cold
oligo, 5 – 7: Control cases (C1 – C3 from Table 1), 8 - 13: ALS cases (ALS 3-5, 9, 12, 13 from
Table 1). (C) is an EMSA using radiolabeled E2F-1 oligo and motor cortex nuclear extracts.
Motor cortex gel lane assignments: 1: Free probe alone, 2: Positive control (3T3 cells), 3 – 5:
Control cases, 6 – 11: ALS cases (case # 3-5, 9, 12, 13 from Table 1). The E2F-1:DNA complex
and free probes are indicated to the left of the figure. (D) depicts densitometric measurement of
the E2F-1: DNA complex using NIH 1.58 software. Controls are denoted in black bars (n = 3)
and ALS cases in stippled bars (n = 6). The p-values were 0.189 for spinal cord extracts and
0.724 for motor cortex using single-factor ANOVA with a 95% confidence interval. Reprinted
from Am J Pathol 2003, 162:823-835 with permission from the American Society for
Investigative Pathology.
2.5.  Discussion
A delicate balance of signals regulates cellular homeostasis. Activation of cell cycle
proteins via extracellular signals can be toxic to post-mitotic neurons in a number of model
systems. We initiated this study to explore improper cell cycle activation and altered nuclear
events as a possible mechanism in SALS. Aside from a previously published brief report and a
study in a G37R mutant SOD1 transgenic mouse [121, 244], this is the first study examining a
role for the G1 to S phase cell cycle proteins in pathogenesis of ALS [122]. We present evidence
for nuclear accumulation of hyperphosphorylated pRb (ppRb) with concurrent increase in
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cytoplasmic E2F-1 immunoreactivity suggesting a role for aberrant activation of G1 to S phase
regulators.
Increased levels of cyclin D1 and its associated kinase, CDK4, in motor neurons of the
affected region in ALS patients suggest aberrant re-activation of the cell cycle. The activation of
G1 to S phase cyclins results in hyperphosphorylation and inactivation of the retinoblastoma
proteins (ppRb). Post-mitotic motor neurons in ALS post-mortem tissues that exhibit altered
levels of the regulators of the restriction point, namely ppRb and E2F-1, are considered to have
“re-entered” the cell cycle. Sample-to-sample variation is likely due to the inherent cell type
heterogeneity of the tissue sample extracts or due to protein degradation that may occur during
the tissue extraction procedure.
During ALS, cellular insults to motor neurons can cause an aberrant activation of motor
neurons and other cells into the G1 phase of the cell cycle. While conditions may not permit
DNA replication and completion of the cell cycle, cell cycle proteins may increase the
vulnerability of motor neurons to further toxic damage and cause apoptosis by reducing the
threshold for cell death. The tumor suppressor, p53, is an important protein in making a cell’s
decision to either arrest cell cycle or direct it towards apoptosis. The finding that G1 to S phase
regulators (ppRb and E2F-1) are present in the same motor neurons that show aberrant levels of
p53 in the lower motor neurons suggests that transactivation of genes downstream of E2F-1
(such as p53) can direct a cell to apoptose. It is intriguing that the remaining Betz cells in the
cortical region of ALS subjects showed no immunoreactivity to p53. A more detailed analysis of
p53 and discussion related to the dichotomous pattern of p53 immunoreactivity will follow in
Chapter 3.
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Improper activation of the cell cycle in motor neurons will alter the function of DNA
binding proteins that can affect overall chromatin structure, thus permitting additional DNA
damage via oxidative injury. Modifications to histones or E2F-1 itself can greatly affect the
association of pRb/E2F-1 and transcriptional activity of E2F-1 or apoptosis [364]. ALSIN, a
putative guanine exchange factor that has sequence homology to RCC1 (regulator of chromatin
condensation) has been implicated in familial ALS (FALS) [91, 107]. RCC1 acts on RAN, a
protein involved in nuclear import and export. Mutation in a protein that is homologous to a
regulator of chromatin structure may make the cell more susceptible to DNA damage. DNA
damage can be exacerbated by various endonucleases that signal various cell death pathways.
One of the intriguing results of our study was immunohistochemical data that indicates an
altered localization of the E2F-1transcription factor. Such alterations have been observed in
studies using AD and SIV-E tissues [121, 245, 355, 362]. The E2F gene family comprises six
members sharing homology in the Rb-binding domains [223, 225, 347]. These isoforms complex
with the Rb family of proteins at different and defined periods of the cell cycle controlling gene
expression within the G1 phase. The different binding states can translate to differences in
subcellular localization of these proteins [365]. The re-distribution of E2F-1 during ALS may
result from the formation of alternative protein:protein complexes containing E2F-1 or the
retention of newly synthesized E2F-1 in the cytoplasm. Alternatively E2F-1 protein contained in
the nucleus may not be recognized by the monoclonal antibody raised against the Rb-binding
epitope and used throughout this study. To discern this, a second anti-E2F-1 antibody was
utilized whose antigenic determinant site does not encompass the Rb-binding domain. Identical
results were obtained with this antibody. Confocal microscopic results however indicate some
E2F-1 immunoreactivity in the nucleus. This might be due to the higher sensitivity of the laser
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scanning confocal microscope to identify low amounts of nuclear E2F-1. Nevertheless, the role
of cytoplasmic E2F-1 in motor neuron cell death warrants further investigations within well
defined in vitro model systems.
To examine the functional role of E2F-1 in the nucleus, gel shift assays were performed
to determine DNA binding activity of E2F-1. The DNA binding activity of E2F-1 in the spinal
cord and motor cortex did not show a significant difference between controls and ALS cases.
This suggests that any changes in E2F-1 transactivational activity may be transient with a greater
tendency for re-distribution into the cytoplasm. An alternate explanation to the cytosolic
accumulation may be alterations in protein turnover. Reduced protein degradation through
proteasomal inhibition may result in increased cytosolic E2F-1. In fact, ubiquitin positive protein
aggregates are neuropathological hallmarks of ALS [67, 68, 73, 74]. Increased E2F-1 and p53
immunoreactivity was also found in the white matter of ALS spinal cord suggesting that cell
cycle proteins in microglia and astrocytes may play a role in ALS. Activated glia can secrete
neurotoxic substances such as cytokines and chemokines, which affect the neuronal milieu and
result in neuronal death.
E2F-1 de-repression by pRb hyperphosphorylation leads to increased expression of
downstream targets such as p53, p73, p14ARF, Apaf-1 and cytochrome c, which are involved in
cell death pathways [366-370]. Although there are reports indicating an increased expression of
p53 in both spinal cord and motor cortex further studies are required to examine the levels of
other proteins regulated by E2F-1 [197]. p53 may directly activate pro-apoptotic genes [371].
Synergism between loss of pRb and activation of E2F-1 has been shown to contribute to p53-
induced apoptosis [366, 372]. In addition, accumulated DNA damage through chromatin
remodeling and de-repression of E2F-1 may contribute to p53-mediated apoptosis.
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The data presented supports a model in which motor neurons are stimulated to enter the
G1 phase of the cell cycle during ALS and activate cell cycle regulating proteins such as pRb
and E2F-1, which assist in regulating motor neuron cell death (Fig 21). We have found increased
levels of cyclin D1 and active CDK4 in the ventral spinal cord and motor cortex of ALS patients,
concurrent with increased phosphorylation of pRb at a site (ser795). In addition, we have
identified increased levels of E2F-1 protein in the cytoplasm of ALS motor neurons. These cell
cycle-related changes may not be the cause for motor neuron death but would most likely reflect
an event as a consequence of neuronal injury. This aspect however cannot be directly inferred
from our study as it pertains to tissues from end-stage of disease. Further functional studies using
in vitro cultures as enumerated in Chapter 7 can be performed to validate our current study.
            
Figure 21 Model of motor neuron cell death induced by activation of cell cycle proteins
In an adult post-mitotic neuron reduced levels of cyclin D-CDK4 results in repression of gene
expression by the interaction of pRb with E2F-1. Also, TRAF proteins complexes with death
receptors (DR) such as p75NTR blocking cell death. However, upon extracellular signals,
increased levels of cyclin D-CDK4 result in hyperphosphorylation of pRb (ppRb) with release of
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E2F-1. Transcriptional activity of E2F-1 results in initiating death signals via induction of
p14ARF, p53, Bax, Apaf-1, and cytochrome C (Cyt C), apoptotic regulators that would in turn
activate pro-apoptotic proteins such as caspase-9 and caspase-3. Alternatively, E2F-1 in the
cytoplasm may interact with TNF receptor associated factors (TRAF) and permit DR mediated
cell death. Activation of these pathways may sensitize the neuron to further toxic insults that
pushes the susceptible neuron towards death. Reprinted from Am J Pathol 2003, 162:823-835 with
permission from the American Society for Investigative Pathology.
The results from this body of work are corroborated by a murine study, which
demonstrates increased expression of CDK4/cyclin D1 and hyperphosphorylation of pRb [244].
This G37R SOD1 mouse model of ALS does not reveal any changes in levels of CDK2 or CDK6
and the authors have not reported anything related to proteins downstream of ppRb [244].
Whether other mouse models will reveal similar changes as from our human post-mortem study
is speculative. However our study of a role for G1 to S phase regulators in ALS coupled with
studies in other neurodegenerative diseases have led to a hypothesized link between oxidative
damage and abortive cell cycling in post-mitotic neurons [373, 374]. Unless more studies
indicate the existence of ploidy supporting the one study performed in AD, and the presence of
G2 to M phase markers in vitro, the theory of an “abortive cell cycling without S phase
progression” in neuronal death will predominate. Future studies will further define the
intracellular signaling pathways involved in cell cycle activation and explore the functional role
of p53 in motor neuron cell death. These studies may reveal that an abortive cell cycling event in
susceptible populations of neurons can lead to a caspase-dependent or caspase-independent
(AIF-mediated) neuronal death.
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3. Neuronal Cell death in ALS: Role of p53 mediated apoptosis
3.1.  Abstract
Apoptosis is a mechanism of cell death reported to occur in many neurodegenerative
diseases, including ALS. Furthermore, the demonstration that caspase inhibitors delay disease
onset and prolong survival in animal models of ALS directly link this energy-dependent mode of
cell death to motor neuron death during ALS (see Chapter 1). We have demonstrated a role for
G1 to S phase regulators in ALS with alteration in the levels of ppRb, E2F-1 and p53 (Chapter
2). We further hypothesize that altered levels of p53 will have a role in motor neuron death
during ALS with concurrent changes in the levels of apoptotic death markers. For this study we
utilized archived human post-mortem motor cortex and spinal cord tissues of ALS and age-
matched non-neurological controls. Through the use of western immunoblotting, light
microscopy as well as laser scanning confocal microscopy, we report elevated levels of nuclear
p53 in remaining ALS spinal cord motor neurons but not the surviving neurons in the motor
cortex. In addition, we demonstrate increased protein levels of Bax, Fas, caspases-8 and -3 in
ALS spinal motor neurons. While caspase-3 and TUNEL stained neurons were also positive for
ppRb, E2F-1 and p53 in spinal motor neurons, we failed to observe this trend in Betz cells in the
motor cortex of ALS subjects. In conclusion we have linked the aberrant re-activation of G1 to S
phase cell cycle regulators to an apoptotic mode of cell death in a p53-dependent manner in ALS
spinal cord motor neurons.
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3.2.  Introduction
The control of cell proliferation or growth arrest is intimately linked to the control of
programmed cell death or apoptosis. Cell cycle components such as pRb, E2F and p53 function
in both cell cycle progression and apoptosis. In fact the promoters of p53, p73, human
cytochrome c1 and apoptotic protease activating factor 1 (APAF1) contain E2F-1 binding sites
suggesting a direct E2F-1-mediated transcriptional regulation [369, 370, 375, 376]. b-amyloid-
mediated toxicity in PC12 cells was found to be mediated by the E2F-1 – p53 – Bax pathway and
the over-expression of E2F-1 in these cells led to the induction of p53 (by E2F-1) and Bax (by
p53) proteins, as well as nuclear fragmentation [377]. These studies directly link E2F-1 to p53
and apoptosis. As the “guardian of the genome”, p53 regulates the cell cycle by triggering
growth arrest or apoptosis due to the presence of errors in DNA acquired during replication or
inability to properly repair DNA damage. Depending on the cell type, over-expression of p53 can
result in either cell growth arrest or apoptosis [226-229]. Conversely, a knockout of p53
produces resistance to apoptosis with the mice typically dying from T-cell lymphomas [230,
378]. Thymocytes from these mice are resistant to DNA damaging agents such as ionizing
radiation and topoisomerase II inhibitors (etoposide) but not to cell death induced by
glucocorticoids or phorbol ester [379]. Thus both p53-dependent and independent cell death
pathways exist. Furthermore, efficient p53-dependent apoptosis is through DNA strand breaks.
Upon completion of synaptogenesis during brain development, adult neurons enter a
quiescent G0 phase. The action of various toxins such as reactive oxygen species or glutamate
can push the neuron into G1. This inappropriate or untimely transition can initiate an apoptotic
response. Indeed both in acute and chronic neurological disease models, a role for aberrant cell
cycle re-activation leading to an increase in p53 function and subsequent apoptosis of neuronal
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cells have been established. These cell death studies include paradigms of b-amyloid, presinilin-
1, DNA damage, oxidative stress, depolarization, and 6-hydroxydopamine (6-OHDA) [380-389].
Inhibition of p53 through the use of antisense and dominant negative constructs protects neurons
from this wide array of insults [383, 388].
While cell death during ALS is believed to be apoptotic in nature, this is an area of active
research and debate. The debate stems from the fact that ALS is a chronic neurodegenerative
disease and apoptosis typically is rapid and occurs early during disease pathogenesis.
Morphological studies involving apoptotic features in SOD1 transgenic models report a high
degree of vacuolation evident in ALS spinal motor neurons. Although vacuoles are not as
evident in human post-mortem tissues, other apoptotic features such as chromatolysis,
somatodendritic attrition and nuclear condensation have been reported [288]. However, factors
such as plausible relatively quick disappearance of apoptotic bodies resulting in low numbers of
apoptosis-positive motor neurons have impeded a clear morphological analysis of apoptosis in
ALS motor neurons. Increased levels of other apoptotic markers such as the carbohydrate antigen
LeY, fractin, p53, Bax, activated caspases, and the apoptosis-related prostate apoptosis response-
4 (PAR-4) proteins lend support for an apoptotic mode of cell death in ALS [119, 126, 127, 197,
266, 290, 305, 390-394]. It is plausible that apoptosis is a relevant mechanism albeit not the only
one in ALS.
Defective DNA repair and enhanced DNA damage are evident in ALS motor neurons
[140, 195, 203, 395]. Increased p53 with concomitant elevation in DNA binding activity has
been demonstrated in motor neurons and astroglia of the affected regions of ALS patients but not
that of controls [197]. These studies are corroborated with studies in an ALS transgenic mouse
over-expressing mutant G86R SOD1 protein [396]. Collectively, these studies suggest a
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functional role for p53 and apoptosis during neurodegenerative diseases. However, the role of
p53 has been questioned due to results obtained from other SOD1 mice studies. One group
generated double transgenics by mating p53-/- mice with the mice expressing the high copy
number G93A mutation (G93A+) [397]. To summarize their results, they reported that the lack
of p53 did not alter disease onset or progression in the double transgenics. Another similar study
(with low copy number G93A mutant mice) reported identical results [398]. The pre-
symptomatic G93A mice in the second study displayed disease-associated vacuoles irrespective
of the genotype of p53. The two reports challenging the role of p53 can however be explained as
a mechanism exclusive to FALS or that there are sequential activation of p53-dependent and -
independent modes of multiple types of cell death (apoptosis, necrosis or paraptosis). Overall,
the role for p53 in ALS remains controversial and unclear.
Amongst the pro-apoptotic genes that p53 regulates are BAX, Apaf-1, SIVA, PUMA and
Fas [371, 399-402]. Pro-apoptotic protein levels such as that of active homodimeric Bax, Bad,
Bid, and Harakiri levels are increased in vulnerable CNS regions in ALS patients [119, 392, 396,
403, 404]. Conversely, the levels of anti-apoptotic proteins such as Bcl-2 and Bcl-XL are
decreased. These alterations in the G93A SOD1 transgenic mice are significantly noticeable as
the neurodegenerative process progresses. In animal studies, the pro-apoptotic proteins activate
caspases that effect the final death blow to the motor neuron. The role for caspases in ALS is
supported by the reports of caspase inhibitors significantly reducing motor neuron death in G93A
mice and PC12 cells [290]. Increased activity of caspase-1, an inflammatory-associated protease
and caspase-3, the effector protease has been reported in human spinal cord as also in G37R,
G85R and G93A SOD1 transgenics [126]. Caspase-12, associated with ER stress has also been
implicated in ALS [405]. In addition the TNF-a / caspase-8 pathway has been associated with
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being a delayed contributor to the degenerative process in a mouse model of ALS [404]. Bax
through the apoptosome / mitochondrial pathway and Fas via the death-receptor / caspase-8
pathway activate the effector caspase (caspase-3), which result in DNA fragmentation.
Programmed cell death involving the Fas / caspase-8 / caspase-3 apoptotic cascade has been
documented in embryonic motor neurons and also in primary motor neurons from the G37R,
G85R and G93A mutant SOD1 ALS transgenics [406].
In spite of all these reports, there is no study addressing the role for p53 and an apoptotic
death cascade downstream of aberrant activation of G1 to S phase regulators. Therefore we
hypothesized that alterations in the cell cycle regulator, p53, will result in concurrent changes in
apoptotic death markers during ALS (Fig 12). We present evidence for increased accumulation
of p53 in the nucleus of ALS spinal cord motor neurons but not neurons of the motor cortex. The
lack of p53 in the motor cortex contradicts previous reports [197]. Laser scanning confocal
microscopy demonstrates that the G1 to S phase cell cycle regulators co-localize with markers of
apoptosis (TUNEL and Caspase-3). Hence, these results suggest a role for p53 and caspases in
conjunction with aberrant re-activation of cell cycle regulators during ALS.
3.3.  Materials and Methods
Protocols for source of tissue samples (2.3.1), immunohistochemistry for light
microscopy (2.3.3), protein extraction (2.3.4), immunoblotting (2.3.5) and statistical analysis
(2.3.7) are described in detail under section 2.3.
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3.3.1.  Antibodies
Monoclonal antibodies were used to detect p53 (Santa Cruz, DO-1), and FAS (Santa
Cruz, B10). Polyclonal antibodies were utilized to detect Actin (Chemicon), BAX (Pharmingen),
Caspase-3 (Cell Signaling), Caspase-8 (Biomeda), p73 (Santa Cruz, H79). For light microscopy,
these antibodies were utilized at dilutions of 1:100 (Caspase-8), 1:150 (p53, Caspase-3, BAX),
1:200 (BAX). For confocal laser scanning microscopy, we used primary antibody concentrations
of 1:80 (ppRb, p53, Caspase-3, Caspase-8, Fas), 1:60 (E2F1).
3.3.2.  Electrophoretic Mobility Shift Assay (EMSA)
Gel mobility shift assays were performed as described in section 2.3.6 with the following
modifications. The sequences used to probe for p53 specific DNA binding activity were: WT
p53 5’-TACAGAAC A T G TCTAAGCATGCTGGGGACT -3’; MT p53 5’-
TACAGAATCGCTCTAAGCATGCTGGGGACT -3’. For competition reactions, unlabeled p53
competitor (3, 30, and 100ng) or unlabeled unrelated competitor (5’-
GATCATTCAGGTCATGACCTGA-3’; 100, and 300ng) oligos were preincubated with the
protein for 5 min on ice prior to addition of labeled probe. The positive control for p53 DNA
binding activity was camptothecin-treated SHYSY5 neuroblastoma cells.
3.3.3.  Terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end
labeling staining (TUNEL)
DNA fragmentation was assayed using the fluorescein based apoptosis detection system
as per manufacturer’s instructions (Promega, USA). Briefly, paraffin embedded sections were
processed as for immunohistochemistry and post-blocking were treated with Proteinase K
97
(20mg/ml) for 15m. They were then incubated with TdT enzyme / nucleotide mix for 1h at 37oC.
For double labeling with confocal laser scanning microscopy, the sections were immunolabeled
with p53 or ppRb after TUNEL labeling. Negative (no enzyme) and positive (DNase I treated)
samples were utilized. Motor neurons positive for TUNEL and cell cycle proteins (ppRb, p53)
were quantified. A total of 30-40 and 20-30 motor neurons in the spinal cord and cortex were
counted respectively at X400 magnification. The study was conducted in a blinded fashion using
11 ALS and 6 age-matched control cases.
3.4.  Results
Aberrant re-activation of G1 to S phase cell cycle proteins can have downstream effects
on cell survival by activating molecules such as p53. To further characterize the role of p53 and
apoptosis in neuronal cell death during ALS, we investigated the levels of p53, Bax, Fas,
Caspases-8 and -3 in human post-mortem tissues from ALS and age-matched control cases. As
described in the previous chapter, we utilized tissue samples from both lumbar spinal cord and
motor cortex (mid- and superior-motor cortical region). The dorsal horn of the spinal cord and
sensory cortex were the internal controls for immunohistochemistry.
3.4.1.  Analysis of death marker protein levels by Western immunoblotting
Western immunoblotting was performed using nuclear, soluble and total tissue lysates
from lumbar spinal cord and motor cortex of 18 ALS and 10 control cases. We show
representative immunoblots from 3 controls and 6 ALS (Fig 22, A and B (Fas and Caspases))
and 5 controls and 7 ALS (Fig 22B, p53 and p73). All immunoblot signals were normalized to
actin and quantitated as previously described. The levels of activated p53 were significantly
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increased in the nuclear extracts and the total lysates of ALS spinal cord (Fig 22, A and B). Since
p53 can transactivate pro-apoptotic molecules such as Bax, we examined the levels of Bax and
other pro-death proteins such as Fas, caspase-8 and caspase-3. Interestingly, the level of the
transmembrane receptor, Fas, was increased in the nuclear lysates in addition to the total tissue
lysate (Fig 22, A and B).
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Figure 22 Increased p53 and death markers in ALS spinal cord tissue lysates
(A) Quantitation of protein expression in nuclear extracts from spinal cord. Black bars are
control cases (n=3) and the gray bars are ALS cases (n=6). Statistical analysis was performed
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using single-factor ANOVA and asterisks indicate p£ 0.05. The p values for p53 and Fas were
0.0006 and 0.089, respectively. All of these were normalized to Actin.
The respective immunoblots are also presented below the graph. “+” indicates positive control,
lanes 1 to 3 are control cases and lanes 4 to 9 are ALS cases.
 (B) Quantitation of protein expression in total tissue extracts from spinal cord. Black bars are
control cases (n=10) and the gray bars are ALS cases (n=18). Statistical analysis was performed
using single-factor ANOVA and asterisks indicate p£ 0.05. The p values for p53, p73, Bax, Fas,
caspase-8 and caspase-3 were 0.009, 0.75, 0.009, 0.03 and 0.018, respectively. All of these were
normalized to Actin. The p values for the ratios of active- to pro caspase-8 and caspase-3 were
0.008 and 0.008, respectively. The lane assignments for the p53, p73 and Bax immunoblots are
as follows: “+” indicates positive control, lanes 1 to 5 are control cases and lanes 6 to 12 are
ALS cases. Lanes for the Fas and Caspases are as follows: “+” indicates positive control, lanes
1 to 3 are control cases and lanes 4 to 9 are ALS cases. The arrows to the right of the BAX blots
indicate that there are two bands (p19 and p21kDa) recognized by the antibody.
We next examined protein expression in the motor cortex by immunoblot (Fig 23). In
contrast to our results from lumbar spinal cord tissues, we observed that p53 was significantly
decreased in nuclear extracts and undetectable in total lysates (Fig 23, A and B). Since E2F-1 can
also activate other members of the p53 family such as p73, we performed immunoblotting to
analyze its levels in ALS motor cortical tissues. While there was no difference in its levels in the
nuclear extracts, it was significantly decreased in the total lysates (Fig 23B). Fas and Caspase-8
exhibited no significant changes in protein levels and the levels of Bax and caspase-3 were
undetectable (Fig 23B).
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Figure 23 Decreased p53, p73 and no change in death markers in ALS motor cortex
tissue lysates
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(A) Quantitation of protein expression in nuclear extracts from motor cortex. The p values for
p53 and p73 were 0.007 and 0.68, respectively. All other details are as described for Fig 22A.
Quantitation of protein expression in total tissue extracts from motor cortex. The p values for
p73, Fas, and  caspase-8 were 0.0007, 0.62, and 0.22, respectively. The lane assignments are as
follows: “+” indicates positive control, lanes 1 to 6 are control cases and lanes 7 to 15 are ALS
cases. All other details are as described for Fig 22B.
3.4.2. Increased immunoreactivity of p53 in ALS spinal cord but not motor cortex
Western immunoblotting of tissue extracts presents the caveat of having a mixed
population of cells. Therefore we utilized immunohistochemistry to analyze cell specific and
subcellular localization of p53 in ALS tissues. Paraffin-embedded sections from lumbar spinal
cord and motor cortex of human ALS and age-matched control cases were analyzed by light
microscopy.
The percentage of p53 immunoreactive motor neurons was only 38.3% in control
subjects (Fig 24A). Much of the p53 in the control cases was cytoplasmic in its localization.
Approximately 83.5% (from a total of 200) of the spinal cord motor neurons in ALS cases
exhibited abundant nuclear accumulation of p53 (Fig 24B). It was negligible or absent in the
dorsal horn sensory neurons (Fig 24C). We then examined if p53 was increased in the surviving
Betz cells of the motor cortex. Sections at different regions of the motor cortex were analyzed for
p53 levels. p53 immunoreactivity was absent in both the motor and sensory neurons of ALS and
the age-matched controls (Fig 24, D to F).
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Figure 24 Increased immunoreactivity of p53 in spinal cord motor neurons but not in
the motor cortex
Lumbar spinal cord (A to C) and motor cortex (D to F) tissues from 18 ALS and 9 non-
neurological disease controls were immunostained for p53 using a phospho-specific anti-p53
antibody. Each panel is at X200 magnification with the insets at X400. All insets are of the same
cases as the lower magnification. Relative to panels A and D (controls), there is nuclear
abundance of p53 in ALS spinal cord (B) but not motor cortex (E). Panels C and F are the
internal controls for the respective regions.
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Figure 25 Increased immunoreactivity of death markers in spinal cord motor neurons
Lumbar spinal cord tissues from 18 ALS and 9 non-neurological disease controls were
immunostained for BAX (A to C), Fas (D to F), caspase-8 (G to I) and caspase-3 (J to L). Each
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panel is at X200 magnification with the insets at X400. All insets are of the same cases as the
lower magnification. Relative to panels A, D, G and J (controls), there is increased BAX (B),
nuclear Fas (E), caspase-8 (H) and caspase-3 (K) in ALS spinal cord motor neurons. Panels C,
F, I and L represent negative staining in unaffected sensory neurons of the ALS spinal cords.
3.4.3. Subcellular distribution of apoptotic death markers in spinal cord and motor
cortex
Similar to p53, we analyzed the distribution of other pro-apoptotic proteins by
immunohistochemistry. Bax immunoreactivity was significantly elevated in ALS spinal motor
neurons but not in the dorsal horn sensory neurons (Fig 25, A to C). Since death receptor
mediated neuronal cell death is evident during development and also in vitro, we examined the
levels of Fas, which associate with death domains containing adaptor proteins (FADD). In the
spinal cord motor neurons of ALS cases, we document increased and specific nuclear
localization for Fas (Fig 25, D to F). Caspase-8 is a downstream effector of Fas activation. We
observed increased active caspase-8 immunoreactivity in the spinal cord motor neurons (Fig 25,
G to I). Finally since both Bax and Fas-mediated death pathways converge on caspase-3, the
effector protease, we analyzed its immunoreactivity in the two affected regions of ALS cases.
We report increased caspase-3 in the spinal motor neurons (Fig 25, J to L). Furthermore,
immunoreactivity to p73 showed no difference in spinal cord or motor cortex of ALS cases (data
not shown).
In the motor cortex, there was positive BAX immunoreactivity in neurons but it was not
very specific to the remaining large pyramidal neurons (data not shown). Fas immunoreactiviy
was negligible in the large pyramidal neurons of the motor cortex (Fig 26A). Caspase-8 staining
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in the motor cortex was predominantly non-specific with little immunoreactivity (Fig 26B) and
was not significantly different from that in the control cases (data not shown). Although the
neurons in the motor cortex exhibited caspase-3 signal (Fig 26C), this was non-specific and its
immunoreactivity was also detected in the cortical neurons of control cases (data not shown).
Figure 26 No change in immunoreactivity of death markers in cortical motor neurons
Motor cortex tissues from 18 ALS and 10 non-neurological disease controls were immunostained
for Fas (A), caspase-8 (B) and caspase-3 (C). Each panel is at X200 magnification with the
insets from the same cases at X400.
3.4.4. Co-localization of cell cycle proteins and apoptotic death markers in ALS
spinal cord and motor cortex
In the previous chapter, we reported co-localization of p53 with ppRb and E2F-1 in
spinal cord motor neurons (Fig 16, A and B).
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Figure 27 Cell cycle transcription factors co-localize with death markers in spinal
motor neurons (A and B)
Lumbar spinal cord (A and B) from 11 ALS and 6 age-matched controls were labeled with the
combinations of p53 or E2F-1 (alexa green conjugated secondary antibody) with active caspase-
3 (Cy5 conjugated secondary antibody). Arrows in the control panels indicate motor neurons.
Asterisk in the Merge (ii) panel indicate ALS motor neurons that are positive for E2F-1 (A) and
p53 (B) but not caspase-3.
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 We further analyzed the co-localization of the transcriptional regulators E2F-1 and p53
with caspase-3, a marker of apoptosis, by laser scanning confocal microscopy. An increased
number of ALS spinal motor neurons exhibited co-localization of p53 / caspase-3 (36.9%) (Fig
28A) and E2F-1 / caspase-3 (21.8%) (Fig 27B). A total of 73 motor neurons from 12 tissue
sections were counted. Caspase-3 positive motor neurons in the ALS cases were not widespread,
i.e., not all motor neurons were positive for caspase-3 (asterisks in Merge (ii) of Fig 27A and B).
The motor neurons in control cases lack E2F-1 immunoreactivity and exhibited low levels of
cytoplasmic caspase-3 (<1%). However, in the few neurons of these control cases that were only
positive for p53 (12.3%) the staining was cytoplasmic. In neurons of the ALS motor cortex p53
and caspase-3 immunoreactivity was negligible or absent corroborating the results from
immunoblotting (Fig 28A). However these motor neurons were positive for ppRb (data not
shown) and E2F-1 (arrowhead in Fig 28B).
Furthermore, we observed that the death receptor Fas co-localized with caspase-8 in the
cytoplasm of spinal cord motor neurons (34.2%) (Fig 29). Both proteins were present in the
nucleus with caspase-8 also localized in the cytoplasm. The nuclear staining of Fas confirmed
the results from light microscopy. In the cortical motor neurons, there was negligible staining for
either protein (data not shown).
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Figure 28 Cell cycle transcription factors co-localize with death markers in cortical
motor neurons (A and B)
Motor cortex from 11 ALS and 6 age-matched controls were labeled with the combinations of
p53 or E2F-1 (alexa green conjugated secondary antibody) with active caspase-3 (Cy5
conjugated secondary antibody). Arrows indicate motor neurons negative for E2F-1, p53 and
Caspase-3. Arrowhead in (A) indicates ALS motor neuron that is positive for E2F-1 but not
caspase-3.
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Figure 29 Fas and Caspase-8 co-localize in spinal motor neurons
Lumbar spinal cord sections from 11 ALS and 6 age-matched controls were labeled with the
combination of caspase-8 (alexa green conjugated secondary antibody) with Fas (Cy5
conjugated secondary antibody). In the ALS motor neurons, Fas (red signal) is present in the
nucleus and co-localized with caspase-8 (yellow color in the bottom left merged image).
3.4.5.  DNA fragmentation as a marker for apoptosis
In addition to caspase-3, terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end-labeling (TUNEL) staining has been used as a measure of nicked or fragmented
DNA, a feature characteristic of apoptosis. There was increased evidence for TUNEL positive
motor neurons in ALS spinal cord but not the motor cortex.
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Figure 30 Increased DNA fragmentation in spinal but not cortical motor neurons
Lumbar spinal cord (A and B) and motor cortex (C and D) sections from 11 ALS and 6 age-
matched controls were double-labeled for TUNEL (FITC-conjugated) and p53 or ppRb (Cy-5
conjugated). Control cases exhibited negligible percentage of double positive (merge) neurons.
Arrows in A and B indicate TUNEL positive motor neurons. ppRb/TUNEL as also p53/TUNEL
were present in the same motor neuron (merge; arrowheads) in the spinal cord (A and B). The
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asterisk in (A) depicts a ppRb(+) but TUNEL(-) ALS motor neuron and the single asterisk in (B)
indicates a p53(-) TUNEL(-) healthy looking motor neuron. Arrowheads in A and B indicate
double positive ALS motor neurons. The cortical motor neurons in ALS cases appeared positive
for ppRb (C) and negative for p53 (D). In both C and D, the motor neurons appear negative for
TUNEL. Arrows indicate control motor neurons and arrowheads indicate ALS motor neurons.
Sections were also analyzed to determine if ALS spinal motor neurons that exhibited
increased ppRb or p53 were positive for TUNEL staining. While we observed about 25% (9/36)
of the ppRb positive neurons to be TUNEL positive, 30.5% (11/36) of the p53 positive motor
neurons were positive for TUNEL staining (arrowheads in Fig 30, A and B, respectively). We
also identified ppRb or p53 positive but TUNEL negative ALS motor neurons (asterisk in Fig 30,
A and B, merge (ii) panel). Approximately 75% of the motor neurons that exhibited TUNEL also
contained activated p53. Furthermore, the motor neurons that were positive both for TUNEL and
p53/ppRb appeared shrunken with fewer processes (arrows in Fig 30, A and B). The neurons that
were TUNEL negative were observed to be larger with intact somatodendritic morphology
(asterisk in Fig 30, A and B, merge (ii) panel). The control cases showed largely a lack of
TUNEL staining (absence of green signal) with little (ppRb, Fig 30A, bottom right quadrant) or
no (p53, Fig 30B, merge (ii) panel) immunoreactivity. In the motor cortex, approximately 64%
(22/34) of the remaining large pyramidal neurons were positive for ppRb (Fig 30C) while only
9% (3/34) of them were p53 positive (Fig 30D). None of the large pyramidal neurons exhibited
DNA fragmentation. There was some amount of non-specific TUNEL immunoflourescence in
small cells in the gray matter of the cortex but not in any of the surviving motor neurons (green
fluorescence in Fig 30, C and D).
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Figure 31 No change in p53 DNA binding activity in ALS motor neurons
Nuclear extracts from lumbar spinal cord and motor cortex of six ALS and three age-matched
control cases were used for EMSA. (A) Competition EMSA using radiolabeled p53 oligo and
either extract from NIH3T3 cells (positive control) (lanes 1 to 3) or spinal cord nuclear extracts
(25mg; lanes 4 to 7) indicating a concentration dependent competition (lanes 2 to 3 and 5 to 7)
when excess cold oligos were used in the binding reaction. The complex remains unaltered when
excess unrelated oligos (lanes 8 to 10) were utilized in the binding reaction. Lane assignments
were as follows: Lane 1: 3T3 extract with hot probe (HP); 2 and 3: 3T3 extract with hot probe
and excess cold oligos (3ng and 100ng, respectively); 4: Spinal cord extract (SCE) with hot
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probe (HP); 5 to 7:  SCE with HP and excess cold oligos (3ng, 30ng and 100ng, respectively); 8
to 10: SCE with HP and excess unrelated oligos (30ng, 100ng and 300ng, respectively); 11:
Free probe.
Panel B is an EMSA using radiolabeled p53 oligo and spinal cord nuclear extracts. Lane
assignments: 1: Free probe; 2 to 4: Control cases; 5 to 10: ALS cases.
Panel C is an EMSA using radiolabeled p53 oligo and motor cortex nuclear extracts. Lane
assignments: 1 to 3: Control cases; 4 to 9: ALS cases; 10: 3T3 extract with 100ng excess cold
oligo; 11: 3T3 extract with 3ng excess cold oligo; 12: 3T3 cells with probe and no cold oligo;
13: Free probe alone.
Panel D depicts densitometric measurement of the p53:DNA complex using NIH 1.58 software
indicating unaltered levels of DNA binding activity. Controls are denoted in black bars (n=3)
and ALS cases in stippled bars (n=6). The p-values were ≥ 0.05 for both the regions of the CNS
using single-factor ANOVA with a 95% confidence interval.
3.4.6.  DNA-binding activity of p53
To determine the functional status of p53 in ALS, DNA binding activity was analyzed
using nuclear extracts of spinal cord and motor cortex. [g-32P]-labeled double-stranded
oligonucleotides containing the consensus p53-binding site were incubated with 25mg of the
nuclear extracts. The p53-DNA complex formation was competed by excess unlabeled p53
oligos but not by mutant p53 oligos thus determining the specificity of the binary complex (Fig
31A). The p53 DNA binding activity in the spinal cord or motor cortex tissues showed no
significant difference in ALS cases compared to the age-matched controls (Fig 31, B to D).
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3.5.  Discussion
The balance between pro- and anti-apoptotic proteins can modulate survival and the
mode of neuronal cell death. There are many studies correlating levels of these proteins to an
apoptotic mode of cell death during ALS. However, there is no study that links aberrant
activation of G1 to S phase regulators to apoptosis in this chronic neurodegenerative disease. p53
is an important nuclear regulatory protein that plays a role both during cell cycle and apoptosis.
In fact, high expression of both cyclin D1 and p53 leads to apoptosis, similar to overexpression
of p53 and c-myc [407] or p53 and E2F-1 [408]. We report here the altered levels of p53 and
pro-death molecules of the apoptotic cascade in human ALS post-mortem tissues. Interestingly
p53 protein levels were increased in the motor neurons and glia of the ALS spinal cord but only
in glia of the motor cortex.
We have previously determined that there is an aberrant activation of G1 to S phase
regulators in ALS motor neurons marked by altered levels of ppRb and E2F-1 [122]. We have
also demonstrated the co-localization of these proteins with p53 (Section 2.4.4). This protein can
be divided into three regions: (1) the amino terminus, containing the transcriptional activation
region; (2) the central portion of the molecule containing highly conserved sequence blocks
throughout which are present oncogenic mutations; (3) the carboxyl terminus, containing both
oligomerization and nuclear localization sequences. While p53 is negatively regulated by direct
protein-protein interactions with modulators such as mdm-2 it is stabilized by the action of CDK
inhibitors such as p14ARF, which is a gene product transactivated by E2F-1. Post-translational
modifications such as phosphorylation can enhance the transcriptional activity of p53 [409].
Our Western immunoblotting results indicate increased levels of phosphorylated p53 in
the nuclear fractions of spinal cord tissue extracts. In normal conditions, p53 is a protein with a
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very short half-life and is rapidly degraded. The presence of elevated levels of p53 in ALS
patients suggests that this protein is aberrantly stabilized either by the down-regulation of
proteins that negatively regulates p53 such as mdm2 or through reduced degradation of p53 via
the proteasomal machinery. It is well documented that the proteasomal machinery is
compromised in neurodegenerative diseases such as ALS with concomitant increases in
aggregate formations. It is also possible that the p53 transcripts are better stabilized in disease
states through RNA binding proteins or post-translational modifications can affect the half-life of
p53 and its consequent activity. It is likely that the accumulation in p53 is due to these effects.
In a previous study, protein levels of nuclear p53 and its DNA binding activity was
increased in affected CNS regions of ALS patients [197]. Contrary to our expectations, we found
no significant difference in the DNA binding activity of p53 in spinal cord in spite of its
enhanced nuclear localization. This is probably due to the fact that the extracts used for both
Westerns and EMSA represent a heterogeneous population of cells (neurons and glia). Our
preliminary analysis at the transcriptional activity of p53 using real-time PCR do suggest an
increase in its nuclear activity as one of its target genes (p21) was up-regulated in ALS spinal
cord tissue extracts but not controls (data not shown). It is likely that in addition to having an
effect at the level of transactivation, p53 could modulate protein-protein interactions both in the
nuclear and cytoplasmic compartments during the disease.
We further dissected p53 localization through immunohistochemistry whereby the
presence of abundant nuclear accumulation of p53 in spinal motor neurons and activated glial
cells suggests the involvement of the cell cycle in motor neuronal death. Such subcellular
alterations in p53 could be in response to DNA damage in addition to re-entry into cell cycle
with subsequent E2F-1 dependent transactivation. DNA damage can activate proteins that induce
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cell cycle arrest and / or DNA repair. However, extensive DNA damage induces neuronal
apoptosis. The presence of p53 in the nucleus of motor neurons that apparently lack dendritic
processes with a rounded cell body suggest that altered localization of active p53 may
correspond to cell atrophy and death.
The results obtained in the spinal cord of ALS patients however were in stark contrast to
that in the motor cortex of these patients. It was surprising that the remaining large pyramidal
cells and other neurons in the motor cortex of these patients showed negligible to no p53
immunoreactivity. The level of this protein was undetectable in any fraction of tissue lysate and
there was no difference in the DNA binding activity. This dichotomous pattern of protein
expression although intriguing suggests two different pathways for loss of motor neurons, one
that is p53 dependent in the lower motor neurons and one p53 independent in the upper motor
neurons. Differential role for p53 might also relate to differences in the site of disease onset
(bulbar vs lumbosacral), which warrants further investigations. In addition, studies in adult mice
and neuronal cell cultures show evidence for localized transcription-independent mechanism of
p53 action in the synapses [410]. In these studies, oxidative and excitotoxic insults increased the
levels of active (phosphorylated) p53 in isolated cortical synaptosomes, which preceded the loss
of synapsin I. This suggests that p53, independent of transactivating its downstream targets, can
have an effect on the dysfunction and degeneration of synapses during neuropathologic
conditions. In addition, DNA damage can also cause alterations to the glial cells and
subsequently affect the motor neurons via a bystander effect. The lack of p53 in the surviving
motor cortex neurons but its presence in the astrocytes of the cortex may indicate such a
phenomenon. For instance, damage to the astrocytic transporters (EAAT2) or the glial
component of the cortical region could initiate a cascade of chemokine / cytokine release, which
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will have an effect on the adjacent neurons. In effect, p53 can damage motor neurons directly or
indirectly. In support of such a theory are the recent findings of increased PARP
immunoreactivity in reactive astrocytes of SALS patients and also in an G93A SOD1 mouse
model [200, 411].
Other homologs of p53 such as p73 are regulated by E2F-1 and there are prior reports of
altered levels of p73 in AD brain [412, 413]. In the absence of p53, we hypothesized that a
homolog such as p73 may exhibit alterations in ALS motor cortex. However, we observed
reduced p73 levels in the motor cortex. In this light, alterations in chromatin structure through
inappropriate regulation of nuclear factors such as p53 or p73 can make DNA increasingly
susceptible to further damage. Mutations or damage to proteins such as Alsin that is implicated
in FALS and with sequence homology to the regulator of chromatin condensation may result in
exacerbating DNA damage. Other events as also acetylation of nuclear factors such as p53 or
p73 can greatly influence a cell to trigger apoptosis. These areas of research warrant further
investigations.
Irrespective of the mechanism that induces cell death, apoptosis involves the induction of
pro-apoptotic genes with downstream activation of caspases. Our Western immunoblots and
confocal microscopy studies suggest the involvement of apoptosis downstream of the aberrant
activation of cell cycle regulators. Both a mitochondrial pathway (increased Bax and caspase-3)
and a death receptor mediated pathway (increased Fas, caspase-8 and caspase-3) may be
involved in the lower motor neuron death in ALS. Caspase-3 staining in the spinal motor neurons
appeared cytoplasmic and punctate. This might suggest its probable association with
mitochondria. The antibody used in immunohistochemistry recognizes active form of caspase-3
and our confocal images do indicate its nuclear localization.
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Fas mediated death pathway in cultured motor neurons from SOD1 mutant transgenics
have been reported [406]. There is evidence for p53 to mediate apoptosis through other
mechanisms other than Bax, one of which, is the Fas mediated death signaling pathway [284]. It
is also known that prostaglandins in ALS spinal cord phosphorylates and activates p53 [414].
Hence it is likely that p53 might act on both the apoptotic pathways with the activation of Fas
possibly due to increased prostaglandins. However, it was intriguing to find Fas, a death-domain
containing membrane receptor, in the nucleus of spinal cord motor neurons. There is no
precedent to this occurrence in scientific literature. Since we have performed peptide blocking
and other control experiments to test the specificity of its localization, we believe that our
immunohistochemical evidence is real and that it may be a processed form of the receptor. The
mode of its nuclear translocation or its nuclear function is unknown. Thus from this study we can
conclude that a caspase-dependent apoptotic mode of cell death occurs in the spinal cord motor
neurons but not in neurons of the motor cortex. A caspase-independent apoptotic mechanism in
the motor cortex however cannot be ruled out by this study. In order to make sure that we are not
biasing our investigation by examining just one area of the motor cortex that project to the spinal
cord, we analyzed sections from the mid- and superior regions of the motor cortex (regions #2 -
#7 in Fig 6B) and report consistent findings. Although these findings contradict earlier reports
wherein alterations of apoptotic proteins were evident in both the spinal cord and motor cortex, it
fits well with the current idea that multiple pathways are involved in neuronal cell death.
Alternatively, it is possible that cell death may not be as extensive in the motor cortex as it is in
the spinal cord. In fact, many of the ALS cases utilized in this study do not exhibit motor cortex
atrophy by gross neuropathological assessment.
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As a measure of DNA damage and apoptosis, we used DNA fragmentation as a marker
using TUNEL staining. When nucleases cleave or nick DNA strands, they result in 3’-hydroxyl
ends being exposed. These hydroxyl groups then serve as substrates for the terminal
deoxynucleotidyl transferase (TdT), which adds deoxyribonucleotides in a template-independent
manner. It was noteworthy to find that there was increased evidence for fragmented DNA in
spinal cord but not the motor cortex. In the spinal cord, the presence of p53 immunoreactivity in
75% of the TUNEL positive motor neurons suggests that DNA damage results in p53
accumulation but is not the only indicator of DNA damage as only 30.5% of the p53 positive
neurons were TUNEL positive. The lack of TUNEL positive motor neurons in the cortex is
consistent with the immunohisto-chemical data presented in this Chapter. Furthermore, these
results are strengthened by the lack of Bax and caspase-3 protein levels in the Betz cells. It is
indeed true that this technique does not differentiate between single-strand (necrosis) and double-
strand (apoptosis) DNA breaks. Nevertheless, our results do indicate the presence of nicked
DNA that co-localizes to the G1 to S phase regulators. These observations coupled with the
presence of activated caspases lend further support for an apoptotic mode of cell death in the
spinal cord.
In conclusion, we have reported alterations in the G1 to S phase transition of cell cycle
with concomitant increases in p53 levels in the spinal cord of ALS patients may direct
susceptible motor neurons to an apoptotic mode of cell death. The same may not be true of the
Betz cells in the motor cortex as illustrated by the apparent lack of p53 or any death markers.
Therefore, these findings suggest a differential mechanism of neuronal cell death in ALS. It is
true that in a chronic neurodegenerative disease such as ALS, it will be difficult to document
apoptosis in post-mortem tissues given the rapidity of the cell death process. However, this study
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in addition to discerning a potential role for p53 and other G1 to S phase regulators in motor
neuronal death provides additional evidence for an apoptotic mode of cell death in ALS.
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4. Assessment of human CSF Proteome stability by SELDI-TOF-MS
4.1.  Abstract
Mass spectrometry-based clinical proteomics is being used to identify diagnostic
biomarkers and surrogate endpoints for a number of human diseases. However, this technique is
sensitive and reliable only to the extent to which samples are appropriately handled and stored.
Assessment of sample-handling conditions is critical to ensure proper utilization of valuable
samples such as cerebrospinal fluid (CSF) in order to obtain reliable and reproducible data. The
aim of this study was to examine the effects of storing samples at room temperature and at 4oC
on the proteome of human CSF using surface-enhanced laser desorption/ionization – time of
flight mass spectrometry (SELDI-TOF-MS). Analysis of variance indicates that differences in
protein profiling were evident within 4 hours at room temperature but after 8 hours when stored
at 4oC. This chapter highlights the importance of standard operating procedures to maintain
integrity of clinical samples.
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4.2.  Introduction
Biomarker discovery for neurodegenerative diseases and neuropsychiatric disorders is at
the forefront of biomedical science research [307]. There are a number of ongoing studies to
identify biomarkers for diagnostics, drug design and discovery in neurological diseases such as
AD, ALS, HIV-encephalitis, and schizophrenia [315, 316, 318, 320, 326, 337, 415-419]. Since
neurons and glial cells of the central nervous system (CNS) are bathed in the CSF, it provides an
ideal medium for clinical neuroproteomics [315, 420]. However, CSF and serum sample
integrity and stability is important for the successful use of very sensitive techniques such as
mass spectrometry-based clinical proteomics. Many of the proteomic studies utilizing CSF or
serum are collaborative multicenter efforts. Proper handling of these valuable samples is key to
obtaining interpretable and reproducible data. When samples are obtained through surgical
procedures or routine specimen collection such as venipuncture, it is likely that pre-analytical
errors such as prolonged storage at room temperature or in the cold can plague the final data
analysis. In a clinical study involving human patients, identification and proper assessment of
biological, pathological and pharmacological variation is important. In addition, instrument
variations such as mass inaccuracy can add to the difficulty for data interpretation. Therefore it is
important to reduce experimental variation by implementing standard operative procedures for
collection, handling, and storage of valuable subject samples.
Despite many clinical proteomic studies using CSF and mass spectrometry, there are no
reports on the stability of CSF proteome over time when stored at different temperatures. While
efforts are made to minimize the time from when the sample is procured till it is processed and
placed in long-term storage, quite often this time is variable from sample to sample or between
institutions. There is a study using proton nuclear magnetic resonance suggesting alterations in
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CSF proteome stability after 72hrs at room temperature but this study has not been performed at
various time points [421]. Recent studies have highlighted the importance of standard operating
protocols (SOP) for clinical plasma samples using a 2D-GE proteomic approach [422]. Another
group published results related to the reproducibility of protein profiles in urine samples
analyzed many months apart [339]. However, there are no reports regarding the SOP for clinical
CSF samples using mass spectrometry. In this report, we utilize CSF from healthy control
subjects and MS-based proteomics to test the stability of the CSF proteome to variations of
temperature and time. We detail evidence that protein stability as inferred from the CSF
proteomic profiling reduces over time when samples are stored at room temperature. Alterations
in the proteomic profile are less pronounced when samples are stored at 4oC prior to its use on
protein chip arrays. This analysis is important to further the field of MS-based clinical
proteomics and develop standardized protocols to proper handling of valuable clinical samples in
a multicenter study.
4.3.  Materials and Methods
4.3.1.  Study Population and Sample Preparation
For study of protein stability, two CSF samples were used from the University of
Pittsburgh. The samples were from healthy adult subjects. CSF was obtained via lumbar
puncture protocol approved by the University of Pittsburgh IRB. Cerebrospinal fluid (CSF) was
immediately centrifuged at 1500 rpm for 5 min at 4oC to remove cellular debris and either
directly used or frozen at -80 oC and thawed on ice prior to use. IRB-approved informed consent
for this procedure was obtained from all subjects. Replicate sample sets either at room
temperature or at 4oC was used within each experiment. Each sample set contained seven
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replicate tubes and incubated for each of the time points – 0, 2, 4, 6, 8, 12, 16 and 24 hours. The
experiments were repeated twice.
CSF samples (20ml) were diluted in 1% trifluoroacetic acid (TFA) to a final TFA
concentration of 0.1% (v/v). Samples were fractionated using C4 ZipTip pipette tips (Millipore)
according to manufacturer’s instructions and eluted onto the spots using a gradient of 75%
acetonitrile (ACN) / 0.1% TFA, 50% ACN / 0.1% TFA and 90% ACN / 0.1% TFA.
4.3.2.  Chip Preparation
Strong anion exchange surface (SAX2 or Q10) ProteinChips (Ciphergen Biosystems,
Inc., Palo Alto, CA) were chosen as initial optimization experiments with this chip yielded
reproducible spectral profiles. The 8 spots on SAX2 chips were equilibrated with 100mM Tris-
HCl pH 8.5 and then fractionated samples were added to the spots (one sample per spot). CSF
samples (20ml) were diluted in 1% trifluoroacetic acid (TFA) to a final TFA concentration of
0.1%. Samples were fractionated using C4 ZipTip pipette tips (Millipore) according to
manufacturer’s instructions and eluted onto the spots using a gradient of 50% acetonitrile (ACN)
/ 0.1% TFA, 75% ACN / 0.1% TFA and 90% ACN / 0.1% TFA. A saturated matrix solution of
4-hydroxy-a-cinnamic acid (containing 50% acetonitrile (v/v) in HPLC-grade water and 0.3%
(v/v) TFA) was then added to the spots. The spots were dried at room temperature before
acquiring spectra using the Ciphergen PBSIIc ProteinChip Reader equipped with an autoloader.
4.3.3.  SELDI-TOF-MS
The spectra of proteins/analytes were generated using a laser intensity range of 190-200
and a detector sensitivity range of 8-9 with a mass deflector setting of 1000 Da for the low mass
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range (1-20kDa). These settings were kept constant for all chips in each experiment. In addition,
we performed two separate experimental runs for each ProteinChip array. Each experiment was
repeated twice. For each experiment one CSF sample was used as an internal standard to
measure intra-assay variability of the mass spectra. The percent coefficient of variance (CV) for
selected mass/charge (m/z) signals (20 peaks) was less than 30%. External calibration of the
ProteinChip Reader was performed using the Ciphergen Biosystems 5-in-1 peptide mix
[(vasopressin (1084.247 Da), somatostatin (1637.903 Da) porcine dynorphin A (2147.5 Da),
human ACTH (2933.5 Da), bovine insulin B chain (3495.941 Da), human recombinant insulin
(5807.653 Da), hirudin (7033.614 Da)]. Human SOD1 (15591.4 Da) was added to this mix.
4.3.4.  Data Analysis
Total ion current of all profiles was used to normalize each of the spectrograms. An
average spectrum for each of the time points was obtained and the raw spectral data consisting of
about 18,400 peak values were utilized for further analysis. Variance (VAR) is a measure of the
average distance between each of a set of m/z features and their mean peak intensity. In other
words, it is the square of the deviation from the mean ((SD)2). Coefficient of variation (COV) is
a relative measure wherein the percent dispersion is a ratio of the magnitude of the standard
deviation to its mean (SD/Mean). The value of VAR or COV is directly proportional to the
degree of variation. The COV for each time point were then used to calculate a whole-profile
grand sum mean deviation (GMSD) from the 0 hour time point of each temperature condition.
All measures of variability were plotted against time. Furthermore the average intensity of all the
m/z values within each time point was analyzed in comparison to zero hour time point by single-
factor analysis of variance (ANOVA) with corresponding f-value and p-value. The null
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hypothesis that two sets of proteome profiles were statistically different was considered
significant when the p-value less than 0.05.
4.4.  Results and Discussion
Calibration with external calibrants, normalization to total ion density and analysis of all
the samples (replicates) from every time point in an experiment was performed at the same time.
An average normalized spectrum of all the replicates for each time point from an experiment was
generated. These were then compared for any differences in protein profiles over time at ambient
temperature and 4 oC. The complete spectral profile in the range between 2 and 20kDa appeared
fairly similar across the different time points for each of the two conditions. However, closer
examination of certain regions of these spectra revealed differences, which increased over time
(Fig 32). In Fig 32, differences in relative abundance and also peak resolution are apparent as
depicted in the m/z range of 11-15kDa. While they appeared within 2-4hrs when samples were
placed at ambient temperature, these differences were noticeable as late as 12hrs when the same
samples were stored at 4oC (Fig 32, see arrows and asterisk).
At ambient temperature arrows ‘a’ and ‘b’ indicate loss of peak resolution by 2hrs and 3-
fold increase in relative abundance within 6hrs, respectively. In addition at ambient temperature,
arrows ‘d’ and ‘e’ represent the loss in peak resolution as early as 2hrs and the appearance of a
shoulder by 2hrs, which is sustained at all subsequent time points. However, in this same
magnified m/z region at 4 oC, we do not observe as much variation. At 4 oC, there is a 3-fold
increase within 2hrs in the peak with the same m/z as the arrow ‘b’ represents in the ambient
temperature spectra. It is interesting to note that while the 0hr spectra at room temperature
appears fairly similar to the 4hr spectral profile at 4 oC, the 6hr ambient temperature profile
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appears identical to the 12hr 4 oC profile (see ‘asterisk’). The peaks represented by the ‘asterisk’
suggest that the CSF proteome becomes increasingly unstable. In addition, comparison of the
profiles at 8-12hrs suggests a delayed instability of the CSF proteome when samples are placed
at 4 oC.
          
Figure 32 CSF spectra representing m/z region of 11 to 15kDa depicting temperature
dependent changes in proteome stability
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Left and right columns represent SAX2 spectra from individual replicates obtained by thawing
and incubating samples at ambient temperature and 4oC for specified timepoints, respectively.
Arrows (a-e) represent alterations in relative abundance or loss of peak resolution over time.
Asterisk depicts a peak doublet present at 6hrs at ambient temperature that is present as late as
12 hrs at 4oC.
These spectral profiling results suggest that as hypothesized the CSF protein spectral
profiles changed much earlier when stored at room temperature when compared to 4oC. They
retained their integrity for an additional 4-6hrs when stored at 4 oC as opposed to ambient
temperature. Furthermore, when peak “b” at room temperature is compared to the peak at 4oC in
Fig. 32, it initially disappears but re-appears at a later time point. While this peak at room
temperature re-appears as early as 6hrs, it re-appears as late as 24hrs at 4oC. These are
indications of gross effects of temperature on the CSF proteome stability. It is also possible that
these apparent differences in peak “b” might be due to the emergence of a very different protein,
possibly a proteolytic fragment of a larger protein. Such changes are important from the context
of peak clustering software and further analysis of mass spectrometric data.
Raw spectral data output from each of the time points, which included about 18,400 m/z
features, were then utilized for analysis of variance. The average variance, a measure of the
deviation from the mean, was determined for the whole profile at each time point with
corresponding standard errors (Fig 33A). There was a gradual increase in VAR up to 8hrs at 4oC
with a delayed sharp increase at 24hrs. In contrast at ambient temperature an increased variance
was noticed as early as 6hrs and this appeared biphasic with a similar sharp increase in variance
at 16hrs. In addition, the average COV across the profile was determined for each time point (Fig
33B). The COV at 4oC and ambient temperature showed negligible differences with a sharp
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increase at 24hrs when stored at 4oC and by 2-4hrs at room temperature. The minimal magnitude
of variations obtained from the VAR and COV results suggest that the CSF proteome is
reproducible within each time point. In other words, the rate of alterations in the proteome
stability is fairly consistent within each of the time points. The observed small changes could
indicate baseline variations present within each time point. Having established the
reproducibility within time points we analyzed if there was any variance across them.
           
Figure 33 Percent variance (A) and coefficient of variance (B) as measures of CSF
proteome stability
(A) Variance of the m/z values within all replicate samples at each time point was calculated for
each of the 18,400 mass peaks within the raw spectral data. The average overall variance (VAR)
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was then computed for each time point and represented as percent variance with corresponding
standard errors of mean. (B) The COV for each time point was determined as the ratio of the
standard deviation over its mean for each of the 18,400 peak values at each time point. The
average COV for each time point was then plotted. In both (A) and (B), solid line represents
samples incubated at 4oC and dashed line represents those at room temperature (RT).
While VAR and COV relate to differences within each time point, GMSD is a statistical
measure that represents true variances relative to the control time point (zero hour). As
demonstrated in Fig 34, the GMSD was fairly constant up to 8hrs signifying that the proteome is
stable with an increase in GMSD or instability in the proteome at 24hrs when stored at 4oC. This
however was not the case at room temperature wherein there was variance as early as 4hrs with a
very sharp significant increase at 24hrs. The measure of GMSD clearly suggests that the rapidity
with which the proteome becomes unstable is greater at room temperature than at 4oC.
Figure 34 GMSD as a statistical measure of variance in the CSF proteome
The difference in mean intensities at each time point relative to the 0 hr time point were
determined and plotted as the GMSD. These values represent the overall deviation or alteration
in the whole profile at each of the seven time points from time zero. While at room temperature,
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variation occurs as early as 2-4hrs with an addition peak between 16 and 24hrs, at 4oC the
overall variation of the profiles does not differ by much until 8hrs.
Additionally, ANOVA of the average intensities yielded statistically significant p values
as early as 2hrs at room temperature and as delayed as long as 16hrs at 4oC (data not shown)
indicating that the profiles at these time points are significantly different from that at the 0hr time
point. These studies were repeated using CSF that was first frozen at -80oC and then thawed on
ice prior to use, i.e., after one freeze/thaw cycle. We obtained comparable results suggesting no
additional proteome alterations.
Our results demonstrate that the CSF proteome stability depends significantly on the
storage conditions as hypothesized. The proteome is unstable as early as 4hrs when stored at
ambient temperature and within 8hrs with a sharp increase at 24hrs when stored at 4oC.
Instability of the CSF proteome may be a result of proteolytic changes or other post-translational
modifications induced by temperature changes. It would be expected that the spectral patterns at
0hr time point both at ambient and 4oC should be similar but there is an apparent difference (Fig
32). Even though the peak intensities are different, the pattern appears fairly similar. Moreover,
represented is an individual spectrum (from 7 replicates). When average peak intensities for the
whole profile are determined the variance at the 0hr time point between the two temperature
conditions is absent (Fig 33). Treating samples with protease inhibitors would further validate
some of the spectral differences. It is the first such study using MS-based proteomics that
addresses measures for quality control. This study demonstrates the necessity to carefully
monitor the time taken to procure and process the CSF samples. Minute alterations in sample
handling conditions can significantly affect protein signals obtained from the mass spectrometer
thus skewing the mass peaks and the resultant efforts of biomarker discovery and validation.
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Furthermore, if such samples are used for 2D-GE based proteomics, temperature induced
alterations in pH / pI can greatly affect the migratory pattern of proteins and hence data
interpretation. Such proteomic changes in clinical plasma samples in a 2-dimensional gel have
been demonstrated [422]. Reducing the time that these CSF samples are placed at ambient or 4oC
prior to storage at -80oC will greatly enhance the quality of the samples for proteomic
approaches. It will also aid in generating interpretable proteomic profiles using the mass
spectrometry based proteomic approach. In conclusion this study underlines the importance of
proper handling and storage of valuable clinical samples.
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5. Post-mortem CSF is not an ideal candidate for biomarker discovery
5.1.  Abstract
Many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), have no
clear diagnostic biomarkers or long-term intervention drugs. Extensive research at the gene and
protein level using post-mortem tissues, animal models and body fluids has indeed provided
molecular targets for clinical trials. Genetic and protein alterations during ALS can be studied
using body fluids such as serum and cerebrospinal fluid (CSF). The latter represents an ideal
medium for analysis because it bathes glial and neuronal cells. CSF may thus present with
protein differences as a result of pathological changes that occur in the CNS during neuronal
death. These differences however may vary quite extensively in samples from living and those
procured at autopsy. Using ALS as a model for neurological disorders, we hypothesized that CSF
profiling for protein alterations from living patients will yield biomarkers that better defines
disease progression than those, which result in CSF obtained at autopsy. Mass spectrometry-
based proteomics using Ciphergen protein chips was utilized for the protein profiling. The CSF
proteome from post-mortem (16 controls and 17 ALS) and living (17 controls and 20 ALS)
subjects were analyzed using a strong anion exchange chip array. Through univariate and
multivariate analysis of resulting spectra, we identified differences in the spectral patterns. This
is the first study outlining spectral differences in CSF proteome from post-mortem and living
ALS subjects using a mass spectrometric approach. These differences suggest the importance of
utilizing CSF from living ALS patients for the identification of early diagnostic biomarkers.
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5.2. Introduction
The reported incidence of CNS related disorders and neurodegenerative diseases are ever
increasing. Although scientific advances have been made in understanding the pathogenic
mechanisms of diseases such as AD, PD, Down’s syndrome, ALS, multiple sclerosis (MS) and
other neuro-psychiatric disorders, none has yet to yield significant biomarkers or long-term
interventions. Proteomic approaches via 2D-GE to study protein alterations in these
neurodegenerative diseases have been extensively utilized. These studies have revealed oxidative
modifications to proteins in diseases such as AD and PD [317, 319-321, 416]. There have been a
number of proteins such as GFAP, myelin basic protein (MBP), neurofilament (NF), nitrated
proteins, S100B protein and ApoE reported to act as a diagnostic measure of CNS disorders but
none have yet to be proven to achieve the level of specificity required for proper early diagnosis
of the disease. This is partly because some of these studies have utilized samples (CSF or tissue
lysates) obtained at autopsy from diseased patients. Due to differing post-mortem interval times
and pre-mortem or agonal state of the patient, protein alterations unrelated to the disease can
affect proteomic analysis. Although there have been a few reports of such changes occurring in
the brains of animals, there are no such studies utilizing human CSF and a MS-based proteomic
approach.
Although CSF is an appropriate sample for biomarker discovery, it is not only important
to properly handle these samples but also make sure that the sample used does not yield un-
interpretable results due to proteome instability (see Chapter 4). There are many factors such as
differences in age, sex, drug regimens that present as confounding factors in addition to other
disease un-related issues such as post-mortem interval time and improper handling of samples.
These factors can strongly influence a clear discrimination between disease state and normal
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controls. Protein alterations that are observed in such situations cannot be ideally referred to as
biomarkers for a disease. It is therefore important to evaluate proteomic alterations that may exist
between living subjects and post-mortem samples. In this study, we hypothesized that the CSF
proteome profile from a living ALS patient will be very different from that of a post-mortem ALS
case. We have utilized CSF samples from living subjects diagnosed with ALS and those
acquired at the time of autopsy. In each category, we have included non-neurological and
neurological (AD) control cases. We conclude that there are numerous spectral differences in the
proteome between these groups of clinical samples. These results suggest the importance of
choosing the right kind of sample for biomarker discovery in CNS related diseases.
5.3.  Materials and Methods
5.3.1.  Study Population
CSF samples from 20 subjects of recently diagnosed / living ALS (L-ALS) and 17
subjects of non-ALS age-matched living controls (L-Ctl) were obtained from the Boston cohort
through our collaborators at Massachusetts General Hospital, MA. Control group included the
following cases: 16 non-neurodegenerative or with no neurologic complaints; one with probable
AD. The average time from clinical onset (date when the patient first reported symptoms) to
when CSF was procured was 352.8 days for the living ALS patients. CSF acquired at time of
autopsy from 17 ALS (PM-ALS), 8 AD and 8 non-neurological control (PM-Ctl) cases from the
University of Pittsburgh cohort was also utilized. These samples were age-matched and matched
for the post-mortem interval time. While the average ages (years) of the ALS and control patients
from the Boston cohort were 49.04 ± 2.78 and 43.4 ± 4.23, respectively; those from the
Pittsburgh cohort were 54 ± 2.5 and 60 ± 3.3, for ALS and control cases, respectively. The
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average post-mortem interval times (hours) for the ALS and control cases from the Pittsburgh
cohort were 6.7 ± 1 and 5.9 ± 0.45, respectively. The ratio of males to females in the Boston
cohort was 2:1.08 whereas in the Pittsburgh cohort, it was 1.66:1.08.
5.3.2.  Sample and Chip Preparation
Sample and chip preparations were as described in section 4.3.1 and 4.3.2 except that 0.5-
4mg of the CSF was utilized. 2D-Quant kit (Amersham, USA) was used to determine protein
concentrations (0.06mg/ml to 0.6mg/ml).
5.3.3.  SELDI-TOF-MS
Experiments were first performed to optimize the Ciphergen ProteinChip (Ciphergen
Biosystems, Inc., Palo Alto, CA) types and binding conditions used in subsequent experiments.
A total of four chip types were used to assay CSF samples: H4 (hydrophobic surface), SAX2
(strong anion exchange surface), WCX2 (weak cation exchange surface), and Zinc-IMAC30
(immobilized metal binding surface) at multiple pH binding conditions. Two protein chips,
SAX2 (strong anionic exchange) and Zn-IMAC30 (immobilized metal affinity chip) exhibited
the best spectral data. The SAX2 chip was utilized for further differential analysis of the post-
mortem and living CSF proteomes. The 8 spots on SAX2 chips were equilibrated with 100mM
Tris-HCl pH 8.5 and then fractionated samples were added to the spots (one sample per spot)
(see section 4.3.2).
The spectra of proteins/analytes were generated using a laser intensity range of 179-185
and a detector sensitivity range of 7-9 with a mass deflector setting of 1000 Da for the low mass
range (2-20kDa). These settings were kept constant for all chips in every experiment. For each
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individual experiment all CSF samples were analyzed in duplicate (two separate spots on two
different ProteinChips) as a measure of inter-experimental variability. We also used one common
CSF sample on every chip of an experiment to assess intra-experimental variability. In addition,
we performed multiple separate experimental runs for each ProteinChip array. The method to
discern percent coefficient of variation (CV) between the chips and calibrants used for
calibration were as described in section 4.3.3.
5.3.4.  Data Analysis
Total ion current of all profiles was used to normalize each of the spectrograms. The
Ciphergen 3.1 Biomarker Wizard application autodetected mass peaks by clustering and
analyzed the output using a non-parametric statistical test, which constituted the univariate
analysis of the data. Peak labeling was performed using second-pass peak selection with a signal
to noise ratio of 1.5. Statistically significant alterations in analyte levels (p < 0.05) were
identified.
For multivariate analyses, protein peaks were analyzed with the Ciphergen 3.1 Biomarker
Pattern Software (BPS) (Ciphergen Biosystems, CA, USA). BPS is a classification algorithm
defining pattern recognition and building classification trees using mass peaks defined by
Biomarker Wizard. Tree-building algorithms determine a set of “IF-THEN” logical conditions
that permit accurate predictions or classification of cases (splits) [332]. Each tree comprises a
parent node and branch or terminal nodes. The key rules to this analytical package are that each
node in a tree is split into exactly two branch nodes (binary), the decision to assign a tree to be
complete and also assigning each branch node to a class outcome. Splitting rules based on a “IF
£ to a threshold value, THEN – Yes, if not – No” are rank ordered on the basis of the quality of
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splits criterion utilizing the GINI and Twoing rules. Once a splitting rule is identified, the
algorithm repeats the process for each branch node until such time when further splitting is not
possible. There is a relative cost value associated with the classification, with a short tree size
defining a low cost value and better classification. BPS is also predictive of sensitivity (correct
classification of disease) and specificity (correct classification of control cases). We employed
10-fold cross validation to predict the error rate of selected trees. During this process, class is
predicted on 10% of withheld samples based on a set of predictors built on the remaining
samples. This process is iterated for each sample and the cumulative error rate is calculated. This
provides a reliable estimate of the independent predictive accuracy of each tree.
5.4. Results and Discussion
The spectra obtained from all experiments were performed in duplicate and analyzed
using the Ciphergen-based software for univariate and multivariate analysis. To account for
reproducibility a CSF sample was used on every chip and the coefficient of variation was
determined to be less than 30% for a total of 25 peaks. Comparison of CSF mass spectra in the
range of 2 to 20kDa in ALS and controls from post-mortem cases and living patients revealed a
number of differences in peak patterns. Differences in peak intensities are illustrated in Figure
35A using representative spectra from each of the four categories of samples analyzed (L-ALS,
L-Ctl, PM-ALS and PM-Ctl). Closer examination of the spectrograms in the m/z range of 4 to
8kDa revealed numerous differences (Figures 35B).
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Figure 35 Representative spectrogram illustrating differences in CSF proteome profile
of post-mortem and recently diagnosed ALS patients in the mass range of 2 -
20kDa (A) and 4 -8kDa (B)
There are distinct differences between PM-ALS and L-ALS indicated by arrowheads in A and B,
the peak at approximately 12.7kDa appears in both these cases (black circle). Arrows in A and B
represent the differences between control and the respective ALS case. The peak at about
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13.367kDa (asterisk) represents a peak that is present in high intensity in the control cases but
reduced in L-ALS CSF and absent in the PM-ALS CSF.
The m/z differences in spectral peak patterns observed when comparing the groups PM-
Ctl / PM-ALS (4.6kDa, 7.5kDa, 7.9kDa) and L-Ctl / L-ALS (2.5kDa and a doublet at around
6.5kDa) are represented by arrows in Fig 35A and B. Interestingly, the intensities of the 6.5kDa
doublet (arrows in Fig 35B) in L-ALS patient was flipped when compared to that of L-Ctl. This
could relate to the 6.5kDa peak being a protein variant in the L-ALS CSF. There were also
observable differences in peak intensities between PM-ALS and L-ALS (approximate m/z
4.6kDa, 4.75kDa, 5kDa and 5.8kDa; arrowheads in Fig 35, A and B). Similarities between PM-
ALS and L-ALS patients were very few or negligible with only one peak at approximately
12.7kDa (black circle in Fig 35A). It is interesting to note that the relative intensity of the peak of
m/z 13.367kDa varied amongst the four groups (L-Ctl > PM-Ctl > L-ALS > PM-ALS). The
intensity of the peak was significantly reduced in PM-ALS compared to the other three
categories (asterisk in Fig 35A).
This underlines the importance of analyzing CSF samples from recently diagnosed ALS
patients if the goal is to identify diagnostic biomarkers. The absence of this peak in the PM-ALS
cases could also be a result of the intrinsic proteome instability during agonal state and signifies
the necessity to assay for biomarkers early on in the disease process.
Additionally when CSF drawn early after onset of disease symptoms (d190) and from
other patients at later times (d390 and d1400) were compared to that of CSF drawn at autopsy,
the spectrograms revealed differences (Fig 36). The spectral patterns were strikingly different in
the post-mortem sample when compared to CSF from recently diagnosed and other living
patients. These differences are most likely due to biological alterations since the sample handling
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conditions for all of these samples were kept consistent. Such differences can have a profound
effect on biomarker discovery. Utilizing post-mortem samples can provide for erroneous
differences that can skew biomarker discovery and validation.
         
Figure 36 Differences in spectral patterns when CSF from living ALS patients (190, 390
or 1400 days from time of symptom onset) are compared to post-mortem
(PM) CSF sample
The x-axis represents the m/z in the range of 2-20kDa and on the y-axis is the relative abundance
of the peaks. The spectra of the PM CSF appear quite different from the rest with the appearance
(about 8-9kDa and about 15kDa) and the disappearance of certain peaks (less than 3kDa).
Having established differences in the spectrogram, we performed statistical analysis of
the differences in the CSF proteome between post-mortem and recently diagnosed ALS patients.
Using the Ciphergen 3.1 biomarker wizard clustering software, peaks were auto-detected and the
output analyzed using a non-parametric univariate analysis. A sample of such a clustering
144
comparing PM-ALS and L-ALS is illustrated in Figure 37. The larger the separation between the
two groups in the cluster for a peak along the y-axis, better is its predictive value.
     
Figure 37 Clustering of spectra using BPS
(A) Representative cluster of protein peaks between 2-20kDa comparing L-ALS and PM-ALS.
(B) The same cluster in between 4-8kDa. The red circles and blue squares denote L-ALS (N =11)
and PM-ALS (N = 16) samples, respectively. The y-axis indicates normalized intensity values in
the log scale.
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Pair-wise univariate comparisons were made between PM-ALS / PM-Ctl, PM-ALS / PM-
AD, L-ALS / L-Ctl and PM-ALS / L-ALS samples from three independent experiments
performed in duplicates. The peaks common to at least two different experiments and those that
were statistically significant with a p value £ 0.02 are represented by histograms (Fig 38 A to D).
The number of peak differences produced by comparing PM-ALS / PM-Ctl, PM-ALS / PM-AD
and L-ALS / L-Ctl pairs were 10, 9 and 8, respectively. However, comparing PM-ALS / L-ALS
samples yielded as many as 27 peak differences. Two m/z signals (6.88kDa and 13.77kDa) were
common to the sample pairs of PM-ALS / PM-AD and L-Ctl / L-ALS. However, the peak signal
at 6.88kDa is the double charged protonated form of the peak at 13.77kDa. Furthermore, the
13.77kDa peak appeared statistically different in PM-Ctl / PM-ALS samples in one of the three
experimental runs. It is notable to mention that while in the PM-ALS this peak was elevated
compared to PM-AD (Fig 38B) or PM-Ctl (data not shown), this intensity of this peak appears to
be significantly decreased in L-ALS compared to L-Ctl CSF samples (Fig 38C). In addition to
these stark differences between PM and recently diagnosed ALS patient sample, there is only
one peak that is similar between the two pairs of samples (Fig 35A, black circles).
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Figure 38 Univariate analysis of CSF from living patients and post-mortem cases
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(A) Ten peaks with statistically significant differences (p value £ 0.01) when comparing CSF
from post-mortem ALS (PM-ALS grey bars, N = 17) and control (black bars, N = 8) cases.
(B)  Eight of the nine peaks had a statistically significant difference with a p value £ 0.01
when comparing CSF from PM-ALS (grey bars, N = 17) and AD (black bars, N = 8) cases. The
2.3kDa had a p value of 0.02.
(C) When CSF from recently diagnosed ALS patients (grey bars, N = 20) and age-matched
controls (black bars, N = 17) were compared, 8 peaks with p values £ 0.01 were observed.
(D)  27 peaks with p values less than 1x10-4 were observed when CSF from recently diagnosed
ALS (L-ALS, grey bars, N = 20) and PM-ALS cases, (black bars, N = 17) were compared by
Mann-Whitney non-parametric univariate analysis.
These results suggest that proteomic differences between post-mortem CSF and that from
recently diagnosed patients or those from living control individuals are very different. Such
differences are further illustrated by the presence of as many as 27 peak differences when the
PM-ALS and L-ALS samples are compared.
Further analysis of the datasets was performed using the biomarker pattern software
algorithm (Ciphergen Biosystems). This multivariate analysis is based on learning a set of rules
on two-thirds of the sample using the features (m/z peaks) as selected by the biowizard clustering
software. With the learnt set of features and a process of cross-validation the rest of the samples
are classified to either of two groups. The percentage of correctly classified control and disease
cases signify the specificity and sensitivity of classification, respectively.
When the PM-Ctl and PM-ALS samples were compared, a total of 17 m/z features were
used to construct 16 trees with an average specificity of 78% and sensitivity of 80.5%. The BPS
classification tree with the best level of sensitivity and specificity for this group comparison is
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illustrated in Figure 39. Four additional peaks were used in the classification but these were
double charged signals (values in parentheses in row 1, Table 4). The average values of
specificity and sensitivity for the pair of L-Ctl and L-ALS were 80% and 91% from 7 trees
constructed using 6 peaks. A classification with the 3.44kDa peak as the root node represented
the best peak with a sensitivity and specificity of 100% and 91%, respectively (data not shown).
While the attribute at 3.44kDa was used as the parent node in as many as 4 different trees, the
2.06kDa peak was present in two different trees as a branch node. This probably implies that
these m/z features may represent attributes with strong predictive value. This failed to occur
when the post-mortem controls and ALS cases were classified using BPS. This constituted a
significant increase (11.5%) in accurately predicting disease state when the samples were from
recently diagnosed cases and not from samples obtained at autopsy.
Prediction Success for Learn Set
Actual
Class
Total
Cases
Percent
Correct
Ctl
N=16
PM-ALS
N=17
Ctl 16 100 16 0
PM-ALS 17 100 0 17
Prediction Success for Test Set
Actual
Class
Total
Cases
Percent
Correct
Ctl
N=17
PM-ALS
N=16
Ctl 16 94 15 1
PM-ALS 17 88 2 15
Figure 39 BPS classification analyzing post-mortem ALS (N = 17) and age-matched
post-mortem non-neurological (N = 8) and neurological (N = 8) controls (total
N = 16)
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(A)  Based on a threshold intensity value, m/z signal is used as a parent node (4.697kDa) and
the total number of samples (N = 33) is split into 2 terminal nodes.
(B)  The algorithm learns using the m/z features and predicts on the entire dataset (N = 33)
considered the “Learn Set”. This resulted in 100% specificity and sensitivity.
(C)  The samples are randomized and tested based on the learnt set of features. This produced
a specificity and sensitivity of 94% and 88%, respectively. One control and two PM-ALS cases
were misclassified.
Groups Compared Peaks (kDa) used by BPS for Classification Trees
Post-mortem controls and ALS 2.04, 2.25, 4.53, 4.7, 4.82, 5.06 (2.5), 5.33, 5.57
(2.77), 5.76 (2.88), 6.63 (3.28), 6.86, 6.98, 7.04, 7.14,
7.43, 7.92, 16.8
Recently diagnosed ALS patients
and Living controls
2.06, 3.44, 4.74, 5.57, 7.49, 8.91
Recently diagnosed ALS patients
and Post-mortem ALS cases
2.19, 3.5, 3.81, 3.91, 4.475, 4.82, 5.58, 7.15, 7.55,
7.98, 13.748, 14.979, 15.13, 15.3, 15.4, 15.5, 15.78,
16, 16.16, 16.5, 16.6
Table 4 Features utilized by BPS for classification and prediction
Peaks denoted in kilodaltons (kDa) were utilized in classifications and predictions in the
different groups indicated on the left column. The bold-faced peaks were also identified by the
univariate analysis (see Fig 38 A to D). m/z features in parentheses indicate that are the double
charged signals. Underlined peaks represent those common to post-mortem and living samples.
This multivariate analysis tool was then used to compare datasets of post-mortem ALS
cases and recently diagnosed ALS patients obtained from three independent experiments. BPS
yielded 31 classification trees using 21 peaks with an average prediction of 89.83% and 91.25%
for PM-ALS and L-ALS cases, respectively (Table 4). A classification with the 3.81kDa peak as
the root node represented the best peak with a sensitivity and specificity of 100% each (data not
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shown). The peaks at 7.55, 15.13, 15.3, 15.5, 16.16 and 16.6kDa were used in multiple trees
again suggesting their possible higher predictive value. There were three peaks recognized by
BPS that were common to post-mortem cases and living subjects (2.04, 4.7 and 5.57kDa,
underlined in Table 4). It is an interesting observation in that it may represent early changes and
remain different throughout the course of the disease. It is likely that the levels of these protein
peaks could fluctuate and may represent a marker for disease progression. A longitudinal study
would help in providing answers to these questions.
The important finding from this study is that CSF obtained at autopsy of an ALS patient
reveals a proteomic profile quite different from that procured from a recently diagnosed patient.
Such proteomic alterations that occur in post-mortem cases might represent an epiphenomenon
and may not necessarily relate to disease-specific changes. Alternatively, the changes observed
in CSF obtained at autopsy may represent degradative products. Even if they happen to be
disease-specific alterations, they most likely represent the end-stage of ALS. From a clinical
diagnostics viewpoint, it is better to obtain early disease biomarkers rather than markers at end-
stage. This supported the hypothesis that post-mortem samples are not ideal candidates for
biomarker discovery. Carefully handled tissue samples from animal models of neurological
diseases wherein the disease progression can be studied in a time-controlled fashion can be
valuable assets to biomarker discovery and validation. It is indeed true that a number of studies
have been conducted using human post-mortem tissues and other samples in an effort to dissect
the molecular mechanisms of a disease. In order to better understand molecular pathways and to
obtain molecular targets for therapeutics, multiple approaches including the use of samples
procured at autopsy are valuable. Characterization of differentially expressed proteins from post-
mortem samples in conjunction with data from other experimental models can lead to a
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hypothesis-driven functional approach to dissecting the mechanisms of neurodegeneration.
However, they are not ideal in attempts to discover biomarkers for CNS-related diseases. In fact
a recent study detailed potential biomarkers for brain injury with relevance to neurodegeneration
via a 2D-GE approach utilizing post-mortem CSF [317]. Although they report alterations in
interesting proteins some of which are associated with rare forms of familial PD, these cannot be
attributed as ‘biomarkers” but purely as protein alterations using which one can hypothesize
disease-specific mechanisms.
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6. Discovery and identification of ALS-specific biomarkers by mass spectrometry-
based proteomics
6.1.  Abstract
Pathological hallmarks for amyotrophic lateral sclerosis (ALS) include degeneration and
loss of motor neurons, protein aggregates in surviving motor neurons and astrogliosis. Although
the molecular mechanisms for this debilitating disease are considered multifactorial, how the
disease initiation and progression remain largely unclear. Recent advances in understanding ALS
pathogenesis have not yielded diagnostic biomarkers or any long-term drug interventions.
Proteomic techniques are a sensitive and valuable tool to discover biomarkers and novel
therapeutic targets within disease-specific biochemical pathways. We hypothesized that
examination of the proteomic profile of cerebrospinal fluid (CSF) from ALS and control subjects
will yield ALS specific protein biomarkers and provide insight into the molecular pathways that
govern this disease. Since CSF bathes the neurons and glia affected during ALS, it may harbor
protein biomarkers at sufficient concentration for detection. CSF samples were fractionated and
profiled on Ciphergen ProteinChip arrays and surface enhanced laser desorption /ionization-time
of flight-mass spectrometry (SELDI-TOF-MS). Univariate analysis performed using the
Ciphergen clustering software yielded statistically significant (p £ 0.01) differences in spectral
peak intensities of approximately 8% of the spectral peaks using two protein chip subtypes
(SAX2 and Zn-IMAC30). Two multivariate analytical algorithms yielded putative biomarker
panels with the Rule Learning (RL) algorithm yielding putative biomarker panels with high
predictive value for ALS. In addition, we have identified a panel of 11 biomarkers from the two
chip arrays through RL analysis that can discriminate the site of disease onset (Bulbar vs Limb
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onset). Furthermore, using ion exchange chromatography followed by tandem MS/MS, we have
enriched and identified three of the spectral signals to be carboxy terminus of the neuroendocrine
secretory protein 7B2 (3.45kDa), cystatin C (13.38kDa) and monomer form of transthyretin
(13.78kDa). These proteins have been validated through SELDI-TOF and western
immunoblotting. The identification and validation have provided plausible targets for drug
design and therapeutics. This is the first such study utilizing CSF samples from ALS patients for
proteomic profiling and the identification of diagnostic biomarkers for ALS.
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6.2.  Introduction
The common thread to a diverse range of neurodegenerative diseases such as Alzheimer’s
disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and ALS are the functional
loss of selective populations of neurons. Many of these diseases lack effective diagnostics and
treatment. A few of these fatal diseases such as ALS have very minimal drug interventions that
have marginal improvement in life span. Given the dearth for diagnostic biomarkers and long-
term therapeutic interventions, the impetuses in the scientific community is for high-throughput
screening for drug targets and also develop a sensitive approach to disease-specific proteomic
profiling.
ALS, one of the most common adult motor neuron diseases, affecting one in every
20,000 individuals exists in both sporadic and familial forms (see Chapter 1). Genetic mutations
observed in FALS may not fully explain the pathogenesis observed in SALS, which is
considered multifactorial [423, 424]. Many approaches, including transgenic animal models, in
vitro models and human post-mortem studies, have been used to try and understand the
pathogenesis of ALS [122, 141, 151, 199, 425-429]. Although these studies have yielded
therapeutic targets, there is only one marketed drug, riluzole, and it has only a modest effect on
survival [302, 303, 430-433]. There are other molecules that have shown promise in animal
studies such as the efficient retrograde delivery of insulin-like growth factor -1 (IGF-1) [206].
However, many of these studies have failed to transform into long-term therapeutic interventions
for ALS patients.
Many neurodegenerative diseases including ALS are termed “proteinopathies”,
characterized by the accumulation of protein abnormalities [434]. Changes in protein
composition of the CSF or serum between non-neurological controls and ALS patients may be
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indicative of alterations in central nervous system (CNS) protein expression or degradative
patterns [435]. New drug targets can be discovered and validated through a systematic
combination of proteomic and bioinformatic approaches, analyzing body fluids from patients.
Identification of ALS specific biomarkers through functional proteomics would aid in rapid
clinical diagnosis, unmasking potential therapeutic targets, and testing drug efficacy in clinical
trials. However alterations can be produced due to reduced stability through improper handling
and storage conditions as enumerated in Chapter 4. In addition, the CSF proteome can be very
different if post-mortem samples are used instead of from recently diagnosed patients and normal
controls (see Chapter 5). These factors necessitate the utilization of properly controlled samples
from patients who have been recently diagnosed with ALS and also samples from normal
controls.
Protein maps from developmental and adult rats, human brains have all been constructed
by the use of two-dimensional gel electrophoresis (2D-GE) coupled to MS [436]. Such studies
have provided information about the diversity of nervous system-specific proteins that can then
be compared in response to injury or disease. AD is associated with a number of defects such as
loss in synaptic function, decreased metabolism with mitochondrial deficiencies, oxidative stress,
defects in proteasome machinery and protein folding. Proteomic approaches by 2D-GE and MS
using AD brain tissues, CSF and animal models have demonstrated alterations in proteins
involved in a number of pathways. Such proteomic studies have also been conducted in forms of
cognitive impairment such as fronto-temporal dementia (FTD), HIV-1 associated cognitive loss,
neuropsychiatric disorders such as schizophrenia, Down’s syndrome, and neurodegenerative
diseases such as PD and HD [316, 318-321, 418, 437].
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Most of the studies in ALS research have utilized a genomic approach or biochemical
assays such as enzyme-linked immunosorbent assays (ELISA) for detecting changes in gene
expression or protein, respectively [149, 191, 438-440]. Proteomic approaches for ALS is limited
with one report each of analysis using in vitro culture models and post-mortem samples [419,
441]. None of the studies have produced a sensitive and specific biomarker. Mass spectrometric
(MS) analysis on the effects of G93A and G37R mutant SOD1 transfected into a motor neuron-
like cell line suggested alterations in proteins associated with antioxidant defenses, proteasome
machinery and nitric oxide metabolism [441]. A recent study identified increased levels of
ceramides, sphingomyelins and cholesterol esters in spinal cords of ALS patients and transgenic
mice using MS/MS, suggesting that MS analysis is a powerful tool [419].
The goal of this study was to identify ALS-specific markers and proteins involved in
different molecular pathways, which can then be used for diagnostics and as molecular targets
for therapeutics. We performed proteomic profiling of CSF from recently diagnosed ALS
patients and control subjects using SELDI-TOF-MS. Diagnostic biomarkers at the clinical onset
of ALS were sought in CSF obtained from ALS patients on average of 385 days from onset of
clinical symptoms. Utilizing two Ciphergen Biosystems ProteinChip arrays and two computer
assisted algorithms (RL and BPS), we have identified disease specific protein peaks. We report
statistically significant changes in 30 mass spectrometric signals (p £ 0.01). We have also
identified predictive biomarker panels by RL that differentiate ALS from control subjects in
blinded test subjects [442]. Peptide mass fingerprinting and sequencing of these markers have
yielded three protein identities. In addition, we identified markers with high predictive value to
discriminate the site of disease onset in these patients. This is the first study to identify a panel of
predictive protein biomarkers in CSF of recently diagnosed ALS patients.
157
6.3.  Materials and Methods
6.3.1.  Study Population and CSF
For the biomarker discovery and identification phase of proteomic study, the training
group included 21 control subjects and 15 patients with a recent clinical diagnosis of ALS by
board certified neurologists specializing in motor neuron diseases. While 14 of the ALS subjects
were sporadic cases, one familial non-SOD1 subject was included (ALS 2, Table 5). The average
ages of the ALS and control cohorts were 49.6 ± 3.4 and 45.2 ± 3.4, respectively. Control group
included the following cases: 12 non-neurodegenerative or with no neurologic complaints; one
with metabolic myopathy; two each with neuralgia and neuropathy; one case each of meningitis,
demyelinating disorder, slowly progressing atypical MND and probable AD. The average time
from clinical onset (date when ALS patient first reported symptoms) to when CSF was obtained
was 385 ± 49.1 days (113-730 days). We also used a separate test group of 20-blinded subjects
as a “diagnostic” set to predict disease status based on predictions generated using the training
group. Among 23 ALS samples, the clinical presentations were either with bulbar onset (N = 7)
or with limb onset (N = 16). These details are summarized in Tables 5 and 6.
6.3.2.  SELDI-TOF-MS
The samples and chips were prepared as enumerated in sections 5.3.2 and 5.3.3. The
IMAC30 arrays were treated with 100mM zinc sulfate followed by washing with 50mM sodium
acetate. These were then repeatedly washed with HPLC-grade water (SIGMA) and phosphate-
buffered saline. The CSF samples that were desalted and concentrated using ZipTips with C4
columns as explained in section 4.3.1 were then applied to the chip arrays. The settings for
SELDI-TOF-MS are as mentioned in 5.3.3.
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Group Diagnosis Age Gender Dz Duration (Days) Site of Dz Onset
Control 1 Normal 37.7 F NA NA
Control 2 Normal 49.5 M NA NA
Control 3 Normal 26 M NA NA
Control 4 Normal 72.3 F NA NA
Control 5 Myopathy 41.2 F NA NA
Control 6 Slowly Prog. MND 41.8 F 765 NA
Control 7 Neuralgia 43.8 F NA NA
Control 8 Neuropathy 34.4 M NA NA
Control 9 Neuropathy 80.5 F NA NA
Control 10 Normal 60.9 M NA NA
Control 11 Normal 29.5 F NA NA
Control 12 Probable AD 50.5 F NA NA
Control 13 Normal 68.2 M NA NA
Control 14 Normal 26.3 M NA NA
Control 15 Neuralgia 39.1 M NA NA
Control 16 Demyelinating Dz 30.6 F NA NA
Control 17 Normal 28.7 M NA NA
Control 18 Normal 40.2 M NA NA
Control 19 Normal 34.4 F NA NA
Control 20 Meningitis 54.8 M NA NA
Control 21 Normal 59.4 F NA NA
ALS 1 ALS 34.3 M 192 Limb
ALS 2 Familial ALS 51.3 F 568 Limb
ALS 3 ALS 57 M 406 Limb
ALS 4 ALS 46.1 M 251 Bulbar
ALS 5 ALS 50.3 M 224 Limb
ALS 6 ALS 56.7 M 572 Limb
ALS 7 ALS 75.4 M 467 Bulbar
ALS 8 ALS 31.8 M 113 Bulbar
ALS 9 ALS 39.3 M 175 Bulbar
ALS 10 ALS 26.6 M 615 Limb
ALS 11 ALS 39.3 M 389 Bulbar
ALS 12 ALS 60.5 F 730 Bulbar
ALS 13 ALS 60.3 F 367 Limb
ALS 14 ALS 59.7 M 190 Limb
ALS 15 ALS 56.2 F 529 Bulbar
Table 5 List of cases in the training set
Dz – Disease; MND – Motor neuron disease; AD – Alzheimer’s Disease
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Group Diagnosis Age Gender Dz Duration (Days) Site of Dz Onset
Control 1 Normal 80.1 F NA NA
Control 2 Meningitis 30.5 F NA NA
Control 3 Normal 41.1 F NA NA
Control 4 Normal 31.6 F NA NA
Control 5 Stroke 75.9 M NA NA
Control 6 Normal 37.1 M NA NA
Control 7 Normal 40.6 F NA NA
Control 8 Lymes Dz 43 F NA NA
Control 9 Normal 23.9 F NA NA
Control 10 Neuropathy 54.2 F NA NA
ALS 1 ALS 29.7 M 360 Limb
ALS 2 ALS 73.7 F 1110 Limb
ALS 3 ALS 61.2 F 392 Limb
ALS 4 ALS 47.5 M 3913 Limb
ALS 5 ALS 58.8 M 289 Limb
ALS 6 ALS 48.8 M 380 Limb
ALS 7 ALS 36.1 M 928 Limb
ALS 8 ALS 74.5 M 1339 Bulbar
ALS 9 ALS 47.4 M 324 Limb
ALS 10 ALS 50.6 M 254 Limb
Table 6 List of cases in the blinded test set
The groups and site of disease (Dz) onset were revealed post-analysis
6.3.3.  Data Analysis
Analysis of the spectrograms using Univariate analysis and BPS were performed as
explained in section 5.3.4. In addition, the samples were analyzed using another bioinformatics
tool called the Rule Learner (RL) algorithm. The RL algorithm was first used for predicting mass
spectra of complex organic molecules [333]. RL creates and searches possible rules by
successive specialization, guided by raw spectral data in a training set and by prior knowledge
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about the data (e.g., clinical diagnosis or symptoms) to define diagnostic biomarkers [334]. RL
learns a set of conditional rules of the form IF-THEN or P1,..,Pk => C, where the left-hand side
(LHS) are premise clauses that describe tests on values of one or more attributes of the training
set (e.g., spectral peaks). The concept conclusion (C) is an assertion that any subject with
features matching the conditions on the LHS of rule is a member of a class (e.g., ALS). RL
learns predictive patterns by starting from rules with a single feature and adding one feature at a
time to partial rules that look most promising. Each partial rule is matched against the training
cases to see how many of the positive cases are correctly predicted and how many of the
negative cases are incorrectly predicted, thus providing statistical guidance to the search. Based
on the training data, quantitative attributes such as spectral peaks are converted to ranges of
discrete values. These are then divided into groups of values representing mean and levels of
standard deviation away from the mean for each attribute. Due to the large amount of data (about
27,000 m/z datapoints), RL was run separately on 10 almost equal subsets of the data to pick
representative biomarkers from each subset. In order to allow these biomarkers to compete
among one another, we performed a final run of RL with the union of such features selected from
each of the previous runs. A 3-fold cross-validation was utilized to tune the RL input parameters
during the training, which produced the final set of rules (i.e., predictors). Evidence gathering is
performed using “weighted voting” wherein each coded sample is assigned a group (ALS or
control) by the casting of a “weighted vote” (the number of training samples that defines a
particular rule). For instance, if a coded sample is predicted to be ALS based on three rules of
which one of them has defined it to be control, then the other two rules that defines the right
hand side (RHS) to be ALS would have “outweighed” the “control” rule. The predictions are
then compared to known clinical diagnosis to determine sensitivity and specificity. Different
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kinds of statistics are employed during data analysis, including an estimation of certainty factor,
together with its positive predictive value and p-value.
6.3.4.  Biomarker Identification by Mass Spectrometric Analysis
Samples (500ul CSF) were fractionated (anion exchange) by gravity flow using Q
HyperD F matrix (Ciphergen Biosystems, USA) in Biospin columns (BioRad, USA). The
columns were first equilibrated using 50mM Tris-HCl at pH 9. Fractions were collected using
buffers at pH of 9 (20mM Tris-Hcl / 0.1% Triton X-100), pH 7 (50mM HEPES / 0.1% Triton X-
100), pH 5, and 4 (100mM Sodium Acetate / 0.1% Triton X-100) and pH 3 (50mM Sodium
Citrate / 0.1% Triton X-100). The column was then washed with a 33% isopropanol / 17%
acetonitrile (ACN)/ 0.1% triflouroacetic acid (TFA) solution (organic fraction). These different
fractions were spotted on SAX2 and NP20 (normal phase) chip to confirm the presence and
purity of relevant spectral peaks.
The aliquots of 50-500ml aliquots were concentrated using YM3 or YM10 filtration
devices (Millipore). The resulting fractions were electrophoresced on a 1D-SDS PAGE and
trypsin digested. Destained and excised bands of interest were incubated with 200ml of 40%
methanol / 10% acetic acid solution to remove SDS. After incubation with 200ml of ACN, the
gel pieces were dried in a speed-vacuum or at 37oC for 10 mins. In order to elute the protein, the
gel pieces were incubated with 20ml of 50% formic acid / 20% ACN / 15% isopropanol (FAPH)
solution for 2 hrs with strong agitation. A small amount of the eluted proteins was spotted onto a
NP20 chip and the rest were dried in a speed-vacuum. The protein pellet was then re-hydrated in
10ml of 25mM ammonium bicarbonate (pH8) containing 0.02mg/ml of sequencing grade -
modified trypsin (Promega) and incubated at 37oC for 16 hrs. The tryptic digests (1-2ml eluates)
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were tested again on NP20 chip surface and the fragments were compared to ProFound protein
databases. These fragments were also applied for sequencing using QStar-TOF-TOF MS/MS (in
collaboration with Ciphergen Biosystems).
6.3.5.  Biomarker Validation
6.3.5.1.  Immuno-SELDI-TOF-MS
The identified proteins were validated using a pre-activated antibody chip array and
Western immunoblotting. Anti-rabbit polyclonal antibodies against cystatin C (DAKO,
Denmark) and transthyretin (DAKO, Denmark) were used for SELDI-TOF and immunoblotting.
Immunoprecipitation for transthyretin using pre-activated chip arrays were performed as
published [443]. Briefly, 5ml of protein A (Sigma, St. Louis, USA) beads (0.1 mg/ml in PBS)
were added to the spots of PS10, pre-activated ProteinChip array, (Ciphergen Biosystems, USA)
and incubated in an humidity chamber for 1hr at room temperature. To reduce non-specificity,
residual active sites were blocked using 100mM Tris-HCl, pH 8.0 for 25mins at room
temperature. The array was washed in 1X PBS three times for 5mins each followed by
incubation of each of the spots with the anti-transthyretin antibody at a concentration of 4.1mg/ml
for 1.5hrs on a slow shaker. The unbound antibodies were then washed away with three 5min
washes in a 15ml tube with 1X PBS. 5mg of the ZipTip fractionated CSF samples from controls
(n = 7) and ALS (n = 7) subjects were added to the spots and incubated in a humidity chamber
for 1.5hrs at room temperature. Spots were washed three times by placing 5ml of 1X PBS on the
spot followed by rinsing once with 5ml of HPLC-water. Once the EAM (SPA, see section 4.3.2)
was added to the spots, the chip was loaded onto the ProteinChip reader (PBS IIc, Ciphergen
163
Biosystems, USA). The settings for laser intensity and sensitivity were 215 and 9, respectively.
The chip was processed and instrument calibrated as explained in sections 4.3.3 and 5.3.3.
6.3.5.2.  Immunoblotting
Western immunoblotting for cystatin C and transthyretin was performed as enumerated in
section 2.3.5 with the following modifications. 25ng (Cystatin C Westerns) and 50ng (TTR
Westerns) of the CSF sample from controls (n = 7) and ALS (n = 7) cases were electrophoresced
on a 10-20% Tris-Tricine Ready Gels (BioRad Laboratories, USA) and transferred to a PVDF
membrane. The primary antibodies were used at a dilution of 1:500.  Purified cystatin C protein
(Calbiochem, USA) and transthyretin (Biodesign, USA) were also utilized. While they were
utilized at a concentration of 1mg for SELDI-TOF, purified TTR at 50ng and cystatin C at 10ng
were utilized for Western immunoblotting.
6.3.5.3.  Immunohistochemistry
Immunohistochemistry for transthyretin by light microscopy using paraffin embedded
sections of lumbar spinal cord from archived human post-mortem tissues was performed as
described in section 2.3.3. Anti-rabbit polyclonal antibodies (DAKO, Denmark) were used at a
concentration of 1:300 to probe sections from 8 control and 16 ALS cases .
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6.4.  Results
SELDI-TOF-MS was used to characterize CSF analytes of ALS and control subjects. By
comparing spectra from the same CSF samples analyzed on SAX2 and IMAC30 chips during an
interval of multiple months, we determined that adequate reproducibility between experiments
was achieved (data not shown). To account for variability within the experiments, we assayed
one CSF sample on a spot of each chip within an experiment and determined that the coefficient
of variability was less than 30% (data not shown). Having established the reproducibility of the
spectral data, we analyzed CSF samples from the training group.
6.4.1.  Identification of differentially expressed protein peaks in ALS by univariate
analysis
Direct comparison of spectra from SAX2 or Zn-IMAC30 chips between control and ALS
subjects revealed very similar protein profiles (Fig 40A), with discernible differences in some
signal intensities (Fig 40B, numbers). The clustering software (Ciphergen version 3.1
BioWizard) autodetected a total of 366 peaks (207 on SAX2 and 159 on Zn-IMAC30 chip) in the
training group (N=36). We used the same software to perform a univariate analysis of both the
SAX2 and Zn-IMAC30 datasets (366 peaks) to identify CSF spectral peaks that exhibited
statistically significant relative peak intensities (Fig 41). We identified 15 protein peaks each
from the SAX2 (Fig 41A) and the Zn-IMAC30 (Fig 41B) datasets, approximately 8% of total
peaks that had a statistically significant difference (p < 0.01) in peak intensity (either increased
or decreased relative abundance). Furthermore, there were 22 other signals from both datasets
with statistically significant difference (p £ 0.05) in peak intensities (data not shown). Thus a
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total of 52 signals (14.2%) exhibited significant alterations in peak intensity, thus representing
putative biomarkers.
Figure 40 Comparison of mass spectra between ALS and Controls using SAX2 chip
Panel A depicts representative spectral peaks of ALS and control subjects on SAX2 chip and is
representative of three independent experiments. Mass-to-charge ratio in kilodaltons (2-20 kDa)
is shown on the x-axis, and the relative abundances (peak intensities) on the y-axis. Panel B is
the magnification (indicated by the arrows) of the spectra in the range of 3 and 6 kDa. Numbers
denote spectral peaks with significant differences (p < 0.05) in relative abundance between
control and ALS subjects as determined by univariate analysis. Numbers 1 – 5 correspond to
spectral peaks 3.923, 4.115, 4.468, 4.807 and 5.866 kDa.
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Figure 41 Univariate analysis of analytes from SAX2 and Zn-IMAC30
SAX2 (A) and Zn-IMAC30 (B) datasets exhibited peak intensities with statistical significance (p
£ 0.01) between ALS (stippled bars) and control (solid black bars) subjects. Mass in kilodaltons
(kDa) is shown on the x-axis, and the mean peak intensity values on the y-axis. Error bars
correspond to standard error of mean (SEM). All analyte signals appeared in greater than 30%
of subjects. Ciphergen biomarker wizard 3.1 - based non-parametric Mann-Whitney test was
used for statistical analysis.
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6.4.2.  CSF Biomarker panels
6.4.2.1.  BPS Analysis
Two computer-assisted algorithms were used to identify potential diagnostic biomarkers
from the CSF spectra in the training group. BPS creates classification trees containing one or
more protein peaks that are used to predict disease status. Protein peaks auto-detected from the
raw data are used in building trees. An example of a classification tree for the SAX2 dataset is
shown in Fig 42A.
The parent or the root node used a peak at 13.77 kDa. 19 subjects with a threshold value
greater than 2.824 placed in the right terminal node were controls. The left node contained 17
subjects that were further split at a 2.19 kDa peak. All three subjects in the resultant left node
with a threshold value of £ 0.313 were controls. The 14 subjects in the right terminal node were
all ALS subjects. This tree resulted in a misclassification of an ALS subject, yielding 93%
sensitivity and 100% specificity during the training phase. BPS then randomizes the dataset
through a 10-fold cross-validation and uses the classification tree to make predictions on all 36
samples that are then compared to the known subject diagnosis. The above tree predicted ALS
subjects during the validation phase with 80% sensitivity and 95% specificity. Additional trees
used peaks observed at 2.014, 2.157, 3.827, 4.964, 6.255, 6.53, 6.79, 6.89, and 6.97 kDa with an
overall sensitivity of 73% and specificity of 83%.
BPS was also used to identify potential biomarkers from the Zn-IMAC30 ProteinChip
dataset (Fig 42B).  In this classification tree, the signal at 3.36 kDa is the parent node. 17
subjects present in the left terminal node with a threshold value of £ 0.342 were all control
subjects. The 19 subjects in the right node were split further using the peak of 2.33 kDa. The
resulting right terminal node with a threshold value of  > 4.122 contained three controls. The 16
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subjects in the left node were further split using the 2.01 kDa signal. All of the 15 subjects in the
right terminal node belonged to the ALS group. This classification tree predicted ALS with
100% sensitivity and specificity during the training phase. The classification tree predicted
subjects as ALS with 93% sensitivity and 95% specificity through cross-validation of the
training set.  Additional trees used signals observed at 3.29, 3.44, 6.48, 6.86, 13.1, and 13.78 kDa
as nodes with an overall sensitivity of 87% and specificity of 86% for the prediction of ALS.
Figure 42 Multivariate analysis of SAX2 (A) and Zinc-IMAC30 (B) datasets using BPS
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(A) Tree representing the SAX2 datasets (N = 3). The relative cost value is 0.248. The
sensitivity and specificity based on cross-validation based on 12 samples is 80% and 95%,
respectively.
(B) Tree representing the Zn-IMAC30 datasets (N = 2). The relative cost value is 0.114. The
sensitivity and specificity based on cross-validation of 12 samples is 93% and 95%, respectively.
BPS classification trees cannot, however, be applied to spectra to make predictions of a
blinded test group. Therefore, we used the Rule Learning (RL) algorithm to create a biomarker
panel that can be directly applied to test subjects for diagnostic predictions. RL creates a series of
learned rules using raw mass spectral data containing 18,000 m/z data points, which are then
used to predict disease status of subjects. RL predicted disease status on one-third (N=12) of the
training set using rules generated on two-thirds (N=24) of the training set.
6.4.2.2.  RL Analysis
For the SAX2 dataset, RL identified 8 rules using 9 mass spectrometric signals (2.649,
3.707, 5.101, 5.828, 10.639, 10.989, 13.681, 14.62 and 15.599 kDa). When these rules were
applied to the 12 coded subjects from the training group, RL predicted ALS with 67%
sensitivity, 83% specificity and 75% accuracy. RL algorithm was also applied to the Zn-
IMAC30 dataset and generated 5 rules using 6 protein peaks (2.201, 5.378, 11.546, 12.874,
15.21, and 16.733 kDa). When these Zn-IMAC30 RL rules were applied to one-third (N=12) of
the training set, RL predicted ALS with 100% sensitivity, 50% specificity and 70% accuracy.
Two of the three control cases that were incorrectly predicted using the Zn-IMAC30 RL rules
were predicted correctly by SAX2 RL rules. Furthermore, an ALS case incorrectly predicted by
SAX2 rules was predicted correctly by the Zn-IMAC30 rules. These results suggest that using
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rules generated from both chip datasets increases the overall predictive value, and the
combination of our ALS data resulted in overall predictive values of 89% sensitivity, 72%
specificity and 86% accuracy. Therefore, we generated “combined” RL rules from both the
SAX2 and Zn-IMAC30 chip datasets validating them first on one-third (N=12) of the training set
(Table 7).
“IF” “THEN”
(SAX2 3.707 in -0.113 <= x < 0.078) Control
(Zn 13.395 in 0.079 <= x < 0.137) Control
(Zn 8.931 in 0.170 <= x < 0.289) Control
(Zn 16.595 in 0.048 <= x < 0.072) Control
(Zn 3.052 in 0.24 <= x < 0.516) Control
(SAX2 7.775 in 4-High) ALS
(Zn 17.087 in 2-Low) ALS
(SAX2 11.524 in 2-Low) ALS
(Zn 8.616 in 2-Low) ALS
(Zn 9.098 in 2-Low) ALS
Table 7 Multivariate analysis of blinded dataset using RL
A representative set of “IF-THEN” rules generated by the RL algorithm. A 3-fold cross
validation test was used and a final set of 10 “combined” rules generated from a total of 36
subjects (15 ALS and 21 control) for diagnostic prediction from both SAX2 and Zn-IMAC30
datasets.  These rules were applied for the “diagnostic” test set of 20-blinded samples.  The
certainty factor and p value for all the rules generated were 1.0 and less than 0.001,
respectively.
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Furthermore, this set rules was applied to make diagnostic predictions from a set of 20-
blinded test subjects. The predictive values for the set of 10 “RL biomarkers” were 80%
sensitivity, 59% specificity and 73% accuracy (Table 8). It is important to note that the time from
symptom onset to CSF draw for the two ALS subjects incorrectly predicted by the biomarker
panel was 1339 (ALS 8, Table 6) and 3913 days (ALS 4, Table 6), respectively. A 10-year
duration from symptom onset to CSF draw best represents a slowly progressing MND, akin to
one subject included within the control group of the training set (Control 6, Table 5). ALS
subjects used to create the biomarker panel had a time from symptom onset until CSF draw of
385 days, significantly closer to clinical onset and suggesting that our biomarker panel is most
predictive for subjects near the time of clinical symptom onset.  Removal of these two slowly
progressing MND cases from the analysis increased the predictive values to 100% sensitivity and
76% accuracy for this group of test subjects (N=18). Thus the overall predictive values for ALS
in all blinded test subjects [N=30, (12+18)] were 92% sensitivity, 59% specificity, and 79%
accuracy (Table 8).
               Predicted
Actual
ALS Control NP
 ALS 12 3 (1*) 0
Control 5 10 2
Table 8 RL analysis of validation (n=12) and blinded (n=20) sample sets
After the predictions were made based on the RL rules, the codes were broken and the
predictions compared to the known clinical diagnosis for each case. The sensitivity and accuracy
was 80% and 73%, respectively. The asterisk indicates the two ALS cases with long duration of
Sensitivity 80% (92%*)
Specificity 59%
Accuracy 73% (79%*)
Coverage 94%
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symptom onset to CSF draw (1339 and 3913 days). When these cases were not considered, the
sensitivity and accuracy indicated with the asterisk increased to 92% and 79%, respectively.
Coverage refers to the percentage of number of predicted cases (ALS + Controls) excluding the
no predictions (NP).
Additionally, using RL, we analyzed all of the samples (n = 52). This set included all the
cases listed in Tables 5 and 6 excluding the cases - ALS 4, ALS 8 in Table 6; Controls 5 and 6 in
Table 5. Uniform sampling created subsets of attributes (approximately 1000 m/z per subset) and
training models were learnt on each of these subsets using 40 of the cases. Then a union of all the
m/z attributes that occurred in all the models was chosen (about 1200 m/z values) by a 5-fold
cross-validation approach. The rules learnt from all the 40 samples were then tested on the
remaining 12 samples. This resulted in 11 m/z peaks or attributes from 12 models, with 7 of the
peaks appearing in 10 or more different models (Table 9).
By differing the parameters of the algorithm such as the certainty factor threshold (as this
value tends towards 1, higher the predictive value of a rule) data was generated by applying the
set of 11 attributes to the test set. The average percent prediction accuracy and percent coverage
from these 12 different model sets were 77 ± 4.8 and 88 ± 1.2. The percent average specificity
and sensitivity were 82 ± 7.7 and 68 ± 2.8, respectively. The chosen attributes in the best model
were: 2.4, 2.46, 6.88, 12.28, 13.64kDa  (SAX2 chip array) and 3, 3.4, 8.9kDa (Zn-IMAC30
array). This model had an average accuracy, coverage, specificity and sensitivity of 91%, 92%,
100% and 75%, respectively. One of the ALS cases was predicted incorrectly 10 of 12 times that
the model was tested. The 2.4kDa peak was chosen as a rule that predicted the RHS of the rule as
control. In each case, it was this rule in combination with another rule that outweighed the 3kDa
peak, which was predicted as ALS.
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Table 9 RL analysis of all subjects (Training set and Blinded set)
The table represents the peaks that were utilized by the algorithm when all the samples were
used to build models from the raw datasets obtained from the two chip arrays. The bold-faced
peaks appeared in at least 10 of a total of 12 different models.
6.4.2.3.  Site of Disease Onset
We also analyzed the predictive value for site of disease onset by utilizing all the ALS
samples except the outliers (ALS 2, 4 and 8 in Table 6). This set constituted a total of 15 subjects
with limb onset and 7 with bulbar onset. The datasets acquired from both SAX2 and Zn-IMAC30
chip arrays were analyzed using the RL algorithm. This analysis yielded a panel of 11 m/z
attributes (2.01, 2.72, 3.44, 9.68, 13.93, 15.3 and 17kDa peaks from SAX2 and 2.6, 5.34, 6.7 and
9.41kDa peaks from Zn-IMAC30 chip). Amongst these peaks, the algorithm used the 3.44kDa
peak iteratively to make correct predictions, suggesting its high positive predictive value (PPV).
RL classified correctly 14 of the 15 limb onset subjects without predicting on one of them (ALS
6 in Table 5). Amongst the 7 bulbar onset cases, it correctly and incorrectly predicted on two and
one subject, respectively. It did not predict on 4 of the 7 subjects. Thus these analyses provided a
prediction accuracy of 95% (Table 10).
Type of ProteinChip Array m/z Attributes (kDa)
SAX2 2.4, 2.46, 6.88, 12.28, 13.647, and 13.674
Zn-IMAC30 3, 3.4, 7, 8.93, and 12
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               Predicted
    Actual
Limb Bulbar NP
Limb 14 0 1
Bulbar 1 2 4
Table 10 RL analysis of site of disease onset in ALS subjects
Amongst 15 and 7 cases with limb and bulbar as the site of disease onset, the RL algorithm
correctly predicted in 14 and 2 cases, respectively. While one limb onset case was a no
prediction (NP), 4 of the bulbar cases were not predicted upon with one bulbar case being
incorrectly predicted. The overall prediction accuracy was 95%..
6.4.3.  Protein Identification
Having established a panel of putative biomarkers through univariate and multivariate
analyses, we sought to identify some of these mass spectroscopic signals. Commercially
available CSF samples as also the CSF from control and ALS subjects were enriched through
anion exchange chromatography and the different fractions were collected (see section 6.3.4).
The application of these fractions onto a SAX2 and NP20 (normal phase) chip arrays revealed
the enrichment of some of the peaks that were identified by the univariate and multivariate
analyses (Fig 41, Tables 7 and 9). Specifically, the peaks enriched in these different fractions
included 3.45 (pH 7), 3.8 (pH 5), 6.25 (pH 4), 6.88 (pH 4) 13.38 (FT / pH 7) and 13.78kDa (pH
4). As mentioned earlier the 6.88kDa peak is the double charged signal of 13.78kDa peak. While
the intensity of 3.44 and 3.8kDa peaks were significantly elevated in ALS cases, the 6.25, 6.88,
13.38 and 13.78kDa peak intensities were decreased in ALS cases (Fig 41). The 6.25 and
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13.78kDa peaks that were identified in pH4 fraction as also the 13.38kDa peak that was present
in the flow through were further analyzed (Fig 43).
The bands identified on a 1D SDS-PAGE were then subjected to in-gel tryptic digestion
followed by tandem mass spectrometry. The in-gel tryptic digests of the 13.38 and 13.78kDa
peaks from the respective fractions yielded proteins represented by the expected mass
spectrometric signals (Fig 44, A, B, and C).
Figure 43 Enrichment of biomarkers by fractionation
CSF was fractionated using Q Hyper D matrix at differing pH conditions. The resultant fractions
were spotted on SAX2 and NP20 (normal phase) chip arrays to determine the fraction in which
the specific peak appeared. The 6.25 and 13.78kDa peaks appeared in the pH 4 fraction (top and
bottom panels, respectively) while the 13.38kDa peak appeared in the flow through (middle
panel).
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Figure 44 1D SDS-PAGE (A), in-gel tryptic digests of the13.38kDa (B) and 13.78kDa
(C) peaks
(A) Representation of a silver stained 1D SDS-PAGE. Lane 1 -  Molecular weight (MW in
kDa to the left of the lane); Lanes 2 to 7 - flow through fraction; lanes 9 and 10 - pH 4 fraction.
The three bands within the box in lanes 3 and 4 (range of 13.38kDa) and the one band within the
box in lanes 9 and 10 (range of 13.78kDa) was used for in-gel tryptic digestion.
(B) The resultant eluate from in-gel tryptic digestion of the band represented by arrow (in
lanes 2 and 3 of (A)) was spotted on a NP20 chip. It revealed the identity of the 13.38kDa peak.
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(C)  Tryptic digestion of the band represented by arrow (in lanes 9 and 10 of (A)) revealed
the 13.78kDa peak.
Peptide mass fingerprints were obtained by analyzing the tryptic digests of the 13.38 and
13.78kDa peaks using tandem MS/MS (Fig 45, A and B). Obtaining the endogenous tryptic
digestion fragments and eliminating the common m/z signals determined specificity of the
peptide masses. The masses of the peptide fragments for the 13.38kDa peak were 1012.14,
1096.15, 1226.47, 1382.79, 1400.76, 1660.93, 1793.1, 1817.03 and 1921.23 daltons. For the
13.78kDa peak, the masses of the peptide fragments in the fingerprint were 1366.82, 1495.02,
1522.91, 1529.89, 1834.15, 2075.24, 2451.46, 2516.48, 2607.52, 2645.6 and 3140.51 daltons.
The identities of these peptides were searched against the ProFound protein database, which
matched the peptide fingerprint of the 13.38kDa peak to human cystatin C and that of the
13.78kDa peak to a monomer form of human transthyretin or retinol binding protein. The
estimated Z score for the 13.38kDa peak (pI of 9.3) was 2.42 and for the 13.78kDa peak (pI of
5.5) was 2.33. In addition, fractionated CSF samples were tryptic digested directly from Zn-
IMAC30 arrays followed by tandem MS/MS identified the 3.45kDa peak to be the carboxy
terminus of the neuroendocrine secretory protein 7B2 (data not shown). When the pH4 fraction
for the 6.25kDa peak was concentrated using a YM-30 microcon, the purity of this peak was
elevated but the in-gel tryptic digestion of the 6.25kDa peak did not yield any protein. Efforts to
purify and identify the 3.8kDa peak also have not yielded positive results.
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Figure 45 Peptide mass fingerprinting of the13.38 (A) and 13.78kDa (B) digests
The specificity of the peptides was determined using the endogenous tryptic digestion fragments
(control band). The peptides identified for both the peaks are represented in A and B in daltons.
There were 9 and 11 peptide fragments (arrows) for 13.38 and 13.78kDa peaks, respectively.
The m/z of the fragments are indicated in the text.
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6.4.4.  Protein Validation
Immuno-SELDI-TOF-MS was performed (see section 6.3.5) to validate the identified
proteins. This resulted in the 13.78kDa and its corresponding double charged peak demonstrating
the decrease in ALS CSF sample compared to control (Fig 46).
Figure 46 Validation of transthyretin (monomer) by Immuno-SELDI-TOF-MS
(A) Single representative spectra of purified human TTR protein (positive control), control (N
= 7) and ALS (N = 7) CSF sample to validate the decreased relative abundance of monomer of
transthyretin (arrows) in ALS CSF samples. The difference in the relative peak intensities of the
13.78kDa between controls and ALS determined by this approach was statistically significant (p
value of 0.02).
(B) Ciphergen- based softwar- assisted gel view of the spectra represented in (A)
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Figure 47 Validation of the 13.78 and 13.38kDa protein peaks by Western blotting
(A) 50ng of control (n = 4; Lanes 1-4) and ALS (n = 4; Lane 5-8) CSF was electrophoresced
on 10-20% Tris-Tricine gels and immunoblotted for transthyretin (TTR). The average ages for
controls and ALS cases were 56.75 ± 5.58 and 66.5 ± 4.97 yrs, respectively and the average time
duration of CSF draw from ALS symptom onset was 572 days. Purified human TTR (50ng) was
used as positive control (lane “+”). The arrows on the right indicate the monomer and
homotetramer form of TTR protein.
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(B) 25ng of protein was used to validate cystatin C by Westerns. The average ages for
controls (Lanes 1 – 6) and ALS (Lanes 7 – 12) cases were 60.66 ± 1.78 and 65.66 ± 4.44 yrs,
respectively and the average time duration of CSF draw from ALS symptom onset was 548 days.
Purified human cystatin C (10ng) was used as positive control (lane “+”). To the left of the
positive control lanes in (A) and (B) are the molecular weight markers indicated in kDa.
(C) Densitometric quantitation of the TTR and cystatin C bands using the NIH 1.58 software.
The relative abundance was expressed per ng CSF protein that was loaded. Single factor
ANOVA was performed with a confidence interval of 95% to compare the protein levels of
controls and ALS. The p values for TTR and cystatin C were 0.02 and 0.04, respectively.
Asterisks indicate the statistical significance.
6.4.5.  Western Immunoblotting for Cystatin C and Transthyretin
We sought to validate the presence of transthyretin and cystatin C by Western
immunoblotting using polyclonal antibodies (DAKO, Denmark). We used purified human TTR
and cystatin C proteins as positive controls for the assays. The levels of the 13.78kDa monomer
of TTR was significantly reduced in ALS CSF compared to control CSF (Fig 47, A and C; p
value = 0.02). The blot also revealed a 55kDa peak, which is the molecular weight of the
homotetramer form of TTR (Fig 47A). This band appeared to be increased in control cases
compared to CSF from ALS subjects. In addition, we performed immunoblotting to examine the
levels of cystatin C and found decreased levels of the protein in ALS CSF (Fig 47, B and C; p
value = 0.047).
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Figure 48 Decreased immunoreactivity of transthyretin in ALS spinal motor neurons
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Human lumbar spinal cord tissues from 16 ALS and 8 non-neurological age-matched disease
control cases were immunostained for transthyretin. The sections were stained with AEC
(antigen of interest appears reddish brown) and counterstained with haematoxylin. All panels
are at X100 magnification with the insets at X200 magnification.
Immunohistochemical (IHC) no primary antibody negative control.
(B) Control case shows healthy motor neurons with increased levels of transthyretin.
(C) ALS spinal motor neuron present with decreased immunoreactivity for transthyretin.
6.4.6.  Immunohistochemistry for Transthyretin
In light of a recent finding in transgenic mouse model for Alzheimer’s disease for the
neuroprotective role for transthyretin, we examined the levels of this protein in human ALS
spinal cord tissue sections [444]. Analysis of 8 control and 16 ALS cases revealed increased
punctate immunoreactivity in the cytoplasm of spinal motor neurons of control cases when
compared to ALS spinal motor neurons (Fig 48).
6.5.  Discussion
In this study we have utilized SELDI-TOF-MS to profile CSF and identify diagnostic
biomarkers for ALS using SAX2 and Zn-IMAC30 chips. By univariate analysis, we report 52
spectral peaks with differences in peak intensities between ALS and control subjects. BPS
generated a panel of 16 biomarkers (peaks common to SAX2 and Zn-IMAC30 were counted
once, i.e., 2.01, 6.48/6.53, 6.86/6.89, 13.77/13.38) from the training group but the algorithm
could not be used to predict ALS in blinded test subjects. However, the biomarker panel
generated by RL predicted ALS disease status in blinded test subjects (N=30) with 92%
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sensitivity, 59% specificity and 79% accuracy. In addition, we have identified three of these
peaks to be the carboxy terminus of neuroendocrine secretory protein 7B2, cystatin C and
transthyretin. We have also validated the presence of cystatin C and transthyretin in ALS CSF.
The clinical diagnosis of ALS is typically made after exhaustive tests to eliminate other
potential causes for the presenting symptoms. A panel of predictive biomarkers would aid in a
more rapid clinical diagnosis, which would not only be beneficial to the patient and family but
also permit initiation of therapeutics at or near the onset of clinical symptoms. Since our goal is
to diagnose ALS at the time of disease onset and ALS affects the motor neurons of the spinal
cord and brain, we examined the CSF proteome, which is in intimate contact with motor neurons
and other cell types affected during ALS.
Our goal for these biomarker panels is not only for early diagnosis, but also to identify
new therapeutic targets and to test drug efficacy in clinical trials. The identification of each
protein biomarker may reveal novel targets for drug therapy. While effective drugs are currently
unavailable, the development of a biomarker signature pattern for ALS will permit a more rapid
discovery of drug therapies. Within clinical trials these biomarkers could be used to determine if
a particular drug or drug combination alters the proteomic signature of the disease, thus
providing a sensitive method to uncover beneficial drug treatment regimens. It is important to
note that the ALS subjects used to identify the biomarker panel had an average time from
symptom onset till CSF draw of 385 days. Since we utilized CSF from ALS patients near the
time of symptom onset, future experiments will involve a longitudinal study to examine
proteomic alterations during disease progression.
In fact in one such longitudinal study, Dr. Pasinetti’s group has identified elevated levels
of a 4.8kDa peak in CSF drawn every 2 months from 14 ALS patients (unpublished data). In
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addition, they have identified decreased levels of two other peaks at 3.8 and 6.3kDa. These were
obtained by SELDI-TOF-MS approach and the use of BPS algorithm. It is interesting that our
study also reveals peak intensity differences between controls and ALS in these three peaks.
However, by univariate analysis the 4.8kDa peak is decreased compared to controls, a trend that
seemingly is different from Dr. Pasinetti’s findings. The difference in trends can be explained by
the fact that while Dr. Pasinetti claims that the marker at 4.8kDa increases as disease progresses,
what we believe is that the putative biomarkers from this study constitutes a set of early disease
biomarkers. Hence it is likely that CSF drawn at a later date from symptom onset may present a
trend as reported by Dr. Pasinetti’s group. Furthermore, it is an interesting observation that the
4.8kDa peak is decreased in CSF from post-mortem ALS cases compared to our set of recently
diagnosed patients (Fig 38D). This suggests that fluctuations in the levels of this protein might
indeed be important for disease progression. With increased sample size, our studies would
identify biomarkers with greater sensitivity and specificity, particular protein biomarkers specific
to the region of disease onset (bulbar vs lumbar) and also be extended to distinguish a spectrum
of motor neuron diseases. In fact our preliminary analysis of predictive value for site of disease
onset using 22 ALS CSF samples provided with a marker at 3.44kDa with high positive
predictive value and overall prediction accuracy of 94%. Such studies if extended to a larger
sample set can yield potential markers that would aid in a clinician determining the type of ALS
(bulbar vs limb onset) and devise patient-specific drug regimens thus improving life expectancy
for an ALS patient.
Although our initial RL analysis yielded rather low specificity (59%), re-analysis by
increasing the training set to 40 samples yielded specificity of 100%. In our study most are
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healthy controls. It would be ideal to obtain high levels of specificity given that in most clinical
settings the distinction between “likely ALS” from other neurological cases has to be diagnosed.
Data from the Ciphergen-based univariate analysis demonstrate that a number of proteins
within the CSF exhibit statistically significant differences in the levels between control and ALS
subjects (Fig 41). This implies that numerous protein alterations occur within the CSF of ALS
patients near time of symptom onset and that SELDI-TOF-MS is a valuable tool to identify such
statistical differences. The proteomic changes may include differential protein expression, altered
post-translational modifications or proteolytic processing. Indeed prior studies have
demonstrated altered levels of numerous proteins in the CSF of ALS patients [149, 445-449].
Multivariate analysis using two separate bioinformatics algorithms (BPS and RL)
identified putative diagnostic biomarkers from the SAX2 and Zn-IMAC30 ProteinChip datasets.
BPS classification trees identified 16 putative protein biomarkers (from a total of 366 peaks) and
provided predictive values for a correct diagnosis of ALS with an average of 80% sensitivity and
85% specificity. These values were from 10-fold cross-validation of 36 samples but BPS
classification trees could not be applied to the 20-blinded test subjects. Since it was not feasible
to predict disease status on blinded samples using BPS, we utilized the RL algorithm.
The RL identified 15 protein peaks from the SAX2 and Zn-IMAC30 chip raw datasets
(27,000 m/z values) as diagnostic indicators [442]. Combining the rules from both the SAX2 and
Zn-IMAC30 chips, RL was able to identify ALS in patients with 89% sensitivity and 72%
specificity in the validation phase. To further validate our RL biomarker panels we tested the
predictive value of the biomarkers against a set of 20 CSF samples from blinded test subjects.
Using RL, there were 6 misclassifications in the blinded set yielding 80% sensitivity and 68%
accuracy. Two ALS cases that were misclassified by RL had a time from symptom onset until
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the date of CSF draw of 1339 and 3913 days, well beyond that of ALS subjects in the training
set. When these two ALS subjects were eliminated for calculations of predictive values, the
result was 100% sensitivity and 76% accuracy. This suggests that the biomarker panel identified
by RL represent early disease-specific diagnostic predictors. Of the control subjects
misclassified, one subject had experienced a change of mental status (confusion) at the end-stage
of renal disease, one subject had leg stiffness with an unknown diagnosis (though multiple
sclerosis has been ruled out), and another experiences arm numbness with a family history of
neurodegenerative disorders.
Having successfully tested the models generated by RL on the blinded set of samples, our
attempt at learning on all of the samples (original training plus the blinded set) excluding the four
outliers yielded a further 11 peaks as putative biomarkers (Table 10). 2 of the 11 attributes as
seen in Table 10 (3 and 8.93kDa peaks from Zn-IMAC30 array) were also part of the “panel of
10 biomarkers” suggesting their possible importance in predicting ALS. This additional analysis
performed on a learn set of 40 samples and under different parameter settings yielded a high
percentage of accuracy, coverage and specificity but low sensitivity compared to the previous
panel obtained from RL (Table 7 and 8). The reduced sensitivity may be the result of using 40
samples for the training set but only 12 for the test group (as opposed to 24 and 20 in the original
RL analysis). Increasing the sample size of the test group may increase the sensitivity and
specificity in future studies. It was interesting to note that one of the two cases that were
predicted appeared incorrect in 10 of the 12 tested models. In each case, the 2.4kDa peak was
appeared. These suggested that the reduced sensitivity due to the incorrect recurrence of this
ALS case might be due to the drug regimen of the ALS patient affecting the CSF sample. Further
analysis is warranted based on the drug regimen of ALS patients.
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Although our initial RL analysis yielded rather low specificity (59%), re-analysis by
increasing the training set to 40 samples yielded specificity of 100%. In our study, we included
some neurologic disease controls within our control group but most were healthy controls. It
would be ideal to obtain high levels of specificity given that in most clinical settings the
distinction between “likely ALS” from other neurological cases is tenous. We predict that further
analysis with the addition of yet more neurologic non-ALS control subjects in our training set
will permit RL to make diagnostic predictions with higher levels of specificity and accuracy.
Such studies can then be extended to distinguish ALS from other motor neuron diseases.
Since both algorithms share similarities with respect to parameters used for analysis,
comparable outcomes and commonalities in biomarker panels would be expected. We report
biomarker panels unique to each algorithm with one common signal (6.8 kDa). This can be
attributed to the fact that although BPS utilizes the principle of Classification and Regression
Trees (CART), the algorithm uses auto-detected peaks via a clustering software and not the raw
data [332]. In addition, the BPS software was unable to predict disease status in blinded test
samples. Our study suggests that when the two programs are compared as analysis tools, RL
fares better for two reasons: the capability of RL to use the raw data with more than 27,000 m/z
spectral values and its ability to provide a means to make diagnostic predictions of blinded test
subjects. Taken together, the panel of predictors (a total of 19 m/z attributes, i.e., 10 peaks from
table 7 and 9 peaks from table 9) obtained from the statistical analyses performed in this study
stress the importance of utilizing multiple bioinformatic algorithms to datamine proteomic
datasets.
We have also obtained protein identities on three peaks (3.45kDa, 13.38kDa and
13.78kDa/6.88kDa) from our biomarker panel. These three peaks (6.88kDa is the double charged
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signal of the 13.78kDa peak) appeared in the panel obtained from the RL analysis (see tables 7
and 9). While we were unable to validate the presence of the carboxy terminus of the
neuroendocrine secretory protein 7B2 (referred to as CT-7B2) due to the lack of commercially
available antibodies, attempts at developing antibodies to CT-7B2 are ongoing. 7B2, a highly
conserved pituitary protein is selectively expressed in the CNS and endocrine tissues but not glial
cells [450, 451]. Human 7B2 protein (27kDa) is localized in the secretory granules of neurons
(including motor neurons) and endocrine cells. It interacts with neuroendocrine cell specific
prohormone convertases 2 (PC2) within the trans-Golgi network (TGN) and aids in the
maturation of pro-PC2. Mature PC2 then catalyzes the convertion of hormone and neuropeptide
precursors into their active form. A convertase called Furin cleaves 7B2 within the Golgi into a
21kDa and carboxy terminus fragment (CT-7B2) but is not required for the maturation of pro-
PC2. Both the 27kDa full-length protein and the CT-7B2 inhibit the function of PC2. Two lysine
residues in the CT of 7B2 are critical for this inhibitory role of the peptide [452]. Furin is
important for inactivation of the inhibitory function of CT-7B2 [453]. Thus 7B2 is important as a
chaperone in the secretory pathway and the CT-7B2 in regulating the function of PC2.
The 21kDa amino terminal portion of the protein and the CT-7B2 has been found in the
CSF [454]. Although it is not an entirely novel occurrence, the presence of CT-7B2 can be linked
to ALS at a mechanistic level since one of the early pathological features during ALS is the
fragmentation of the golgi complex [168-170]. This event coupled with ER stress may greatly
dysregulate the secretory pathway. Motor neurons are highly metabolic and depend on proper
protein folding and transport. With the functional loss of these neurons during ALS, secretory
chaperone proteins such as 7B2, which are normally localized to the neuronal secretory granules
could be released into the local environment and acted upon by various proteases such as Furin.
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The peptide fragments can then be released into the CSF that bathes the neurons and glia in the
CNS. The loss in integrity of the golgi complex and important chaperone proteins from the
secretory granules can affect normal neuronal connectivity by impeding the secretory pathway.
In addition, the 7B2 protein has been shown to function as a chaperone in the maturation of
growth factors such as IGF-1 [455]. The lack of growth factors and trophic support is a factor
implicated during ALS [118]. Hence with the cleavage and release of full-length protein into the
CSF, there would be reduced levels of the 7B2 protein in the tissues to carry out their chaperone
function.
Cystatin C, a 13.3kDa secreted protein belongs to the class of cysteine protease inhibitors
playing an important role in regulating extracellular protein homeostasis in the CNS. During cell
death processes that occur in neurological diseases, there are a number of proteases that can
cause degradation. However, with high concentrations of the protease inhibitors in the CNS,
these proteases can be held in check. In fact, the choroid plexus is a major site for the production
of cystatin C and the CSF concentration of this protein is about 5.5-times higher than serum
[456]. Mutations in this protein have been associated with a rare disease called hereditary brain
amyloid angiopathy wherein amyloid depositions occur along the walls of cerebral vessels this
reducing the CSF concentrations of the protein [457]. Initially considered a reliable marker for
diseases pertaining to glomerular filtration, it has recently been considered a CSF diagnostic
marker for neurodegenerative diseases such as AD, CJD, pain, and brain injury [458-462]. In
AD, the protein localizes with b-amyloid. The CSF levels of this protein are increased in AD,
CJD and in the dorsal horn during active pain states. Cystatin C localizes to protein aggregates
such as Bunina bodies in ALS subjects [463, 464]. It can thus be concentrated in the tissue with
subsequent reduction in the CSF. If the protein is sequestered in aggregates and a small part of it
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remains in the CSF, it is likely that the altered balance between proteases and their inhibitors
(such as cystatin C) can play a role in motor neuron death.
In our study, we observed decreased peak intensities of this protein by mass
spectrometry. Our attempts at validating this marker by immuno-SELDI-TOF-MS or Western
immunoblotting have barely yielded positive results. The application of anti-cystatin C
antibodies and fractionated CSF samples to pre-activated chip arrays resulted in non-specific
peaks (data not shown). Future experiments utilizing other antibodies or immunoprecipitation
protocols using protein G beads can be performed. The Western blots from controls (n = 6) and
ALS (n = 6) yield barely significant differences (p value of 0.047). It is possible that molecular
techniques are not able to distinguish the level of differences in CSF cystatin C. Although
cystatin C appears to be a marker common to many neurodegenerative diseases and not ALS
specific, further analysis of it should not be eliminated. It is likely that validation using antibody
chips may be a better approach than Western immunoblotting for cystatin C because the former
is more sensitive than immunoblotting. This argument may be strengthened by the fact that the
peak intensities of cystatin C based on which it was picked by our statistical analyses to be a
marker, was not as significantly different as for instance, transthyretin [444]. In light of this a
enzyme-linked immuno sorbent assay (ELISA) using CSF samples for the validation of cystatin
C may provide fruitful answers. It would be interesting to correlate the CSF levels of cystatin C
to that in the brain and spinal cord tissues.
Transthyretin (TTR) or prealbumin is a 55kDa homotetramer that is synthesized
predominantly in the choroid plexus and liver being secreted into the CSF and plasma,
respectively [465]. There are variant forms of TTR with both normal and variant forms of TTR
present in amyloid fibrils of diseases such as familial amyloidotic polyneuropathy that affects the
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peripheral nerves and familial amyloid cardiomyopathy. It is required for the transport of
thyroxine and by associating with retinol-binding protein also transports retinol / vitamin A in
the brain [466, 467]. One of the important functions of retinoic acid is to serve as an antioxidant.
In addition, the ventral spinal cord is a region that specifically expresses retinol-binding protein
during neural development [468]. The expression levels of retinol-binding mRNA are elevated in
the spinal cord of ALS post-mortem tissues [438, 469]. It is plausible that the levels of TTR
protein might also be increased in the ALS spinal cord tissues with a concomitant decrease in the
CSF as we observe in the mass spectrometric analysis. Hence, it would be relevant to correlate
the levels of TTR by immunohistochemistry and immunoblotting of tissue samples. Indeed the
immunoreactivity of transthyretin in ALS spinal motor neurons of human post-mortem tissues
was much lesser than those in the spinal motor neurons of age-matched control cases (Fig 48).
This finding correlates to the study wherein transthyretin was found to be neuroprotective in
transgenic mouse model of Alzheimer’s disease [444]. Thus, it is likely that low levels of
transthyretin in motor neurons could decrease its neuroprotective function. The mechanism of its
neuroprotection is unknown. It is known to form aggregates and since aggregate formation in
ALS is well documented, it is possible that transthyretin would sequester proteins critical for
normal functioning and survival of motor neurons.
In addition, the choroid plexus is a “sink” for lead and elevated levels of lead in the CNS
cause neurotoxicity. Studies have demonstrated that the levels of TTR are decreased in CSF after
lead exposure [470]. With the site of production of TTR being in close proximity to the CNS and
its association with neurological disorders, it is likely that our results demonstrate the decreased
levels of monomeric form of TTR to be a true diagnostic measure for ALS. Although we have
not examined levels of the full length TTR protein the fact that the levels of the monomer form
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of TTR in ALS patients are greatly reduced compared to normal controls suggests that there is
imbalance in the homeostasis of thyroid hormones in the CNS of these patients, most likely as a
secondary effect of motor neuron degeneration or may act as a co-factor during disease
progression. Alternatively, increased levels of heavy metals may also occur during ALS leading
to reduced levels of TTR in the CSF. In fact the levels of TTR are also decreased in CSF of
patients with neuropsychiatric disorders such as bipolar syndromes, schizophrenia and
depression [471]. Additionally, serum TTR levels are reduced during malnutrition. Thus it has
been suggested to act as a nutritional marker and a marker of the metabolic state of the body
[472]. Given that MND leads to reduced metabolism and muscle atrophy, one could hypothesize
that serum TTR levels in ALS patients should likely be decreased compared to those of the
control subjects.
Since the analyzed sample set include patients with CSF drawn at an early stage of the
disease (average of 385 days from symptom onset), we believe that proteins such as CT-7B2,
cystatin C and TTR could act as diagnostic markers for ALS and also provide information
towards molecular pathways. This is the first such study for this fatal neurodegenerative disease
and hence we consider these to be “novel biomarkers” for the disease. With two of the three
proteins being part of the neuroendocrine system (CT-7B2 and TTR), it is likely that there is a
secondary neuroendocrine effect during MND. Further analyses of the spectral patterns with a
larger sample size will provide information regarding the ALS specific nature of these proteins.
This study points towards a possible role of the neuroendocrine system during ALS. Additional
studies are required to obtain amino acid sequence information for more of the putative
biomarkers obtained through RL analysis and to characterize the expression pattern and function
of each analyte. In conclusion, we have identified CSF markers for ALS that may provide a way
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for rapid diagnosis near the time of symptom onset. The identification of at least three of the
protein peaks by a SELDI-TOF-MS technique in the CSF of ALS subjects demonstrates the
feasibility of the MS approach.
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7. Future Directions
7.1. In vitro motor neuron cultures to dissect the functional role for cell cycle
proteins,  p53 and pro-death molecules during ALS
Our study using archived human autopsy tissues from sporadic ALS cases provides
evidence for altered expression of cell cycle proteins and transcription factors during ALS.
Autopsy tissues reflect end-stage disease thereby necessitating the study of an in vitro model
system using primary spinal motor neuron cultures from wild type mouse or rat embryos. In vitro
models permit control over the extracellular environment and monitoring of selective neuronal
vulnerability in individual neurons. Using such an in vitro model, the hypothesis of aberrant and
abortive cell cycle re-entry in response to extracellular insults such as glutamate, hydrogen
peroxide or various cytokines could be tested.
Previously published reports and our preliminary results in generating spinal cord
cultures from E13 mice embryos provide evidence for the feasibility of the technique [473] (Fig
49). Briefly, a metrizamide density gradient centrifugation procedure was utilized to sort the
large cells (motor neurons) from the small cells. The large cells were cultured in complete
neurobasal medium supplemented with neurotrophic factors. To provide a more physiological
milieu and enhance survival, we used neuronal / astrocytic co-cultures.
Four-well dishes (NUNC) and coverslips in 6-well dishes were used for initial
characterization studies to identify the cell types by light and immunoflorescent microscopy.
Antibodies for b-tubulin (Fig 50, Panel A) and microtubule-associated protein (MAP-2) (Fig 50,
Panel B) labeled all the neuronal cell bodies and dendritic processes. Neurons with large cell
bodies were identified using antibodies against p75, the low affinity neurotrophic receptor (Fig
196
50, Panel C). Unfortunately efforts to sustain the cultures for further analysis failed and the
proposal to identify alterations in aberrant re-activation of cell cycle proteins in this in vitro
model was aborted. However this model is very useful to test the reactivation of the G1 to S
phase regulators and their functional significance in motor neuron death.
Figure 49 Schematic representation for murine spinal motor neuron cultures
Spinal cords from E13 murine embryos will be dissected, meninges removed and dissociated by
triturations followed by pelleting through a 4% BSA/L-15 density cushion. The cells will be
centrifuged using a 6.5% metrizamide density centrifugation. A dense band formed at the
interface of the medium / metrizamide of large cells will be collected as motor neurons and the
small cells with most of them comprised of glial cells will be plated on 4-well dishes for
immunocytochemistry with different neuronal and glial markers or toxicity survival assays.
The in vitro culture can be treated with acute/chronic doses of glutamate or peroxide (Fig
51) and assayed for altered cell cycle gene expression, protein localization and transcriptional
activity of cell cycle regulators. Glutamate binds to its cognate cell surface receptors resulting in
an increase in levels of intracellular calcium and formation of oxidative free radicals. Hydrogen
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peroxide results in injury by an increase in hydroxyl radicals (OH-.). Since ALS is a slow
progressive disease, a chronic exposure will be a better model for the disease. The role for cell
cycle regulators in response to these toxic insults can then be studied using this in vitro model.
Figure 50 Immunoflourescent staining for b-tubulin (A), MAP2 (B), p75 (C)
About 10,000 cells comprised primarily of large motor neurons but also glia were plated on
Nunc 4-well plates or coverslips pre-coated with poly-D-ornithine and laminin. Neurons were
grown in neurobasal medium supplemented with B27, 1ng/ml BDNF, 10ng/ml GDNF and CNTF
for up to 10 days in vitro (DIV) with media replenished 50% every 4 days. These were then fixed
in 2% paraformaldehyde / 0.1% glutaraldehyde for 15mins at 37oC. They were then
permeabilized in 0.25% triton X-100 / 3% H2O2, blocked in 5% milk/PBS and stained with anti-
b-tubulin (Biogenex), anti-MAP2 (DAKO) and anti-p75NTR (Chemicon). The left panel in (A) is a
bright field image of 10 DIV motor neuron stained forb-tubulin with the right panel the same
image in fluorescence. While b-tubulin and MAP2 are general neuronal markers, p75NTR is
specific for embryonic motor neurons. Extensive neuronal arborizations are also clearly
visualized. All panels are images at X200 magnification.
Functional role for cell cycle proteins in neuronal death can be tested using
pharmacological inhibitors of cdk4, & ppRb, kinase-inactive constructs of cdk4, & dominant
negative constructs of DP1, antisense constructs of E2F-1, & p53 proteins and modified oligos of
E2F1, & p53 proteins. Based on results from the cultures from wild type mice/rodents, similar
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approaches could be used to study the effects of glutamate and hydrogen peroxide in spinal
motor neuron cultures from SOD-1 and NF-L transgenics. In addition cultures from E2F-1-/- and
p53-/- could be utilized to define a role for these transcriptional regulators in motor neuron death
in response to toxins.
Figure 51 Motor neuron culture protocol to test aberrant cell cycle hypothesis
A schematic flow depicting protocol to test toxicity and survival of in vitro motor neuron cultures
when treated with glutamate (excitotoxic injury, ET) and hydrogen peroxide (oxidative injury,
OI). Effects on both acute (10min) and chronic (24hr) treatments at a range of time points can be
tested. Survival can be tested by trypan blue exclusion and MTT assays.
Although this in vitro model is well established in the field of ALS, there are some
drawbacks to the system and its use to test our hypothesis. (i) The yield of motor neurons could
pose a problem. To circumvent this problem, anti-p75 or anti-choline acetyltransferase (ChAT)
antibodies-based magnetic beads could be used to purify motor neurons and culture them on
feeder layers of glial cells. (ii) It is likely that cell cycle re-activation is a downstream effect
during ALS pathogenesis and may not relate to insults from any one toxic molecule. This would
entail testing the hypothesis by treating the cultures with a combination of these toxic insults.
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7.2. Dissect the role for re-activation of cell cycle and p53-mediated motor neuron
death in animal models of ALS (in vivo)
The SOD1 transgenic animal model developed 10 years ago has been well characterized
and used extensively for understanding ALS pathogenesis. The most commonly used model is
the high copy number mutant G93A SOD1 transgenic mouse, which exhibits extensive loss of
spinal cord motor neurons [103]. Many studies have documented that transgenics with high copy
number of G93A remain non-pathological and non-symptomatic until about 60 days (d60). The
disease typically progresses from 80 to 110 days with maximal pathological and symptomatic
stages at d90 – d105. By d120, the mice develop MND and are sacrificed. In an elegant series of
experiments, Kong and Xu characterized the low copy number G93A mouse with slower
development of MND symptoms into distinct disease stages [pre-muscle weakness (PMW), rapid
decline (RD), slow decline (SD) and paralysis or end-stage (PAR)] based on muscle strength
[161]. They document increased vacuolation and mitochondrial degeneration with concomitant
loss in muscle strength at the RD stage followed by a slower process of disease progression.
In this set of preliminary experiments, we utilized paraffin embedded spinal cord sections
from the different disease stages (PMW, RD, SD and PAR) to examin alterations in the G1 to S
phase regulators at the level of light microscopy (see section). Although the levels of ppRb was
increased in the 240 days non-transgenic (Fig 52, Top panel A) and the 60 days mutant SOD1
transgenic (Fig 52, Top panel B), all the surviving motor neurons at the RD stage (Fig 52, Top
panel D) exhibited elevated ppRb. The increase in levels of ppRb is observed right at the RD
stage when motor function is rapidly lost and prior to significant motor neuron cell loss. During
the PAR stage when there is an extensive loss of motor neurons, few of them exhibited ppRb
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immunoreactivity (Fig 52, Top panel F). There is one report using a G37R mouse model wherein
researchers have documented altered levels of CDK4, cyclin D1 and ppRb [244].
Figure 52 Spinal cord sections from G93A SOD1 transgenics and non-transgenic
littermates immunostained for ppRb (A), E2F-1 (B) and p53 (C)
For each of the three proteins, the different panels are as follows:
(A) 240d Non-transgenic, (B) 60d G93A, (C) pre-muscle weakness (PMW) G93A,
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(D) Rapid decline (RD) G93A, (E) Slow decline (SD) G93A, (F) Paralysis (PAR) G93A. The
inset in panel A for E2F-1 is immunostaining in a section of a 240d transgenic for WT SOD1.
Figure 53 Western immunoblot for ppRb (A) and E2F-1 (B) in G93A spinal cord
Nuclear lysates from d60 (pre-symptomatic), d90 (disease progression), and d120 (end-stage)
G93A spinal cord tissues were prepared as enumerated in Chapter 2. 100mg of protein was
loaded on 10% gel, blotted on PVDF membrane and probed with anti-ppRb (A), anti-E2F-1 (B)
and anti-actin (C) antibodies. We observe an increase in nuclear ppRb (A) and E2F-1 (B) at d90
and d120 compared to d60. Levels of actin (C) remain unaffected. The number of samples
examined per group was only 2. “M” indicates marker lane and “+” indicates the positive
control for ppRb.
These results corroborated immunoblots of nuclear extracts from d60 (non-symptomatic),
d90 (disease progression) and d120 (end-stage) of the high copy number G93A mice spinal cords
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(in colloboration with ALS Therapy Development Foundation, ALS-TDF, MA). There was an
increase in ppRb at d90 (n=2) and d120 (n=2) compared to d60 (n=2) (Fig 53). Immunostaining
for E2F-1 in the motor neurons fail to exhibit any differences across the different disease stages
of the low copy G93A mouse (Fig 52, Middle panels A-F). This could be a phenomenon specific
for low copy number because preliminary immunoblot analysis using the high copy G93A
mouse revealed an increase in E2F-1 levels at d90 and d120 compared to d60 (Fig 53).
It is possible that ppRb has cellular effects independent of increased E2F-1 through protein-
protein interactions. Furthermore, p53 immunostaining was not evident in the motor neurons but
there was increased immunoreactivity in the white matter of the low copy number G93A mouse
spinal cord sections. This could relate to possible DNA damage induced in the glia that would
then have a bystander effect on the neurons. Although these results are preliminary warranting
further investigations, it provides avenues to better understand the human disease by in vivo
functional analysis at different disease stages. It paves the way to use dominant negative
constructs or pharmacological inhibitors and even develop double transgenics such as G93A /
E2F-1-/- or G93A / p53-/- to further dissect cell cycle related pathways to motor neuron death.
7.3.  Determine the Functional Role for Cytoplasmic E2F-1
The findings of altered subcellular distribution of the transcription factor, E2F-1, in the
affected motor neurons (lower and upper) is consistent with the hypothesis that E2F-1 re-
localization may trigger indirect cell death signaling mechanisms. This event deviates from the
classical model of E2F-1 mediated activation of gene expression. To discern a role for aberrantly
localized E2F-1 in the ALS tissues, we hypothesized that it might associate with anti-apoptotic
proteins such as tumor necrosis receptor associated factors (TRAF). Interaction of E2F-1 with
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members of the TRAF family of adaptor proteins that mediate intracellular signaling initiates
alternative death cascades. The presence of TRAF2 or TRAF6 proteins in the cytoplasm of
motor neurons sequesters the death receptors (DR), aiding in survival of the neuron. However,
E2F-1 located in the cytoplasm may induce complex formation with TRAF proteins to impede
their function, thus releasing death receptors that could now induce cell death via the p75NTR
pathway or other death pathways [474, 475].
Our preliminary results indicate that E2F-1 co-localize with TRAF2 in 48.5% of the
spinal motor neurons. Motor neurons in the controls exhibit cytoplasmic TRAF2 and very
negligible E2F-1 (Fig 54). It would be an interesting question to address in response to toxic
insults on primary cultures or even examine E2F-1 mediated protein-protein interactions utilizing
cultures from the SOD1 transgenics. There is an ever increasing line of evidence for multiple
pathways in neuronal cell death and investigations to discern a role for E2F-1 in the cytoplasm
will further molecular research and drug design for ALS.
Figure 54 Human lumbar sections from control (n=6) and ALS (n=11) cases were
double-labeled for E2F-1 and TRAF2
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E2F-1 (FITC-conjugated secondary antibody) and TRAF2 (Cy5-conjugated secondary antibody)
are present in the same ALS motor neuron (48.7% out of 76 counted MN) as noticed in the
merged image with yellow signifying their co-localization (bottom left quadrant). Control cases
failed to show this co-localization with negligible E2F-1 but some amount of the anti-apoptotic
TRAF2 protein present (red signal).
Furthermore, it would be interesting to explore the role of transcriptional regulators such
as E2F-1, p53 and p73 on chromatin re-modeling during cell death in ALS. In fact one of the
gene products associated with FALS is ALSIN (ALS2, see section 1.3.6) that has sequence
homology to a regulator of chromatin condensation [107, 476]. Mutations in such proteins and
changes to chromatin may make DNA vulnerable to accumulate more damage through the action
of ROS. The association of CBP with a DNA repair enzyme (thymine DNA glycosylase) further
links transcription, HATs and DNA damage [477]. Although we believe that the re-activation of
cell cycle is an abortive attempt and does not proceed beyond the G1 to S phase transition, it
would be interesting to examine the role of other cyclin / CDK complexes, G1/M phase markers,
and other cell cycle regulators such as the cdc25 family of proteins that may be involved in
apoptosis.
7.4.  MS-based proteomics approach to study protein alterations during ALS in
an animal model using plasma and spinal cord tissue samples
Having established the feasibility of a mass spectrometric protein profiling approach in
identifying disease related changes (see Chapter 6), it could be extended to animal models of the
disease. SELDI-TOF-MS could be used to examine the proteome of plasma and spinal cord
tissues from G93A mutant SOD1 mice. Comparing the proteome in normal wild type (WT), non-
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symptomatic transgenics (G93A, d50-60), during disease progression (d90-105) and end-stage
(d120) will help in identifying disease-associated proteomic alterations. Spinal cord tissue
samples from these different stages can also be analyzed for region-specific protein changes.
As proof of principle in utilizing spinal cord tissue lysates, we performed experiments
using human spinal cord extracts. Analysis using SAX2 chips identified a distinct protein
difference at 50kDa (Fig 55A). This peak was elevated in ALS spinal cord tissues compared to
control cases. Further analysis of this peak by tryptic digestion of the band from a 1D-SDS
PAGE gel (Fig 55B) followed by peptide mass fingerprinting using a MS/MS system (Applied
Biosystems 4700) identified the 50kDa peak to be GFAP. This was validated by the use of
antibody protein array and SELDI-TOF MS. The surface of the chip was coated with monoclonal
anti-GFAP antibody and as a positive control we demonstrated that it could pull down
commercially available purified GFAP protein. The antibody also recognized the 50kDa peak in
the ALS spinal cord tissue extracts (Fig 55C). Astrogliosis is a pathological hallmark of ALS that
has been well documented. GFAP, a marker of activated astrocytes is increased in human and
animal ALS tissues through various techniques. This provided a proof-of concept for the use of
spinal cord tissues from animal models.
Analysis of plasma and tissue samples from the transgenic mice could provide insight in
to ALS pathogenesis. Identification of putative biomarkers through spectral analysis and amino
acid sequencing followed by validation through immunoblotting or immunohistochemistry will
provide for avenues to test the effectiveness of the markers in diagnostics and therapeutics.
These molecular approaches will help identify cell specific and sub-cellular localization of these
biomarkers providing clues to their involvement in key biochemical pathways. Proteomic
patterns in serum/plasma samples from transgenics and those from human patients from the “U
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Pitt” cohort can be compared. These studies will help in validating the animal model for ALS
and point plausible mechanistic commonalities between SALS and FALS. If common peaks are
not observed, then it is likely that it is a poor model to perform pre-clinical drug screening.
Figure 55 Identification and validation of glial fibrillary acidic protein (GFAP) in ALS
spinal cord lysates
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(A) Representative spectra comparing spinal cord tissue lysates from controls (n = 4) and
ALS (n = 4) in the range of 20-80 kDa. The orange oval illustrates the 50kDa peak that differs in
peak intensity between controls and ALS.
 A coomasie-stained 1D SDS-PAGE of spinal cord tissue lysates from a control
and ALS case each. Arrow on the right indicates the 50kDa band. The lane assignments are as
follows: lane 1 – Molecular weight marker with the mass mentioned on the left in kilodaltons,
lane 2 – purified human GFAP protein (10mg), lane 3 –control spinal cord lysate (400mg total
protein), lane 4 – ALS spinal cord lysate (400mg total protein).
(C)  Antibody-chip based SELDI-TOF-MS for validation of the 50kDa protein. 1mg of
anti-GFAP antibody coated on each of the spots except in the negative control, which was coated
with anti-TNF-a antibody. 5mg of purified GFAP protein was used as the positive control, which
reveals a 50kDa peak (arrow) and a double charged peak at about 25kDa (arrowhead).
Compared to the control lysate, the ALS tissue lysate reveals a peak at 50kDa similar to the
positive control validating that the 50kDa antigen that the antibody is recognizing is GFAP. The
negative control that had anti-TNF-a antibody did not recognize the purified GFAP protein.
7.5.  A longitudinal biomarker study in ALS patients
The human CSF biomarker discovery study can be validated with an increased number of
samples and then proceed to identify other protein biomarkers. These will be added to the current
list of identified biomarkers with continued validation of these in hypothesis-driven disease
mechanisms through biochemical and molecular techniques. Similar proteomic approaches
towards a longitudinal human study utilizing both CSF and serum samples can be performed. In
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fact this has been initiated and a cohort of samples are currently being procured at the University
of Pittsburgh under the guidance of Drs. Lacomis and Bowser. Such a study will hopefully
identify specific biomarkers as the disease progresses as the CSF / serum donors (ALS patients
and non-neurological controls) would have a follow-up visit 6 or 9 months from the initial draw
date. This longitudinal study has been undertaken in conjunction with studying the genomics and
metabolomics (in collaboration with Day Neuromuscular Center, Harvard Medical School and
Metabolon Inc., NC, respectively) providing a three-pronged cutting-edge approach to
diagnostics and therapeutics. Such biomarkers may also be valuable as surrogate markers of
disease progression that can be used in clinical trials to test drug effectiveness. This would have
a dramatic impact on our ability to find effective drug treatments for ALS.
7.6.  Proteomics for ALS: The future
One of the key aspects to identifying disease-specific biomarkers is the recruitment of
both the control and patient population. It would be beneficial to obtain a substantial number of
non-ALS neurologic control cases and identify protein changes specific to ALS patients by
comparing to this group of control cases. Obtaining high degree of specificity in a study
comparing these sets of samples is key to classifying protein alterations as obtained through a
MS-based proteomic approach as ALS-specific biomarkers. This in itself presents the caveat in
that it is difficult to obtain enough number of such non-neurologic cases that present with early
clinical symptoms. Another caveat in the field is the presence of a spectrum of motor neuron
diseases all of which present with some overlapping clinical symptoms. This necessitates the
procurement of clinical samples from patients who have been clearly stratified amongst this
spectrum of motor neuron diseases. Diagnostic biomarkers obtained from a carefully selected
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patient population can then be tested for their validity. It is possible that a number of these
markers could pose a challenge with respect to drug design because some of their functions may
be multimodal affecting different physiological arms.
From the context of clinical diagnostics, there are some drawbacks to MS-based
proteomic approach using CSF samples. (i) In a clinical diagnostic lab setting, plasma or serum
would be the sample of choice as opposed to CSF. Hence, it will be essential to correlate the
identified CSF markers to serum / plasma specific markers for ALS. As enumerated earlier in
section 7.5, a longitudinal study by procuring both CSF and serum samples from the same
patient will greatly substantiate our current findings. (ii) MS-based proteomics cannot infiltrate
all diagnostic labs, both from the matters of cost effectiveness and time of assays. MS can still be
used for the biomarker discovery and validation phases but one would have to develop molecular
techniques such as ELISA in the diagnostic labs.
In conclusion, although our work is incipient for the discovery of ALS-specific
biomarkers, it shows promise and has provided a platform for bridging the gap between the basic
and clinical science.
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8. Concluding Remarks
The work performed stretches from dissecting the molecular pathways involved in motor
neuron degeneration to biomarker discovery for clinical diagnostics in ALS. We have
successfully established a role for cell cycle proteins and our studies demonstrate that the motor
neurons in ALS undergo an abortive attempt at re-entry into cell cycle (Chapter 2). This we
consider an important factor that contributes to an apoptotic mode of cell death. This however is
dichotomous within the surviving motor neurons in the two affected regions in ALS, namely
spinal cord and motor cortex (Fig 56). Our studies did not indicate cell death in the motor cortex
evident by the absence of p53 and the death markers in the surviving neurons (Chapter 3). Even
if altered activation of cell cycle proteins and transcriptional regulators are an epiphenomenon to
a primary pathogenic process; it still provides molecular targets for therapeutic interventions.
The exact sequence of the events involved in the “abortive re-entry of motor neurons into cell
cycle” can be studied using in vitro and animal model systems (Chapter 7). In addition, this study
opens avenues to examine the role for DNA damage and chromatin remodeling in the context of
the p53 family of transcription factors.
Translating bench work to the bedside is the objective of biomedical research. We have
successfully attempted to achieve this goal by the identification and characterization of protein
abnormalities in clinical samples as putative biomarkers (Chapter 6). The Ciphergen ProteinChip
system is a powerful technique for biomarker discovery and proteomic analysis. We have
utilized SELDI-TOF-MS and multiple bioinformatic algorithms to identify putative biomarkers
for ALS. Having established this technology, the present study has extensively provided avenues
to further the use of MS-based proteomics to identify - (i) molecular markers involved in
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different biochemical pathways during onset and progression of ALS; (ii) aid in rapid diagnosis
in a clinical setting; (iii) biomarkers to monitor responses to drugs in longitudinal studies.
     
Figure 56 Motor neuron death in ALS
This study provides evidence for dichotomy in the motor neuron death (MND) pathways in spinal
cord and motor cortical regions. In a healthy motor neuron the transmembrane receptors such
as FAS (dark green bar) and tumor necrosis factor receptor (TNFR; horseshoe) with their death
domain adaptor proteins such as (FAS associated via death domain; FADD; black bar) are held
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in check by their association with anti-apoptotic proteins such as TNFR-associated factors
(TRAF; blue crescent). In the nucleus (large brown oval), the retinoblastoma (pRb) protein
(green circle) in its hypophosphorylated state associates with the E2F-1/DP1 heterodimer (red
and yellow boxes) and represses transcription (yellow arrow with a red X). Toxic extracellular
insults such as glutamate, oxidative stress and cytokines can re-activate the G1 to S phase
regulators in both spinal cord and cortical motor neurons. The re-activation leads to an active
cyclin/CDK complex (aqua pentagon/grey box) that hyperphosphorylates pRb (spiked red circle)
and de-represses the transcriptional activity of E2F-1 (green block arrow).
Lower Motor Neuron Death (L-MND) - In the spinal cord motor neuron, increase in p53
can lead to increased levels of BAX (blue strips) and caspase-3(pink “pac mans”). Alternatively,
through the interactions of FAS-ligand / FAS, activated caspase-8 (purple ellipse) can result in
increased caspase 3. FAS could be mis- localized to the nucleus (dark green bars), the function
of which is unknown. TRAFs that are released could associate with the mis-localized E2F-1 and
through protein-protein interactions cause L-MND.
Upper Motor Neuron Death (U-MND) - In the cortical motor neurons, there is a lack of p53,
BAX, FAS, caspase-8 and caspase-3 in the motor neurons. However, p53 in the astrocytes (green
star) can possibly lead to upper MND (U-MND) by yet to be determined pathways. Similar to L-
MND, TRAFs could interact with cytoplasmic E2F-1.
Thus, this body of work has successfully traversed the pathological basis of ALS
from molecular mechanisms to biomarker discovery.
213
BIBLIOGRAPHY
1. Shepherd, G.M., Neurobiology. 2nd ed. 1988, New York: Oxford University Press. xiv,
685.
2. Parent, A. and M.B. Carpenter, Carpenter's human neuroanatomy. 9th ed. 1996,
Baltimore: Williams & Wilkins. xii, 1011.
3. Shepherd, G.M., Foundations of the neuron doctrine. History of neuroscience ; no. 6.
1991, New York: Oxford University Press. ix, 338.
4. Corvino, V., et al., S100B protein and 4-hydroxynonenal in the spinal cord of wobbler
mice. Neurochem Res, 2003. 28(2): p. 341-5.
5. Hirsch, E.C., et al., The role of glial reaction and inflammation in Parkinson's disease.
Ann N Y Acad Sci, 2003. 991: p. 214-28.
6. Schofield, E., et al., Severity of gliosis in Pick's disease and frontotemporal lobar
degeneration: tau-positive glia differentiate these disorders. Brain, 2003. 126(Pt 4): p.
827-40.
7. Wilson, J.M., et al., Decrease in glial glutamate transporter variants and excitatory
amino acid receptor down-regulation in a murine model of ALS-PDC. Neuromolecular
Med, 2003. 3(2): p. 105-18.
8. Kandel, E., Principles of neural science. 3rd ed ed. 2005.
214
9. Arendt, T., Synaptic plasticity and cell cycle activation in neurons are alternative effector
pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and
yang of neuroplasticity. Prog Neurobiol, 2003. 71(2-3): p. 83-248.
10. Dickey, C.A., et al., Selectively reduced expression of synaptic plasticity-related genes in
amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci, 2003. 23(12): p.
5219-26.
11. Arendt, T., Neurodegeneration and plasticity. Int J Dev Neurosci, 2004. 22(7): p. 507-14.
12. Robbins, S.L., R.S. Cotran, and V. Kumar, Robbins' pathologic basis of disease. 4th ed.
1989, Philadelphia: Saunders. xiii, 1519.
13. Martin, J.H., Neuroanatomy : text and atlas. 2nd ed. 1996, Stamford, Conn.: Appleton &
Lange. xxiii, 578.
14. Leigh, P.N. and M. Swash, Motor neuron disease : biology and management. 1995,
London ; New York: Springer-Verlag. xviii, 468.
15. Kuncl, R.W., Motor neuron disease. 2002, London: W. B. Saunders. xiii, 198.
16. Swash, M. and J. Desai, Motor neuron disease: classification and nomenclature.
Amyotroph Lateral Scler Other Motor Neuron Disord, 2000. 1(2): p. 105-12.
17. Eisen, A. and C. Krieger, Amyotrophic lateral sclerosis : a synthesis of research and
clinical practice. 1998, Cambridge ; New York: Cambridge University Press. xx, 303.
18. Kihira, T., et al., Involvement of Onuf's nucleus in amyotrophic lateral sclerosis. J Neurol
Sci, 1997. 147(1): p. 81-8.
19. Anneser, J.M., et al., Glial proliferation and metabotropic glutamate receptor expression
in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol, 2004. 63(8): p. 831-40.
215
20. Bergmann, M., M. Volpel, and K. Kuchelmeister, Onuf's nucleus is frequently involved in
motor neuron disease/amyotrophic lateral sclerosis. J Neurol Sci, 1995. 129(2): p. 141-6.
21. Charcot, J.M. and C.G. Goetz, Charcot, the clinician : the Tuesday lessons : excerpts
from nine case presentations on general neurology delivered at the Salpãetriáere
Hospital in 1887-88 by Jean-Martin Charcot. 1987, New York: Raven Press. xxx, 193.
22. Goetz, C.G., Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot.
Muscle Nerve, 2000. 23(3): p. 336-43.
23. Critchley, E.M.R. and A. Eisen, Diseases of the spinal cord. Clinical medicine and the
nervous system. 1992, London ; New York: Springer-Verlag. xiii, 453.
24. Le Forestier, N., et al., Does primary lateral sclerosis exist? A study of 20 patients and a
review of the literature. Brain, 2001. 124(Pt 10): p. 1989-99.
25. Le Forestier, N., et al., Primary lateral sclerosis: further clarification. J Neurol Sci,
2001. 185(2): p. 95-100.
26. Verma, A. and W.G. Bradley, Atypical motor neuron disease and related motor
syndromes. Semin Neurol, 2001. 21(2): p. 177-87.
27. Brain, W.R.B., Diseases of the nervous system. 6th ed. 1962, London, New York,:
Oxford University Press. x, 879.
28. Roling, D.B., A.R. La Spada, and K.H. Fischbeck, Kennedy's disease. Neurology, 1993.
43(11): p. 2424-5.
29. Fischbeck, K.H., The expanded trinucleotide repeat in Kennedy's disease. Proc Assoc
Am Physicians, 1995. 107(2): p. 228-30.
30. Fischbeck, K.H., et al., Androgen receptor mutation in Kennedy's disease. Philos Trans R
Soc Lond B Biol Sci, 1999. 354(1386): p. 1075-8.
216
31. Borasio, G.D. and R.G. Miller, Clinical characteristics and management of ALS. Semin
Neurol, 2001. 21(2): p. 155-66.
32. Shaw, P.J. and M.J. Strong, Motor neuron disorders. Blue books of practical neurology ;
28. 2003, Amsterdam ; Boston: Butterworth-Heinemann. xvi, 569 , [10] of plates.
33. Eisen, A. and M. Weber, The motor cortex and amyotrophic lateral sclerosis. Muscle
Nerve, 2001. 24(4): p. 564-73.
34. Majoor-Krakauer, D., P.J. Willems, and A. Hofman, Genetic epidemiology of
amyotrophic lateral sclerosis. Clin Genet, 2003. 63(2): p. 83-101.
35. Armon, C., Western Pacific ALS/PDC and flying foxes: What's next? Neurology, 2003.
61(3): p. 291-2.
36. Armon, C., Environmental risk factors for amyotrophic lateral sclerosis.
Neuroepidemiology, 2001. 20(1): p. 2-6.
37. Cleveland, D.W. and J.D. Rothstein, From Charcot to Lou Gehrig: deciphering selective
motor neuron death in ALS. Nat Rev Neurosci, 2001. 2(11): p. 806-19.
38. Mayeux, R., Epidemiology of neurodegeneration. Annu Rev Neurosci, 2003. 26: p. 81-
104.
39. Norris, F., et al., Onset, natural history and outcome in idiopathic adult motor neuron
disease. J Neurol Sci, 1993. 118(1): p. 48-55.
40. Rudnicki, S.A., Estrogen replacement therapy in women with amyotrophic lateral
sclerosis. J Neurol Sci, 1999. 169(1-2): p. 126-7.
41. Nakamizo, T., et al., Protection of cultured spinal motor neurons by estradiol.
Neuroreport, 2000. 11(16): p. 3493-7.
217
42. Haley, R.W., Excess incidence of ALS in young Gulf War veterans. Neurology, 2003.
61(6): p. 750-6.
43. Horner, R.D., et al., Occurrence of amyotrophic lateral sclerosis among Gulf War
veterans. Neurology, 2003. 61(6): p. 742-9.
44. Rose, M.R., Gulf War service is an uncertain trigger for ALS. Neurology, 2003. 61(6): p.
730-1.
45. Brooks, B.R., El Escorial World Federation of Neurology criteria for the diagnosis of
amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic
Lateral Sclerosis of the World Federation of Neurology Research Group on
Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral
sclerosis" workshop contributors. J Neurol Sci, 1994. 124 Suppl: p. 96-107.
46. Brooks, B.R., et al., El Escorial revisited: revised criteria for the diagnosis of
amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord,
2000. 1(5): p. 293-9.
47. Belsh, J.M., Diagnostic challenges in ALS. Neurology, 1999. 53(8 Suppl 5): p. S26-30;
discussion S35-6.
48. Ilzecka, J. and Z. Stelmasiak, Creatine kinase activity in amyotrophic lateral sclerosis
patients. Neurol Sci, 2003. 24(4): p. 286-7.
49. Iwasaki, Y., et al., Amyotrophic lateral sclerosis and thyroid function. J Neurol, 1989.
236(6): p. 373-4.
50. van Schaik, I.N., et al., Diagnostic value of GM1 antibodies in motor neuron disorders
and neuropathies: a meta-analysis. Neurology, 1995. 45(8): p. 1570-7.
218
51. Lamb, N.L. and B.M. Patten, Clinical correlations of anti-GM1 antibodies in
amyotrophic lateral sclerosis and neuropathies. Muscle Nerve, 1991. 14(10): p. 1021-7.
52. Niebroj-Dobosz, I., P. Janik, and H. Kwiecinski, Serum IgM anti-GM1 ganglioside
antibodies in lower motor neuron syndromes. Eur J Neurol, 2004. 11(1): p. 13-6.
53. Eisen, A., Clinical electrophysiology of the upper and lower motor neuron in
amyotrophic lateral sclerosis. Semin Neurol, 2001. 21(2): p. 141-54.
54. Daube, J.R., Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor
neuron disorders. Muscle Nerve, 2000. 23(10): p. 1488-502.
55. de Carvalho, M., et al., Clinical and neurophysiological evaluation of progression in
amyotrophic lateral sclerosis. Muscle Nerve, 2003. 28(5): p. 630-3.
56. Aggarwal, A. and G. Nicholson, Detection of preclinical motor neurone loss in SOD1
mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry,
2002. 73(2): p. 199-201.
57. Pioro, E.P., et al., Detection of cortical neuron loss in motor neuron disease by proton
magnetic resonance spectroscopic imaging in vivo. Neurology, 1994. 44(10): p. 1933-8.
58. Ellis, C.M., et al., A proton magnetic resonance spectroscopic study in ALS: correlation
with clinical findings. Neurology, 1998. 51(4): p. 1104-9.
59. Sarchielli, P., et al., Magnetic resonance imaging and 1H-magnetic resonance
spectroscopy in amyotrophic lateral sclerosis. Neuroradiology, 2001. 43(3): p. 189-97.
60. Iwasaki, Y., et al., Muscle morphometry in amyotrophic lateral sclerosis. Int J Neurosci,
1991. 58(3-4): p. 165-70.
61. Krivickas, L.S., et al., Skeletal muscle fiber function and rate of disease progression in
amyotrophic lateral sclerosis. Muscle Nerve, 2002. 26(5): p. 636-43.
219
62. Ludolph, A.C. and U. Knirsch, Problems and pitfalls in the diagnosis of ALS. J Neurol
Sci, 1999. 165 Suppl 1: p. S14-20.
63. Traynor, B.J., et al., Amyotrophic lateral sclerosis mimic syndromes: a population-based
study. Arch Neurol, 2000. 57(1): p. 109-13.
64. Ince, P.G., J. Lowe, and P.J. Shaw, Amyotrophic lateral sclerosis: current issues in
classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol,
1998. 24(2): p. 104-17.
65. Brooks, B.R., Diagnostic dilemmas in amyotrophic lateral sclerosis. J Neurol Sci, 1999.
165 Suppl 1: p. S1-9.
66. Hayashi, S., et al., Pathological study of the diffuse myelin pallor in the anterolateral
columns of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci, 2001. 188(1-2):
p. 3-7.
67. Hirano, A., Neuropathology of ALS: an overview. Neurology, 1996. 47(4 Suppl 2): p.
S63-6.
68. Piao, Y.S., et al., Neuropathology with clinical correlations of sporadic amyotrophic
lateral sclerosis: 102 autopsy cases examined between 1962 and 2000. Brain Pathol,
2003. 13(1): p. 10-22.
69. Obal, I., et al., Recruitment of activated microglia cells in the spinal cord of mice by ALS
IgG. Neuroreport, 2001. 12(11): p. 2449-52.
70. Schiffer, D., et al., Reactive astrogliosis of the spinal cord in amyotrophic lateral
sclerosis. J Neurol Sci, 1996. 139 Suppl: p. 27-33.
71. Levine, J.B., et al., Astrocytes interact intimately with degenerating motor neurons in
mouse amyotrophic lateral sclerosis (ALS). Glia, 1999. 28(3): p. 215-24.
220
72. Oyanagi, K. and M. Wada, Neuropathology of parkinsonism-dementia complex and
amyotrophic lateral sclerosis of Guam: an update. J Neurol, 1999. 246 Suppl 2: p. II19-
27.
73. Kato, S., et al., Pathological characterization of astrocytic hyaline inclusions in familial
amyotrophic lateral sclerosis. Am J Pathol, 1997. 151(2): p. 611-20.
74. Wada, M., et al., Bunina bodies in amyotrophic lateral sclerosis on Guam: a
histochemical, immunohistochemical and ultrastructural investigation. Acta Neuropathol
(Berl), 1999. 98(2): p. 150-6.
75. Takahashi, T., et al., Amyotrophic lateral sclerosis with numerous axonal spheroids in
the corticospinal tract and massive degeneration of the cortex. Acta Neuropathol (Berl),
1997. 94(3): p. 294-9.
76. Toyoshima, I., et al., Kinesin and cytoplasmic dynein in spinal spheroids with motor
neuron disease. J Neurol Sci, 1998. 159(1): p. 38-44.
77. Kato, S., et al., Copper chaperone for superoxide dismutase co-aggregates with
superoxide dismutase 1 (SOD1) in neuronal Lewy body-like hyaline inclusions: an
immunohistochemical study on familial amyotrophic lateral sclerosis with SOD1 gene
mutation. Acta Neuropathol (Berl), 2001. 102(3): p. 233-8.
78. Iseki, E., Dementia with Lewy bodies: reclassification of pathological subtypes and
boundary with Parkinson's disease or Alzheimer's disease. Neuropathology, 2004. 24(1):
p. 72-8.
79. Singleton, A. and K. Gwinn-Hardy, Parkinson's disease and dementia with Lewy bodies:
a difference in dose? Lancet, 2004. 364(9440): p. 1105-7.
221
80. Hamilton, R.L. and R. Bowser, Alzheimer disease pathology in amyotrophic lateral
sclerosis. Acta Neuropathol (Berl), 2004. 107(6): p. 515-22.
81. Mackenzie, I.R. and H. Feldman, Extrapyramidal features in patients with motor neuron
disease and dementia; a clinicopathological correlative study. Acta Neuropathol (Berl),
2004. 107(4): p. 336-40.
82. Wilson, C.M., et al., Cognitive impairment in sporadic ALS: a pathologic continuum
underlying a multisystem disorder. Neurology, 2001. 57(4): p. 651-7.
83. Kasai, K., et al., Differences in evoked potential characteristics between DRPLA patients
and patients with progressive myoclonic epilepsy: preliminary findings indicating
usefulness for differential diagnosis. Epilepsy Res, 1999. 37(1): p. 3-11.
84. Zoccolella, S., et al., ALS-plus: 5 cases of concomitant amyotrophic lateral sclerosis and
parkinsonism. Neurol Sci, 2002. 23 Suppl 2: p. S123-4.
85. Oyanagi, K., et al., Amyotrophic lateral sclerosis of Guam: the nature of the
neuropathological findings. Acta Neuropathol (Berl), 1994. 88(5): p. 405-12.
86. Plato, C.C., et al., Amyotrophic lateral sclerosis and parkinsonism-dementia complex of
Guam: changing incidence rates during the past 60 years. Am J Epidemiol, 2003.
157(2): p. 149-57.
87. Itoh, N., et al., Biochemical and ultrastructural study of neurofibrillary tangles in
amyotrophic lateral sclerosis/parkinsonism-dementia complex in the Kii peninsula of
Japan. J Neuropathol Exp Neurol, 2003. 62(7): p. 791-8.
88. Ikemoto, A., A. Hirano, and I. Akiguchi, Neuropathology of amyotrophic lateral
sclerosis with extra-motor system degeneration: characteristics and differences in the
222
molecular pathology between ALS with dementia and Guamanian ALS. Amyotroph
Lateral Scler Other Motor Neuron Disord, 2000. 1(2): p. 97-104.
89. Bigio, E.H., et al., Frontotemporal and motor neurone degeneration with neurofilament
inclusion bodies: additional evidence for overlap between FTD and ALS. Neuropathol
Appl Neurobiol, 2003. 29(3): p. 239-53.
90. Rosen, D.R., et al., Mutations in Cu/Zn superoxide dismutase gene are associated with
familial amyotrophic lateral sclerosis. Nature, 1993. 362(6415): p. 59-62.
91. Hadano, S., et al., A gene encoding a putative GTPase regulator is mutated in familial
amyotrophic lateral sclerosis 2. Nat Genet, 2001. 29(2): p. 166-73.
92. Puls, I., et al., Mutant dynactin in motor neuron disease. Nat Genet, 2003. 33(4): p. 455-
6.
93. Munch, C., et al., Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS.
Neurology, 2004. 63(4): p. 724-6.
94. Chen, Y.Z., et al., DNA/RNA helicase gene mutations in a form of juvenile amyotrophic
lateral sclerosis (ALS4). Am J Hum Genet, 2004. 74(6): p. 1128-35.
95. Veldink, J.H., L.H. Van Den Berg, and J.H. Wokke, The future of motor neuron
diseaseThe challenge is in the genes. J Neurol, 2004. 251(4): p. 491-500.
96. Deng, H.X., et al., Amyotrophic lateral sclerosis and structural defects in Cu,Zn
superoxide dismutase. Science, 1993. 261(5124): p. 1047-51.
97. Bowling, A.C., et al., Superoxide dismutase concentration and activity in familial
amyotrophic lateral sclerosis. J Neurochem, 1995. 64(5): p. 2366-9.
98. Robberecht, W., et al., Cu/Zn superoxide dismutase activity in familial and sporadic
amyotrophic lateral sclerosis. J Neurochem, 1994. 62(1): p. 384-7.
223
99. Bowling, A.C., et al., Superoxide dismutase activity, oxidative damage, and
mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis.
J Neurochem, 1993. 61(6): p. 2322-5.
100. Andersen, P.M., et al., Amyotrophic lateral sclerosis associated with homozygosity for an
Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet, 1995. 10(1): p. 61-6.
101. Marklund, S.L., et al., Normal binding and reactivity of copper in mutant superoxide
dismutase isolated from amyotrophic lateral sclerosis patients. J Neurochem, 1997.
69(2): p. 675-81.
102. Reaume, A.G., et al., Motor neurons in Cu/Zn superoxide dismutase-deficient mice
develop normally but exhibit enhanced cell death after axonal injury. Nat Genet, 1996.
13(1): p. 43-7.
103. Gurney, M.E., et al., Motor neuron degeneration in mice that express a human Cu,Zn
superoxide dismutase mutation. Science, 1994. 264(5166): p. 1772-5.
104. Rosen, D.R., et al., A frequent ala 4 to val superoxide dismutase-1 mutation is associated
with a rapidly progressive familial amyotrophic lateral sclerosis. Hum Mol Genet, 1994.
3(6): p. 981-7.
105. Hentati, A., et al., Linkage of a commoner form of recessive amyotrophic lateral sclerosis
to chromosome 15q15-q22 markers. Neurogenetics, 1998. 2(1): p. 55-60.
106. Hentati, A., et al., Linkage of recessive familial amyotrophic lateral sclerosis to
chromosome 2q33-q35. Nat Genet, 1994. 7(3): p. 425-8.
107. Yang, Y., et al., The gene encoding alsin, a protein with three guanine-nucleotide
exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis.
Nat Genet, 2001. 29(2): p. 160-5.
224
108. Otomo, A., et al., ALS2, a novel guanine nucleotide exchange factor for the small
GTPase Rab5, is implicated in endosomal dynamics. Hum Mol Genet, 2003. 12(14): p.
1671-87.
109. Chance, P.F., et al., Linkage of the gene for an autosomal dominant form of juvenile
amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet, 1998. 62(3): p.
633-40.
110. Blair, I.P., et al., A gene for autosomal dominant juvenile amyotrophic lateral sclerosis
(ALS4) localizes to a 500-kb interval on chromosome 9q34. Neurogenetics, 2000. 3(1): p.
1-6.
111. Probst, A., et al., Axonopathy and amyotrophy in mice transgenic for human four-repeat
tau protein. Acta Neuropathol (Berl), 2000. 99(5): p. 469-81.
112. Hand, C.K., et al., A novel locus for familial amyotrophic lateral sclerosis, on
chromosome 18q. Am J Hum Genet, 2002. 70(1): p. 251-6.
113. Al-Chalabi, A., et al., Deletions of the heavy neurofilament subunit tail in amyotrophic
lateral sclerosis. Hum Mol Genet, 1999. 8(2): p. 157-64.
114. Tomkins, J., et al., Novel insertion in the KSP region of the neurofilament heavy gene in
amyotrophic lateral sclerosis (ALS). Neuroreport, 1998. 9(17): p. 3967-70.
115. Lambrechts, D., et al., VEGF is a modifier of amyotrophic lateral sclerosis in mice and
humans and protects motoneurons against ischemic death. Nat Genet, 2003. 34(4): p.
383-94.
116. Zheng, C., et al., Vascular endothelial growth factor prolongs survival in a transgenic
mouse model of ALS. Ann Neurol, 2004. 56(4): p. 564-7.
225
117. Guillot, S., et al., Local GDNF expression mediated by lentiviral vector protects facial
nerve motoneurons but not spinal motoneurons in SOD1(G93A) transgenic mice.
Neurobiol Dis, 2004. 16(1): p. 139-49.
118. Bruijn, L.I., T.M. Miller, and D.W. Cleveland, Unraveling the mechanisms involved in
motor neuron degeneration in ALS. Annu Rev Neurosci, 2004. 27: p. 723-49.
119. Mu, X., et al., Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis
spinal cord motor neurons. Ann Neurol, 1996. 40(3): p. 379-86.
120. Nguyen, M.D., W.E. Mushynski, and J.P. Julien, Cycling at the interface between
neurodevelopment and neurodegeneration. Cell Death Differ, 2002. 9(12): p. 1294-306.
121. Ranganathan, S., S. Scudiere, and R. Bowser, Hyperphosphorylation of the
retinoblastoma gene product and altered subcellular distribution of E2F-1 during
Alzheimer's disease and amyotrophic lateral sclerosis. J Alzheimers Dis, 2001. 3(4): p.
377-385.
122. Ranganathan, S. and R. Bowser, Alterations in G(1) to S phase cell-cycle regulators
during amyotrophic lateral sclerosis. Am J Pathol, 2003. 162(3): p. 823-35.
123. Bruijn, L.I., et al., Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant
independent from wild-type SOD1. Science, 1998. 281(5384): p. 1851-4.
124. Pasinelli, P., et al., Caspase-1 and -3 are sequentially activated in motor neuron death in
Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl
Acad Sci U S A, 2000. 97(25): p. 13901-6.
125. Przedborski, S., H. Mitsumoto, and L.P. Rowland, Recent advances in amyotrophic
lateral sclerosis research. Curr Neurol Neurosci Rep, 2003. 3(1): p. 70-7.
226
126. Pasinelli, P., et al., Caspase-1 is activated in neural cells and tissue with amyotrophic
lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl
Acad Sci U S A, 1998. 95(26): p. 15763-8.
127. Vukosavic, S., et al., Bax and Bcl-2 interaction in a transgenic mouse model of familial
amyotrophic lateral sclerosis. J Neurochem, 1999. 73(6): p. 2460-8.
128. Yoshihara, T., et al., Differential expression of inflammation- and apoptosis-related
genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic
lateral sclerosis. J Neurochem, 2002. 80(1): p. 158-67.
129. Deng, H.X., et al., Two novel SOD1 mutations in patients with familial amyotrophic
lateral sclerosis. Hum Mol Genet, 1995. 4(6): p. 1113-6.
130. Crow, J.P., et al., Decreased zinc affinity of amyotrophic lateral sclerosis-associated
superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by
peroxynitrite. J Neurochem, 1997. 69(5): p. 1936-44.
131. Boukaftane, Y., et al., Identification of six novel SOD1 gene mutations in familial
amyotrophic lateral sclerosis. Can J Neurol Sci, 1998. 25(3): p. 192-6.
132. Gong, Y.H. and J.L. Elliott, Metallothionein expression is altered in a transgenic murine
model of familial amyotrophic lateral sclerosis. Exp Neurol, 2000. 162(1): p. 27-36.
133. Nagano, S., et al., Reduction of metallothioneins promotes the disease expression of
familial amyotrophic lateral sclerosis mice in a dose-dependent manner. Eur J Neurosci,
2001. 13(7): p. 1363-70.
134. Puttaparthi, K., et al., Disease progression in a transgenic model of familial amyotrophic
lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins. J
Neurosci, 2002. 22(20): p. 8790-6.
227
135. Pehar, M., et al., Peroxynitrite-induced cytotoxicity in cultured astrocytes is associated
with morphological changes and increased nitrotyrosine immunoreactivity. Neurotox
Res, 2002. 4(2): p. 87-93.
136. Cassina, P., et al., Peroxynitrite triggers a phenotypic transformation in spinal cord
astrocytes that induces motor neuron apoptosis. J Neurosci Res, 2002. 67(1): p. 21-9.
137. Bruijn, L.I., et al., Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine
or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease
implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked
superoxide dismutase 1 mutant. Proc Natl Acad Sci U S A, 1997. 94(14): p. 7606-11.
138. Strong, M.J., et al., Nitration of the low molecular weight neurofilament is equivalent in
sporadic amyotrophic lateral sclerosis and control cervical spinal cord. Biochem
Biophys Res Commun, 1998. 248(1): p. 157-64.
139. Liu, D., et al., The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen
species and elevated oxidation of protein, DNA, and membrane phospholipids. Faseb J,
1999. 13(15): p. 2318-28.
140. Bogdanov, M., et al., Increased oxidative damage to DNA in ALS patients. Free Radic
Biol Med, 2000. 29(7): p. 652-8.
141. Subramaniam, J.R., et al., Mutant SOD1 causes motor neuron disease independent of
copper chaperone-mediated copper loading. Nat Neurosci, 2002. 5(4): p. 301-7.
142. Azzouz, M., et al., Prevention of mutant SOD1 motoneuron degeneration by copper
chelators in vitro. J Neurobiol, 2000. 42(1): p. 49-55.
143. Taylor, J.P., J. Hardy, and K.H. Fischbeck, Toxic proteins in neurodegenerative disease.
Science, 2002. 296(5575): p. 1991-5.
228
144. Wood, J.D., T.P. Beaujeux, and P.J. Shaw, Protein aggregation in motor neurone
disorders. Neuropathol Appl Neurobiol, 2003. 29(6): p. 529-45.
145. Urushitani, M., et al., Proteasomal inhibition by misfolded mutant superoxide dismutase
1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J
Neurochem, 2002. 83(5): p. 1030-42.
146. Hyun, D.H., et al., Proteasomal inhibition causes the formation of protein aggregates
containing a wide range of proteins, including nitrated proteins. J Neurochem, 2003.
86(2): p. 363-73.
147. Heath, P.R. and P.J. Shaw, Update on the glutamatergic neurotransmitter system and the
role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve, 2002. 26(4): p. 438-
58.
148. Arundine, M. and M. Tymianski, Molecular mechanisms of calcium-dependent
neurodegeneration in excitotoxicity. Cell Calcium, 2003. 34(4-5): p. 325-37.
149. Perry, T.L., et al., Amyotrophic lateral sclerosis: amino acid levels in plasma and
cerebrospinal fluid. Ann Neurol, 1990. 28(1): p. 12-7.
150. Rothstein, J.D., et al., Chronic inhibition of glutamate uptake produces a model of slow
neurotoxicity. Proc Natl Acad Sci U S A, 1993. 90(14): p. 6591-5.
151. Kawahara, Y., et al., Human spinal motoneurons express low relative abundance of
GluR2 mRNA: an implication for excitotoxicity in ALS. J Neurochem, 2003. 85(3): p.
680-9.
152. Pieri, M., et al., alpha-Amino-3-hydroxy-5-methyl-isoxazole-4-propionate receptors in
spinal cord motor neurons are altered in transgenic mice overexpressing human Cu,Zn
superoxide dismutase (Gly93-->Ala) mutation. Neuroscience, 2003. 122(1): p. 47-58.
229
153. Van Den Bosch, L., et al., Protective effect of parvalbumin on excitotoxic motor neuron
death. Exp Neurol, 2002. 174(2): p. 150-61.
154. Ince, P., et al., Parvalbumin and calbindin D-28k in the human motor system and in
motor neuron disease. Neuropathol Appl Neurobiol, 1993. 19(4): p. 291-9.
155. Lin, C.L., et al., Aberrant RNA processing in a neurodegenerative disease: the cause for
absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron, 1998.
20(3): p. 589-602.
156. Rothstein, J.D., L.J. Martin, and R.W. Kuncl, Decreased glutamate transport by the brain
and spinal cord in amyotrophic lateral sclerosis. N Engl J Med, 1992. 326(22): p. 1464-
8.
157. Rothstein, J.D., et al., Selective loss of glial glutamate transporter GLT-1 in amyotrophic
lateral sclerosis. Ann Neurol, 1995. 38(1): p. 73-84.
158. Meyer, T., et al., The EAAT2 (GLT-1) gene in motor neuron disease: absence of
mutations in amyotrophic lateral sclerosis and a point mutation in patients with
hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry, 1998. 65(4): p. 594-6.
159. Meyer, T., et al., The RNA of the glutamate transporter EAAT2 is variably spliced in
amyotrophic lateral sclerosis and normal individuals. J Neurol Sci, 1999. 170(1): p. 45-
50.
160. Munch, C., et al., Differential RNA cleavage and polyadenylation of the glutamate
transporter EAAT2 in the human brain. Brain Res Mol Brain Res, 2000. 80(2): p. 244-51.
161. Kong, J. and Z. Xu, Massive mitochondrial degeneration in motor neurons triggers the
onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci,
1998. 18(9): p. 3241-50.
230
162. Jaarsma, D., et al., Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice
causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron
death and accelerates motoneuron disease in mice expressing a familial amyotrophic
lateral sclerosis mutant SOD1. Neurobiol Dis, 2000. 7(6 Pt B): p. 623-43.
163. Higgins, C.M., C. Jung, and Z. Xu, ALS-associated mutant SOD1G93A causes
mitochondrial vacuolation by expansion of the intermembrane space and by involvement
of SOD1 aggregation and peroxisomes. BMC Neurosci, 2003. 4(1): p. 16.
164. Liu, J., et al., Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to
spinal mitochondria. Neuron, 2004. 43(1): p. 5-17.
165. Flanagan, S.W., et al., Overexpression of manganese superoxide dismutase attenuates
neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J
Neurochem, 2002. 81(1): p. 170-7.
166. Albers, D.S. and M.F. Beal, Mitochondrial dysfunction and oxidative stress in aging and
neurodegenerative disease. J Neural Transm Suppl, 2000. 59: p. 133-54.
167. Strong, M.J., I. Wakayama, and R.M. Garruto, The neuronal cytoskeleton in disorders of
late onset and slow progression. Ann N Y Acad Sci, 1993. 679: p. 388-93.
168. Gonatas, N.K., et al., Fragmentation of the Golgi apparatus of motor neurons in
amyotrophic lateral sclerosis. Am J Pathol, 1992. 140(3): p. 731-7.
169. Mourelatos, Z., et al., Fragmentation of the Golgi apparatus of motor neurons in
amyotrophic lateral sclerosis (ALS). Clinical studies in ALS of Guam and experimental
studies in deafferented neurons and in beta,beta'-iminodipropionitrile axonopathy. Am J
Pathol, 1994. 144(6): p. 1288-300.
231
170. Fujita, Y., et al., The Golgi apparatus is fragmented in spinal cord motor neurons of
amyotrophic lateral sclerosis with basophilic inclusions. Acta Neuropathol (Berl), 2002.
103(3): p. 243-7.
171. Stieber, A., J.O. Gonatas, and N.K. Gonatas, Aggregation of ubiquitin and a mutant ALS-
linked SOD1 protein correlate with disease progression and fragmentation of the Golgi
apparatus. J Neurol Sci, 2000. 173(1): p. 53-62.
172. Mourelatos, Z., et al., The Golgi apparatus of spinal cord motor neurons in transgenic
mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early,
preclinical stages of the disease. Proc Natl Acad Sci U S A, 1996. 93(11): p. 5472-7.
173. Rao, M.V. and R.A. Nixon, Defective neurofilament transport in mouse models of
amyotrophic lateral sclerosis: a review. Neurochem Res, 2003. 28(7): p. 1041-7.
174. Julien, J.P., S. Couillard-Despres, and J. Meier, Transgenic mice in the study of ALS: the
role of neurofilaments. Brain Pathol, 1998. 8(4): p. 759-69.
175. Williamson, T.L., et al., Absence of neurofilaments reduces the selective vulnerability of
motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-
linked superoxide dismutase 1 mutant. Proc Natl Acad Sci U S A, 1998. 95(16): p. 9631-
6.
176. Beaulieu, J.M. and J.P. Julien, Peripherin-mediated death of motor neurons rescued by
overexpression of neurofilament NF-H proteins. J Neurochem, 2003. 85(1): p. 248-56.
177. Kong, J. and Z. Xu, Overexpression of neurofilament subunit NF-L and NF-H extends
survival of a mouse model for amyotrophic lateral sclerosis. Neurosci Lett, 2000. 281(1):
p. 72-4.
232
178. Lee, M.K., J.R. Marszalek, and D.W. Cleveland, A mutant neurofilament subunit causes
massive, selective motor neuron death: implications for the pathogenesis of human motor
neuron disease. Neuron, 1994. 13(4): p. 975-88.
179. Williamson, T.L. and D.W. Cleveland, Slowing of axonal transport is a very early event
in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci, 1999. 2(1):
p. 50-6.
180. Bajaj, N.P., et al., Cyclin dependent kinase-5 (CDK-5) phosphorylates neurofilament
heavy (NF-H) chain to generate epitopes for antibodies that label neurofilament
accumulations in amyotrophic lateral sclerosis (ALS) and is present in affected motor
neurones in ALS. Prog Neuropsychopharmacol Biol Psychiatry, 1999. 23(5): p. 833-50.
181. Nguyen, M.D., R.C. Lariviere, and J.P. Julien, Deregulation of Cdk5 in a mouse model of
ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron, 2001. 30(1): p.
135-47.
182. Schiffer, D. and V. Fiano, Astrogliosis in ALS: possible interpretations according to
pathogenetic hypotheses. Amyotroph Lateral Scler Other Motor Neuron Disord, 2004.
5(1): p. 22-5.
183. Pramatarova, A., et al., Neuron-specific expression of mutant superoxide dismutase 1 in
transgenic mice does not lead to motor impairment. J Neurosci, 2001. 21(10): p. 3369-74.
184. Clement, A.M., et al., Wild-type nonneuronal cells extend survival of SOD1 mutant motor
neurons in ALS mice. Science, 2003. 302(5642): p. 113-7.
185. Appel, S.H., et al., Increased intracellular calcium triggered by immune mechanisms in
amyotrophic lateral sclerosis. Clin Neurosci, 1995. 3(6): p. 368-74.
233
186. Offen, D., et al., Antibodies from ALS patients inhibit dopamine release mediated by L-
type calcium channels. Neurology, 1998. 51(4): p. 1100-3.
187. Henkel, J.S., et al., Presence of dendritic cells, MCP-1, and activated
microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol,
2004. 55(2): p. 221-35.
188. Van Den Bosch, L., et al., Minocycline delays disease onset and mortality in a transgenic
model of ALS. Neuroreport, 2002. 13(8): p. 1067-70.
189. Drachman, D.B., et al., Cyclooxygenase 2 inhibition protects motor neurons and
prolongs survival in a transgenic mouse model of ALS. Ann Neurol, 2002. 52(6): p. 771-
8.
190. Hall, E.D., et al., Relationship of oxygen radical-induced lipid peroxidative damage to
disease onset and progression in a transgenic model of familial ALS. J Neurosci Res,
1998. 53(1): p. 66-77.
191. Simpson, E.P., et al., Increased lipid peroxidation in sera of ALS patients: a potential
biomarker of disease burden. Neurology, 2004. 62(10): p. 1758-65.
192. Pratico, D. and S. Sung, Lipid peroxidation and oxidative imbalance: early functional
events in Alzheimer's disease. J Alzheimers Dis, 2004. 6(2): p. 171-5.
193. Zarkovic, K., 4-hydroxynonenal and neurodegenerative diseases. Mol Aspects Med,
2003. 24(4-5): p. 293-303.
194. Rao, A.V. and B. Balachandran, Role of oxidative stress and antioxidants in
neurodegenerative diseases. Nutr Neurosci, 2002. 5(5): p. 291-309.
195. Warita, H., et al., Oxidative damage to mitochondrial DNA in spinal motoneurons of
transgenic ALS mice. Brain Res Mol Brain Res, 2001. 89(1-2): p. 147-52.
234
196. Mawrin, C., et al., Single-cell analysis of mtDNA deletion levels in sporadic amyotrophic
lateral sclerosis. Neuroreport, 2004. 15(6): p. 939-43.
197. Martin, L.J., p53 is abnormally elevated and active in the CNS of patients with
amyotrophic lateral sclerosis. Neurobiol Dis, 2000. 7(6 Pt B): p. 613-22.
198. Cho, K.J., et al., Reactive astrocytes express p53 in the spinal cord of transgenic mice
expressing a human Cu/Zn SOD mutation. Neuroreport, 1999. 10(18): p. 3939-43.
199. Kim, S.H., et al., PARP expression is increased in astrocytes but decreased in motor
neurons in the spinal cord of sporadic ALS patients. J Neuropathol Exp Neurol, 2003.
62(1): p. 88-103.
200. Koh, S.H., et al., Epigallocatechin gallate prevents oxidative-stress-induced death of
mutant Cu/Zn-superoxide dismutase (G93A) motoneuron cells by alteration of cell
survival and death signals. Toxicology, 2004. 202(3): p. 213-25.
201. Olkowski, Z.L., Mutant AP endonuclease in patients with amyotrophic lateral sclerosis.
Neuroreport, 1998. 9(2): p. 239-42.
202. Kisby, G.E., J. Milne, and C. Sweatt, Evidence of reduced DNA repair in amyotrophic
lateral sclerosis brain tissue. Neuroreport, 1997. 8(6): p. 1337-40.
203. Shaikh, A.Y. and L.J. Martin, DNA base-excision repair enzyme apurinic/apyrimidinic
endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of
individuals with amyotrophic lateral sclerosis. Neuromolecular Med, 2002. 2(1): p. 47-
60.
204. Borthwick, G.M., et al., Mitochondrial enzyme activity in amyotrophic lateral sclerosis:
implications for the role of mitochondria in neuronal cell death. Ann Neurol, 1999.
46(5): p. 787-90.
235
205. Lu, Y.Y., et al., Intramuscular injection of AAV-GDNF results in sustained expression of
transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport.
Neurosci Res, 2003. 45(1): p. 33-40.
206. Kaspar, B.K., et al., Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS
model. Science, 2003. 301(5634): p. 839-42.
207. Bilak, M.M., A.M. Corse, and R.W. Kuncl, Additivity and potentiation of IGF-I and
GDNF in the complete rescue of postnatal motor neurons. Amyotroph Lateral Scler
Other Motor Neuron Disord, 2001. 2(2): p. 83-91.
208. Sun, W., H. Funakoshi, and T. Nakamura, Overexpression of HGF retards disease
progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci,
2002. 22(15): p. 6537-48.
209. Kato, S., et al., Expression of hepatocyte growth factor and c-Met in the anterior horn
cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS):
immunohistochemical studies on sporadic ALS and familial ALS with superoxide
dismutase 1 gene mutation. Acta Neuropathol (Berl), 2003. 106(2): p. 112-20.
210. Berger, M.M., et al., Detection and cellular localization of enterovirus RNA sequences in
spinal cord of patients with ALS. Neurology, 2000. 54(1): p. 20-5.
211. Karpati, G. and M.C. Dalakas, Viral hide-and-seek in sporadic ALS: a new challenge.
Neurology, 2000. 54(1): p. 6-7.
212. Nix, W.A., et al., Failure to detect enterovirus in the spinal cord of ALS patients using a
sensitive RT-PCR method. Neurology, 2004. 62(8): p. 1372-7.
213. Walker, M.P., et al., Absence of echovirus sequences in brain and spinal cord of
amyotrophic lateral sclerosis patients. Ann Neurol, 2001. 49(2): p. 249-53.
236
214. Jubelt, B. and H.L. Lipton, ALS: persistent scientists do not find persisting enteroviruses.
Neurology, 2004. 62(8): p. 1250-1.
215. Ross, M.E., Cell division and the nervous system: regulating the cycle from neural
differentiation to death. Trends Neurosci, 1996. 19(2): p. 62-8.
216. Ohnuma, S., A. Philpott, and W.A. Harris, Cell cycle and cell fate in the nervous system.
Curr Opin Neurobiol, 2001. 11(1): p. 66-73.
217. Nurse, P., Y. Masui, and L. Hartwell, Understanding the cell cycle. Nat Med, 1998.
4(10): p. 1103-6.
218. Hartwell, L.H. and M.B. Kastan, Cell cycle control and cancer. Science, 1994.
266(5192): p. 1821-8.
219. Hatakeyama, M., et al., Collaboration of G1 cyclins in the functional inactivation of the
retinoblastoma protein. Genes Dev, 1994. 8(15): p. 1759-71.
220. Weinberg, R.A., The retinoblastoma protein and cell cycle control. Cell, 1995. 81(3): p.
323-30.
221. Hatakeyama, M. and R.A. Weinberg, The role of RB in cell cycle control. Prog Cell
Cycle Res, 1995. 1: p. 9-19.
222. Bagchi, S., R. Weinmann, and P. Raychaudhuri, The retinoblastoma protein copurifies
with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell, 1991. 65(6):
p. 1063-72.
223. Chellappan, S.P., et al., The E2F transcription factor is a cellular target for the RB
protein. Cell, 1991. 65(6): p. 1053-61.
224. Hiebert, S.W., et al., The interaction of RB with E2F coincides with an inhibition of the
transcriptional activity of E2F. Genes Dev, 1992. 6(2): p. 177-85.
237
225. Black, A.R. and J. Azizkhan-Clifford, Regulation of E2F: a family of transcription
factors involved in proliferation control. Gene, 1999. 237(2): p. 281-302.
226. Eliyahu, D., et al., Wild-type p53 can inhibit oncogene-mediated focus formation. Proc
Natl Acad Sci U S A, 1989. 86(22): p. 8763-7.
227. Finlay, C.A., P.W. Hinds, and A.J. Levine, The p53 proto-oncogene can act as a
suppressor of transformation. Cell, 1989. 57(7): p. 1083-93.
228. Yonish-Rouach, E., et al., Wild-type p53 induces apoptosis of myeloid leukaemic cells
that is inhibited by interleukin-6. Nature, 1991. 352(6333): p. 345-7.
229. Shaw, P., et al., Induction of apoptosis by wild-type p53 in a human colon tumor-derived
cell line. Proc Natl Acad Sci U S A, 1992. 89(10): p. 4495-9.
230. Donehower, L.A., et al., Mice deficient for p53 are developmentally normal but
susceptible to spontaneous tumours. Nature, 1992. 356(6366): p. 215-21.
231. Macleod, K.F., Y. Hu, and T. Jacks, Loss of Rb activates both p53-dependent and
independent cell death pathways in the developing mouse nervous system. Embo J, 1996.
15(22): p. 6178-88.
232. Phillips, A.C., et al., Induction of DNA synthesis and apoptosis are separable functions of
E2F-1. Genes Dev, 1997. 11(14): p. 1853-63.
233. Phillips, A.C. and K.H. Vousden, E2F-1 induced apoptosis. Apoptosis, 2001. 6(3): p.
173-82.
234. Copani, A., et al., Activation of cell-cycle-associated proteins in neuronal death: a
mandatory or dispensable path? Trends Neurosci, 2001. 24(1): p. 25-31.
235. Herrup, K., et al., Divide and die: cell cycle events as triggers of nerve cell death. J
Neurosci, 2004. 24(42): p. 9232-9.
238
236. Bowser, R. and M.A. Smith, Cell cycle proteins in Alzheimer's disease: plenty of wheels
but no cycle. J Alzheimers Dis, 2002. 4(3): p. 249-54.
237. Becker, E.B. and A. Bonni, Cell cycle regulation of neuronal apoptosis in development
and disease. Prog Neurobiol, 2004. 72(1): p. 1-25.
238. Morris, E.J. and H.M. Geller, Induction of neuronal apoptosis by camptothecin, an
inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell
Biol, 1996. 134(3): p. 757-70.
239. Copani, A., et al., Mitotic signaling by beta-amyloid causes neuronal death. Faseb J,
1999. 13(15): p. 2225-34.
240. Park, D.S., et al., Cyclin-dependent kinases participate in death of neurons evoked by
DNA-damaging agents. J Cell Biol, 1998. 143(2): p. 457-67.
241. Park, D.S., et al., Multiple pathways of neuronal death induced by DNA-damaging
agents, NGF deprivation, and oxidative stress. J Neurosci, 1998. 18(3): p. 830-40.
242. Jordan-Sciutto, K., J. Rhodes, and R. Bowser, Altered subcellular distribution of
transcriptional regulators in response to Abeta peptide and during Alzheimer's disease.
Mech Ageing Dev, 2001. 123(1): p. 11-20.
243. Kruman, II, et al., Cell cycle activation linked to neuronal cell death initiated by DNA
damage. Neuron, 2004. 41(4): p. 549-61.
244. Nguyen, M.D., et al., Cell cycle regulators in the neuronal death pathway of amyotrophic
lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosci, 2003. 23(6): p.
2131-40.
245. Jordan-Sciutto, K.L., et al., Response of cell cycle proteins to neurotrophic factor and
chemokine stimulation in human neuroglia. Exp Neurol, 2001. 167(2): p. 205-14.
239
246. Vincent, I., et al., Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating
neurons of Alzheimer's disease brain. J Neurosci, 1997. 17(10): p. 3588-98.
247. Arendt, T., et al., Aberrancies in signal transduction and cell cycle related events in
Alzheimer's disease. J Neural Transm Suppl, 1998. 54: p. 147-58.
248. Jordan-Sciutto, K.L., et al., Expression patterns of retinoblastoma protein in Parkinson
disease. J Neuropathol Exp Neurol, 2003. 62(1): p. 68-74.
249. Ogawa, O., et al., Increased p27, an essential component of cell cycle control, in
Alzheimer's disease. Aging Cell, 2003. 2(2): p. 105-10.
250. McShea, A., A.F. Wahl, and M.A. Smith, Re-entry into the cell cycle: a mechanism for
neurodegeneration in Alzheimer disease. Med Hypotheses, 1999. 52(6): p. 525-7.
251. Yang, Y., D.S. Geldmacher, and K. Herrup, DNA replication precedes neuronal cell
death in Alzheimer's disease. J Neurosci, 2001. 21(8): p. 2661-8.
252. Volbracht, C., et al., Apoptosis in caspase-inhibited neurons. Mol Med, 2001. 7(1): p. 36-
48.
253. Zhan, R.Z., et al., Both caspase-dependent and caspase-independent pathways may be
involved in hippocampal CA1 neuronal death because of loss of cytochrome c From
mitochondria in a rat forebrain ischemia model. J Cereb Blood Flow Metab, 2001. 21(5):
p. 529-40.
254. Roy, M. and R. Sapolsky, Neuronal apoptosis in acute necrotic insults: why is this
subject such a mess? Trends Neurosci, 1999. 22(10): p. 419-22.
255. Sperandio, S., I. de Belle, and D.E. Bredesen, An alternative, nonapoptotic form of
programmed cell death. Proc Natl Acad Sci U S A, 2000. 97(26): p. 14376-81.
240
256. Cuervo, A.M., Autophagy and aging--when "all you can eat" is yourself. Sci Aging
Knowledge Environ, 2003. 2003(36): p. pe25.
257. Selimi, F., et al., Lurcher GRID2-induced death and depolarization can be dissociated in
cerebellar Purkinje cells. Neuron, 2003. 37(5): p. 813-9.
258. Larsen, K.E., et al., Methamphetamine-induced degeneration of dopaminergic neurons
involves autophagy and upregulation of dopamine synthesis. J Neurosci, 2002. 22(20): p.
8951-60.
259. Zhu, X., G. Perry, and M.A. Smith, Amyotrophic lateral sclerosis: a novel hypothesis
involving a gained 'loss of function' in the JNK/SAPK pathway. Redox Rep, 2003. 8(3): p.
129-33.
260. Florez-McClure, M.L., et al., The p75 neurotrophin receptor can induce autophagy and
death of cerebellar Purkinje neurons. J Neurosci, 2004. 24(19): p. 4498-509.
261. Thornberry, N.A. and Y. Lazebnik, Caspases: enemies within. Science, 1998. 281(5381):
p. 1312-6.
262. Li, W.P., et al., Terminal dUTP nick end labeling (TUNEL) positive cells in the different
regions of the brain in normal aging and Alzheimer patients. J Mol Neurosci, 1997. 8(2):
p. 75-82.
263. Beilharz, E.J., et al., Mechanisms of delayed cell death following hypoxic-ischemic injury
in the immature rat: evidence for apoptosis during selective neuronal loss. Brain Res Mol
Brain Res, 1995. 29(1): p. 1-14.
264. Hara, H., et al., Inhibition of interleukin 1beta converting enzyme family proteases
reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci U S A, 1997.
94(5): p. 2007-12.
241
265. Schulz, J.B., M. Weller, and M.A. Moskowitz, Caspases as treatment targets in stroke
and neurodegenerative diseases. Ann Neurol, 1999. 45(4): p. 421-9.
266. Ekegren, T., et al., Upregulation of Bax protein and increased DNA degradation in ALS
spinal cord motor neurons. Acta Neurol Scand, 1999. 100(5): p. 317-21.
267. Estevez, A.G., et al., Induction of nitric oxide-dependent apoptosis in motor neurons by
zinc-deficient superoxide dismutase. Science, 1999. 286(5449): p. 2498-500.
268. Dragunow, M., et al., In situ evidence for DNA fragmentation in Huntington's disease
striatum and Alzheimer's disease temporal lobes. Neuroreport, 1995. 6(7): p. 1053-7.
269. Hirsch, E.C., et al., Dopaminergic neurons degenerate by apoptosis in Parkinson's
disease. Mov Disord, 1999. 14(2): p. 383-5.
270. Tatton, N.A., Increased caspase 3 and Bax immunoreactivity accompany nuclear
GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol, 2000.
166(1): p. 29-43.
271. Tatton, W.G., et al., Apoptosis in Parkinson's disease: signals for neuronal degradation.
Ann Neurol, 2003. 53 Suppl 3: p. S61-70; discussion S70-2.
272. Thomas, L.B., et al., DNA end labeling (TUNEL) in Huntington's disease and other
neuropathological conditions. Exp Neurol, 1995. 133(2): p. 265-72.
273. Martin, L.J., et al., Injury-induced apoptosis of neurons in adult brain is mediated by
p53-dependent and p53-independent pathways and requires Bax. J Comp Neurol, 2001.
433(3): p. 299-311.
274. Martin, L.J., et al., Early events of target deprivation/axotomy-induced neuronal
apoptosis in vivo: oxidative stress, DNA damage, p53 phosphorylation and subcellular
redistribution of death proteins. J Neurochem, 2003. 85(1): p. 234-47.
242
275. Friedlander, R.M., Apoptosis and caspases in neurodegenerative diseases. N Engl J Med,
2003. 348(14): p. 1365-75.
276. Ashkenazi, A. and V.M. Dixit, Death receptors: signaling and modulation. Science,
1998. 281(5381): p. 1305-8.
277. Hakem, R., et al., Differential requirement for caspase 9 in apoptotic pathways in vivo.
Cell, 1998. 94(3): p. 339-52.
278. Li, P., et al., Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex
initiates an apoptotic protease cascade. Cell, 1997. 91(4): p. 479-89.
279. Liu, X., et al., DFF, a heterodimeric protein that functions downstream of caspase-3 to
trigger DNA fragmentation during apoptosis. Cell, 1997. 89(2): p. 175-84.
280. Liu, X., et al., The 40-kDa subunit of DNA fragmentation factor induces DNA
fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci U S A,
1998. 95(15): p. 8461-6.
281. Enari, M., et al., A caspase-activated DNase that degrades DNA during apoptosis, and its
inhibitor ICAD. Nature, 1998. 391(6662): p. 43-50.
282. Matsushita, K., et al., Fas receptor and neuronal cell death after spinal cord ischemia. J
Neurosci, 2000. 20(18): p. 6879-87.
283. Sakurai, M., et al., Delayed selective motor neuron death and fas antigen induction after
spinal cord ischemia in rabbits. Brain Res, 1998. 797(1): p. 23-8.
284. Sharma, K., et al., Death the Fas way: regulation and pathophysiology of CD95 and its
ligand. Pharmacol Ther, 2000. 88(3): p. 333-47.
285. Yu, S.W., et al., Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by
apoptosis-inducing factor. Science, 2002. 297(5579): p. 259-63.
243
286. Stringer, J.R., et al., Increased mutation in mice genetically predisposed to oxidative
damage in the brain. Mutat Res, 2004. 556(1-2): p. 127-34.
287. Klein, J.A., et al., The harlequin mouse mutation downregulates apoptosis-inducing
factor. Nature, 2002. 419(6905): p. 367-74.
288. Martin, L.J., Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible
contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol, 1999.
58(5): p. 459-71.
289. Pasinelli, P., et al., Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind
and aggregate with Bcl-2 in spinal cord mitochondria. Neuron, 2004. 43(1): p. 19-30.
290. Li, M., et al., Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse
model. Science, 2000. 288(5464): p. 335-9.
291. Kostic, V., et al., Bcl-2: prolonging life in a transgenic mouse model of familial
amyotrophic lateral sclerosis. Science, 1997. 277(5325): p. 559-62.
292. Bendotti, C., et al., Early vacuolization and mitochondrial damage in motor neurons of
FALS mice are not associated with apoptosis or with changes in cytochrome oxidase
histochemical reactivity. J Neurol Sci, 2001. 191(1-2): p. 25-33.
293. Kalra, S., D.L. Arnold, and N.R. Cashman, Biological markers in the diagnosis and
treatment of ALS. J Neurol Sci, 1999. 165 Suppl 1: p. S27-32.
294. Turner, M.R., M.J. Parton, and P.N. Leigh, Clinical trials in ALS: an overview. Semin
Neurol, 2001. 21(2): p. 167-75.
295. Festoff, B.W., Z. Suo, and B.A. Citron, Prospects for the pharmacotherapy of
amyotrophic lateral sclerosis : old strategies and new paradigms for the third
millennium. CNS Drugs, 2003. 17(10): p. 699-717.
244
296. Du, Y., et al., Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the
MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A, 2001. 98(25): p. 14669-
74.
297. Lin, S., et al., Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free
radical production in rat cerebellar granule neurons. Life Sci, 2003. 72(14): p. 1635-41.
298. Tikka, T.M. and J.E. Koistinaho, Minocycline provides neuroprotection against N-
methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol, 2001. 166(12): p.
7527-33.
299. Kelly, K.J., et al., Minocycline inhibits apoptosis and inflammation in a rat model of
ischemic renal injury. Am J Physiol Renal Physiol, 2004. 287(4): p. F760-6.
300. Scarabelli, T.M., et al., Minocycline inhibits caspase activation and reactivation,
increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of
cytochrome C and smac/DIABLO. J Am Coll Cardiol, 2004. 43(5): p. 865-74.
301. Zhu, S., et al., Minocycline inhibits cytochrome c release and delays progression of
amyotrophic lateral sclerosis in mice. Nature, 2002. 417(6884): p. 74-8.
302. Zhang, W., M. Narayanan, and R.M. Friedlander, Additive neuroprotective effects of
minocycline with creatine in a mouse model of ALS. Ann Neurol, 2003. 53(2): p. 267-70.
303. Kriz, J., G. Gowing, and J.P. Julien, Efficient three-drug cocktail for disease induced by
mutant superoxide dismutase. Ann Neurol, 2003. 53(4): p. 429-36.
304. Friedlander, R.M., et al., Inhibition of ICE slows ALS in mice. Nature, 1997. 388(6637):
p. 31.
245
305. Vukosavic, S., et al., Delaying caspase activation by Bcl-2: A clue to disease retardation
in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci, 2000. 20(24):
p. 9119-25.
306. Cascante, M., et al., Metabolic control analysis in drug discovery and disease. Nat
Biotechnol, 2002. 20(3): p. 243-9.
307. Frank, R. and R. Hargreaves, Clinical biomarkers in drug discovery and development.
Nat Rev Drug Discov, 2003. 2(7): p. 566-80.
308. Hanash, S., Disease proteomics. Nature, 2003. 422(6928): p. 226-32.
309. Petricoin, E., et al., Clinical proteomics: revolutionizing disease detection and patient
tailoring therapy. J Proteome Res, 2004. 3(2): p. 209-17.
310. Fung, E.T., G.L. Wright, Jr., and E.A. Dalmasso, Proteomic strategies for biomarker
identification: progress and challenges. Curr Opin Mol Ther, 2000. 2(6): p. 643-50.
311. Chambers, G., et al., Proteomics: a new approach to the study of disease. J Pathol, 2000.
192(3): p. 280-8.
312. Freeman, W.M. and S.E. Hemby, Proteomics for protein expression profiling in
neuroscience. Neurochem Res, 2004. 29(6): p. 1065-81.
313. Butterfield, D.A., D. Boyd-Kimball, and A. Castegna, Proteomics in Alzheimer's disease:
insights into potential mechanisms of neurodegeneration. J Neurochem, 2003. 86(6): p.
1313-27.
314. Davidsson, P., et al., Clinical mass spectrometry in neuroscience. Proteomics and
peptidomics. Cell Mol Biol (Noisy-le-grand), 2003. 49(5): p. 681-8.
315. Morrison, R.S., et al., Proteomic analysis in the neurosciences. Mol Cell Proteomics,
2002. 1(8): p. 553-60.
246
316. Luo, X., et al., Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive
impairment. Neurology, 2003. 60(12): p. 1931-7.
317. Lescuyer, P., et al., Identification of post-mortem cerebrospinal fluid proteins as potential
biomarkers of ischemia and neurodegeneration. Proteomics, 2004. 4(8): p. 2234-41.
318. Jiang, L., et al., Proteomic analysis of the cerebrospinal fluid of patients with
schizophrenia. Amino Acids, 2003. 25(1): p. 49-57.
319. Castegna, A., et al., Proteomic identification of oxidatively modified proteins in
Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin
carboxy-terminal hydrolase L-1. Free Radic Biol Med, 2002. 33(4): p. 562-71.
320. Castegna, A., et al., Proteomic identification of nitrated proteins in Alzheimer's disease
brain. J Neurochem, 2003. 85(6): p. 1394-401.
321. Choe, L.H., et al., Studies of potential cerebrospinal fluid molecular markers for
Alzheimer's disease. Electrophoresis, 2002. 23(14): p. 2247-51.
322. Lubec, G., et al., Expression of the dihydropyrimidinase related protein 2 (DRP-2) in
Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and
dysregulated at the protein level. J Neural Transm Suppl, 1999. 57: p. 161-77.
323. Zabel, C., et al., Alterations in the mouse and human proteome caused by Huntington's
disease. Mol Cell Proteomics, 2002. 1(5): p. 366-75.
324. Zabel, C. and J. Klose, Influence of Huntington's Disease on the Human and Mouse
Proteome. Int Rev Neurobiol, 2004. 61: p. 241-83.
325. Bajo, M., et al., Proteomic evaluation of intermediary metabolism enzyme proteins in
fetal Down's syndrome cerebral cortex. Proteomics, 2002. 2(11): p. 1539-46.
247
326. Kim, S.H., et al., Human brain nucleoside diphosphate kinase activity is decreased in
Alzheimer's disease and Down syndrome. Biochem Biophys Res Commun, 2002. 296(4):
p. 970-5.
327. Karas, M. and F. Hillenkamp, Laser desorption ionization of proteins with molecular
masses exceeding 10,000 daltons. Anal Chem, 1988. 60(20): p. 2299-301.
328. Hillenkamp, F. and M. Karas, Mass spectrometry of peptides and proteins by matrix-
assisted ultraviolet laser desorption/ionization. Methods Enzymol, 1990. 193: p. 280-95.
329. Hillenkamp, F., et al., Matrix-assisted laser desorption/ionization mass spectrometry of
biopolymers. Anal Chem, 1991. 63(24): p. 1193A-1203A.
330. Issaq, H.J., et al., The SELDI-TOF MS approach to proteomics: protein profiling and
biomarker identification. Biochem Biophys Res Commun, 2002. 292(3): p. 587-92.
331. Boguski, M.S. and M.W. McIntosh, Biomedical informatics for proteomics. Nature,
2003. 422(6928): p. 233-7.
332. Breiman, L., Classification and regression trees. The Wadsworth statistics/probability
series. 1993, Belmont, Calif.: Wadsworth International Group. 358.
333. Feigenbaum, E.A.a.B., B.G., Dendral and meta-dendral roots: Knowledge systems and
expert system applications. Artificial Intelligence, 1993. 59: p. 233-240.
334. Provost, F.a.F., T., Robust classification for imprecise environments. Machine Learning,
2001. 42: p. 203-231.
335. Petricoin, E.F., et al., Use of proteomic patterns in serum to identify ovarian cancer.
Lancet, 2002. 359(9306): p. 572-7.
336. Sorace, J.M. and M. Zhan, A data review and re-assessment of ovarian cancer serum
proteomic profiling. BMC Bioinformatics, 2003. 4(1): p. 24.
248
337. Butterfield, D.A., Proteomics: a new approach to investigate oxidative stress in
Alzheimer's disease brain. Brain Res, 2004. 1000(1-2): p. 1-7.
338. Zheng, P.P., et al., Identification of tumor-related proteins by proteomic analysis of
cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol,
2003. 62(8): p. 855-62.
339. Rogers, M.A., et al., Proteomic profiling of urinary proteins in renal cancer by surface
enhanced laser desorption ionization and neural-network analysis: identification of key
issues affecting potential clinical utility. Cancer Res, 2003. 63(20): p. 6971-83.
340. McGregor, E. and M.J. Dunn, Proteomics of heart disease. Hum Mol Genet, 2003. 12
Spec No 2: p. R135-44.
341. Campa, M.J., et al., Protein expression profiling identifies macrophage migration
inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung
cancer. Cancer Res, 2003. 63(7): p. 1652-6.
342. Toda, M. and S.J. Ono, Genomics and proteomics of allergic disease. Immunology, 2002.
106(1): p. 1-10.
343. Li, J., et al., Proteomics and bioinformatics approaches for identification of serum
biomarkers to detect breast cancer. Clin Chem, 2002. 48(8): p. 1296-304.
344. Ornstein, D.K., et al., Serum proteomic profiling can discriminate prostate cancer from
benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0
ng/ml. J Urol, 2004. 172(4 Pt 1): p. 1302-5.
345. Dwek, M.V. and A.A. Alaiya, Proteome analysis enables separate clustering of normal
breast, benign breast and breast cancer tissues. Br J Cancer, 2003. 89(2): p. 305-7.
249
346. Zhang, L., et al., Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1
activity of CD8 antiviral factor. Science, 2002. 298(5595): p. 995-1000.
347. Dyson, N., The regulation of E2F by pRB-family proteins. Genes Dev, 1998. 12(15): p.
2245-62.
348. Heintz, N., Cell death and the cell cycle: a relationship between transformation and
neurodegeneration? Trends Biochem Sci, 1993. 18(5): p. 157-9.
349. Dyson, N., pRB, p107 and the regulation of the E2F transcription factor. J Cell Sci
Suppl, 1994. 18: p. 81-7.
350. Giovanni, A., et al., E2F1 mediates death of B-amyloid-treated cortical neurons in a
manner independent of p53 and dependent on Bax and caspase 3. J Biol Chem, 2000.
275(16): p. 11553-60.
351. Nagy, Z., M.M. Esiri, and A.D. Smith, The cell division cycle and the pathophysiology of
Alzheimer's disease. Neuroscience, 1998. 87(4): p. 731-9.
352. Park, D.S., et al., Involvement of retinoblastoma family members and E2F/DP complexes
in the death of neurons evoked by DNA damage. J Neurosci, 2000. 20(9): p. 3104-14.
353. Jacks, T., et al., Effects of an Rb mutation in the mouse. Nature, 1992. 359(6393): p. 295-
300.
354. Tsai, K.Y., et al., Mutation of E2f-1 suppresses apoptosis and inappropriate S phase
entry and extends survival of Rb-deficient mouse embryos. Mol Cell, 1998. 2(3): p. 293-
304.
355. Jordan-Sciutto, K.L., L.M. Malaiyandi, and R. Bowser, Altered distribution of cell cycle
transcriptional regulators during Alzheimer disease. J Neuropathol Exp Neurol, 2002.
61(4): p. 358-67.
250
356. Padmanabhan, J., et al., Role of cell cycle regulatory proteins in cerebellar granule
neuron apoptosis. J Neurosci, 1999. 19(20): p. 8747-56.
357. Park, D.S., et al., Cell cycle regulators in neuronal death evoked by excitotoxic stress:
implications for neurodegeneration and its treatment. Neurobiol Aging, 2000. 21(6): p.
771-81.
358. Lee, S.S., et al., Cell cycle aberrations by alpha-synuclein over-expression and cyclin B
immunoreactivity in Lewy bodies. Neurobiol Aging, 2003. 24(5): p. 687-96.
359. Park, D.S., S.E. Farinelli, and L.A. Greene, Inhibitors of cyclin-dependent kinases
promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic
neurons. J Biol Chem, 1996. 271(14): p. 8161-9.
360. Park, D.S., et al., Cyclin dependent kinase inhibitors and dominant negative cyclin
dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J
Neurosci, 1997. 17(23): p. 8975-83.
361. Park, D.S., et al., G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases
suppress camptothecin-induced neuronal apoptosis. J Neurosci, 1997. 17(4): p. 1256-70.
362. Jordan-Sciutto, K.L., et al., Induction of cell-cycle regulators in simian immunodeficiency
virus encephalitis. Am J Pathol, 2000. 157(2): p. 497-507.
363. Miller, F.D., C.D. Pozniak, and G.S. Walsh, Neuronal life and death: an essential role
for the p53 family. Cell Death Differ, 2000. 7(10): p. 880-8.
364. Boutillier, A.L., E. Trinh, and J.P. Loeffler, Selective E2F-dependent gene transcription
is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem,
2003. 84(4): p. 814-28.
251
365. Verona, R., et al., E2F activity is regulated by cell cycle-dependent changes in
subcellular localization. Mol Cell Biol, 1997. 17(12): p. 7268-82.
366. Trinh, E., A.L. Boutillier, and J.P. Loeffler, Regulation of the retinoblastoma-dependent
Mdm2 and E2F-1 signaling pathways during neuronal apoptosis. Mol Cell Neurosci,
2001. 17(2): p. 342-53.
367. Irwin, M., et al., Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature,
2000. 407(6804): p. 645-8.
368. Bates, S., et al., p14ARF links the tumour suppressors RB and p53. Nature, 1998.
395(6698): p. 124-5.
369. Furukawa, Y., et al., Apaf-1 is a mediator of E2F-1-induced apoptosis. J Biol Chem,
2002. 277(42): p. 39760-8.
370. Luciakova, K., et al., Activity of the human cytochrome c1 promoter is modulated by
E2F. Biochem J, 2000. 351(Pt 1): p. 251-6.
371. Miyashita, T. and J.C. Reed, Tumor suppressor p53 is a direct transcriptional activator
of the human bax gene. Cell, 1995. 80(2): p. 293-9.
372. Nahle, Z., et al., Direct coupling of the cell cycle and cell death machinery by E2F. Nat
Cell Biol, 2002. 4(11): p. 859-64.
373. Klein, J.A. and S.L. Ackerman, Oxidative stress, cell cycle, and neurodegeneration. J
Clin Invest, 2003. 111(6): p. 785-93.
374. Smith, M.A., et al., Metabolic, metallic, and mitotic sources of oxidative stress in
Alzheimer disease. Antioxid Redox Signal, 2000. 2(3): p. 413-20.
375. O'Connor, D.J., et al., Physical and functional interactions between p53 and cell cycle
co-operating transcription factors, E2F1 and DP1. Embo J, 1995. 14(24): p. 6184-92.
252
376. Seelan, R.S., et al., The human p73 promoter: characterization and identification of
functional E2F binding sites. Neoplasia, 2002. 4(3): p. 195-203.
377. Ramalho, R.M., et al., Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic
acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem, 2004. 90(3):
p. 567-75.
378. Harvey, M., et al., Genetic background alters the spectrum of tumors that develop in p53-
deficient mice. Faseb J, 1993. 7(10): p. 938-43.
379. Clarke, A.R., et al., Thymocyte apoptosis induced by p53-dependent and independent
pathways. Nature, 1993. 362(6423): p. 849-52.
380. Blum, D., et al., p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in
PC12 cells. Brain Res, 1997. 751(1): p. 139-42.
381. Chan, S.L., et al., Presenilin-1 mutations sensitize neurons to DNA damage-induced
death by a mechanism involving perturbed calcium homeostasis and activation of
calpains and caspase-12. Neurobiol Dis, 2002. 11(1): p. 2-19.
382. Daily, D., et al., The involvement of p53 in dopamine-induced apoptosis of cerebellar
granule neurons and leukemic cells overexpressing p53. Cell Mol Neurobiol, 1999.
19(2): p. 261-76.
383. Tieu, K., et al., Inhibition of 6-hydroxydopamine-induced p53 expression and survival of
neuroblastoma cells following interaction with astrocytes. Neuroscience, 2001. 103(1): p.
125-32.
384. Honma, H., L. Gross, and A.J. Windebank, Hypoxia-induced apoptosis of dorsal root
ganglion neurons is associated with DNA damage recognition and cell cycle disruption
in rats. Neurosci Lett, 2004. 354(2): p. 95-8.
253
385. Enokido, Y., et al., Involvement of p53 in DNA strand break-induced apoptosis in
postmitotic CNS neurons. Eur J Neurosci, 1996. 8(9): p. 1812-21.
386. O'Hare, M.J., et al., Induction and modulation of cerebellar granule neuron death by
E2F-1. J Biol Chem, 2000. 275(33): p. 25358-64.
387. Puttonen, K.A., et al., Increased p53 levels without caspase-3 activity and change of cell
viability in 6-hydroxydopamine-treated CV1-P cells. Cell Biol Toxicol, 2003. 19(3): p.
177-87.
388. Jordan, J., et al., Role and regulation of p53 in depolarization-induced neuronal death.
Neuroscience, 2003. 122(3): p. 707-15.
389. Kitamura, Y., et al., Hydrogen peroxide-induced apoptosis mediated by p53 protein in
glial cells. Glia, 1999. 25(2): p. 154-64.
390. Pedersen, W.A., et al., The prostate apoptosis response-4 protein participates in motor
neuron degeneration in amyotrophic lateral sclerosis. Faseb J, 2000. 14(7): p. 913-24.
391. Spooren, W.P. and B. Hengerer, DNA laddering and caspase 3-like activity in the spinal
cord of a mouse model of familial amyotrophic lateral sclerosis. Cell Mol Biol (Noisy-le-
grand), 2000. 46(1): p. 63-9.
392. Shinoe, T., et al., Upregulation of the pro-apoptotic BH3-only peptide harakiri in spinal
neurons of amyotrophic lateral sclerosis patients. Neurosci Lett, 2001. 313(3): p. 153-7.
393. Yoshiyama, Y., et al., Apoptosis related antigen, Le(Y) and nick-end labeling are positive
in spinal motor neurons in amyotrophic lateral sclerosis. Acta Neuropathol (Berl), 1994.
88(3): p. 207-11.
394. de la Monte, S.M., et al., P53- and CD95-associated apoptosis in neurodegenerative
diseases. Lab Invest, 1998. 78(4): p. 401-11.
254
395. Kikuchi, H., et al., Impairment of mitochondrial DNA repair enzymes against
accumulation of 8-oxo-guanine in the spinal motor neurons of amyotrophic lateral
sclerosis. Acta Neuropathol (Berl), 2002. 103(4): p. 408-14.
396. Gonzalez de Aguilar, J.L., et al., Alteration of the Bcl-x/Bax ratio in a transgenic mouse
model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling
pathway. Neurobiol Dis, 2000. 7(4): p. 406-15.
397. Kuntz, C.t., et al., Absence of p53: no effect in a transgenic mouse model of familial
amyotrophic lateral sclerosis. Exp Neurol, 2000. 165(1): p. 184-90.
398. Prudlo, J., et al., Motor neuron cell death in a mouse model of FALS is not mediated by
the p53 cell survival regulator. Brain Res, 2000. 879(1-2): p. 183-7.
399. Fortin, A., et al., The proapoptotic gene SIVA is a direct transcriptional target for the
tumor suppressors p53 and E2F1. J Biol Chem, 2004. 279(27): p. 28706-14.
400. Nakano, K. and K.H. Vousden, PUMA, a novel proapoptotic gene, is induced by p53.
Mol Cell, 2001. 7(3): p. 683-94.
401. Fortin, A., et al., APAF1 is a key transcriptional target for p53 in the regulation of
neuronal cell death. J Cell Biol, 2001. 155(2): p. 207-16.
402. Munsch, D., et al., Human and mouse Fas (APO-1/CD95) death receptor genes each
contain a p53-responsive element that is activated by p53 mutants unable to induce
apoptosis. J Biol Chem, 2000. 275(6): p. 3867-72.
403. Guegan, C., et al., Recruitment of the mitochondrial-dependent apoptotic pathway in
amyotrophic lateral sclerosis. J Neurosci, 2001. 21(17): p. 6569-76.
404. Guegan, C., et al., Instrumental activation of bid by caspase-1 in a transgenic mouse
model of ALS. Mol Cell Neurosci, 2002. 20(4): p. 553-62.
255
405. Wootz, H., et al., Caspase-12 cleavage and increased oxidative stress during motoneuron
degeneration in transgenic mouse model of ALS. Biochem Biophys Res Commun, 2004.
322(1): p. 281-6.
406. Raoul, C., et al., Motoneuron death triggered by a specific pathway downstream of Fas.
potentiation by ALS-linked SOD1 mutations. Neuron, 2002. 35(6): p. 1067-83.
407. Evan, G.I., et al., Induction of apoptosis in fibroblasts by c-myc protein. Cell, 1992.
69(1): p. 119-28.
408. Wu, X. and A.J. Levine, p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad
Sci U S A, 1994. 91(9): p. 3602-6.
409. Ryan, K.M., A.C. Phillips, and K.H. Vousden, Regulation and function of the p53 tumor
suppressor protein. Curr Opin Cell Biol, 2001. 13(3): p. 332-7.
410. Gilman, C.P., et al., p53 is present in synapses where it mediates mitochondrial
dysfunction and synaptic degeneration in response to DNA damage, and oxidative and
excitotoxic insults. Neuromolecular Med, 2003. 3(3): p. 159-72.
411. Chung, Y.H., et al., Reactive astrocytes express PARP in the central nervous system of
SOD(G93A) transgenic mice. Brain Res, 2004. 1003(1-2): p. 199-204.
412. Stiewe, T. and B.M. Putzer, Role of the p53-homologue p73 in E2F1-induced apoptosis.
Nat Genet, 2000. 26(4): p. 464-9.
413. Wilson, C., et al., The p53 homologue p73 accumulates in the nucleus and localizes to
neurites and neurofibrillary tangles in Alzheimer disease brain. Neuropathol Appl
Neurobiol, 2004. 30(1): p. 19-29.
256
414. Kondo, M., et al., 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous
electrophile that induces neuronal apoptosis. Proc Natl Acad Sci U S A, 2002. 99(11): p.
7367-72.
415. Tilleman, K., et al., Proteomics analysis of the neurodegeneration in the brain of tau
transgenic mice. Proteomics, 2002. 2(6): p. 656-65.
416. Korolainen, M.A., et al., Proteomic analysis of protein oxidation in Alzheimer's disease
brain. Electrophoresis, 2002. 23(19): p. 3428-33.
417. Butterfield, D.A. and D. Boyd-Kimball, Proteomics analysis in Alzheimer's disease: new
insights into mechanisms of neurodegeneration. Int Rev Neurobiol, 2004. 61: p. 159-88.
418. Tsuji, T., et al., Proteomic profiling and neurodegeneration in Alzheimer's disease.
Neurochem Res, 2002. 27(10): p. 1245-53.
419. Cutler, R.G., et al., Evidence that accumulation of ceramides and cholesterol esters
mediates oxidative stress-induced death of motor neurons in amyotrophic lateral
sclerosis. Ann Neurol, 2002. 52(4): p. 448-57.
420. Kim, S.I., et al., Neuroproteomics: expression profiling of the brain's proteomes in health
and disease. Neurochem Res, 2004. 29(6): p. 1317-31.
421. Levine, J., et al., Stability of CSF metabolites measured by proton NMR. J Neural
Transm, 2000. 107(7): p. 843-8.
422. Hulmes, J.D., et al., An investigation of plasma collection, stabilization, and storage
procedures for proteomic analysis of clinical samples. Clinical Proteomics, 2004. 1(1): p.
17-32.
423. Bruijn, L.I., Amyotrophic lateral sclerosis: from disease mechanisms to therapies.
Biotechniques, 2002. 32(5): p. 1112, 1114, 1116 passim.
257
424. Strong, M. and J. Rosenfeld, Amyotrophic lateral sclerosis: a review of current concepts.
Amyotroph Lateral Scler Other Motor Neuron Disord, 2003. 4(3): p. 136-43.
425. Rosen, D.R., et al., Mutations in Cu/Zn superoxide dismutase gene are associated with
familial amyotrophic lateral sclerosis. Nature, 1993. 362(6415): p. 59-62.
426. Valentine, J.S. and P.J. Hart, Misfolded CuZnSOD and amyotrophic lateral sclerosis.
Proc Natl Acad Sci U S A, 2003. 100(7): p. 3617-22.
427. Nagai, M., et al., Rats expressing human cytosolic copper-zinc superoxide dismutase
transgenes with amyotrophic lateral sclerosis: associated mutations develop motor
neuron disease. J Neurosci, 2001. 21(23): p. 9246-54.
428. Van Westerlaak, M.G., et al., Chronic mitochondrial inhibition induces glutamate-
mediated corticomotoneuron death in an organotypic culture model. Exp Neurol, 2001.
167(2): p. 393-400.
429. Menzies, F.M., et al., Mitochondrial dysfunction in a cell culture model of familial
amyotrophic lateral sclerosis. Brain, 2002. 125(Pt 7): p. 1522-33.
430. Riviere, M., et al., An analysis of extended survival in patients with amyotrophic lateral
sclerosis treated with riluzole. Arch Neurol, 1998. 55(4): p. 526-8.
431. Klivenyi, P., et al., Neuroprotective effects of creatine in a transgenic animal model of
amyotrophic lateral sclerosis. Nat Med, 1999. 5(3): p. 347-50.
432. Gurney, M.E., et al., Benefit of vitamin E, riluzole, and gabapentin in a transgenic model
of familial amyotrophic lateral sclerosis. Ann Neurol, 1996. 39(2): p. 147-57.
433. Rothstein, J.D., Of mice and men: reconciling preclinical ALS mouse studies and human
clinical trials. Ann Neurol, 2003. 53(4): p. 423-6.
258
434. Paulson, H.L., Protein fate in neurodegenerative proteinopathies: polyglutamine diseases
join the (mis)fold. Am J Hum Genet, 1999. 64(2): p. 339-45.
435. Rohlff, C., Proteomics in molecular medicine: applications in central nervous systems
disorders. Electrophoresis, 2000. 21(6): p. 1227-34.
436. Fountoulakis, M., Application of proteomics technologies in the investigation of the
brain. Mass Spectrom Rev, 2004. 23(4): p. 231-58.
437. Marcotte, E.R., L.K. Srivastava, and R. Quirion, cDNA microarray and proteomic
approaches in the study of brain diseases: focus on schizophrenia and Alzheimer's
disease. Pharmacol Ther, 2003. 100(1): p. 63-74.
438. Malaspina, A., N. Kaushik, and J. de Belleroche, Differential expression of 14 genes in
amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J
Neurochem, 2001. 77(1): p. 132-45.
439. Shibata, N., et al., Accumulation of protein-bound 4-hydroxy-2-hexenal in spinal cords
from patients with sporadic amyotrophic lateral sclerosis. Brain Res, 2004. 1019(1-2): p.
170-7.
440. Beuche, W., et al., Matrix metalloproteinase-9 is elevated in serum of patients with
amyotrophic lateral sclerosis. Neuroreport, 2000. 11(16): p. 3419-22.
441. Allen, S., et al., Analysis of the cytosolic proteome in a cell culture model of familial
amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses,
and nitric oxide synthetic pathways. J Biol Chem, 2003. 278(8): p. 6371-83.
442. Gopalakrishnan, V., et al., Proteomic data mining challenges in identification of disease
biomarkers from variable resolution mass spectra. Proceedings of SIAM Bioinformatics
Workshop, 2004: p. 1-10.
259
443. Schweigert, F.J., K. Wirth, and J. Raila, Characterization of the microheterogeneity of
transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci,
2004. 2(1): p. 5.
444. Stein, T.D., et al., Neutralization of transthyretin reverses the neuroprotective effects of
secreted amyloid precursor protein (APP) in APPSW mice resulting in tau
phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J
Neurosci, 2004. 24(35): p. 7707-17.
445. La Bella, V., J.C. Goodman, and S.H. Appel, Increased CSF glutamate following
injection of ALS immunoglobulins. Neurology, 1997. 48(5): p. 1270-2.
446. Smith, R.G., et al., Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with
sporadic amyotrophic lateral sclerosis. Ann Neurol, 1998. 44(4): p. 696-9.
447. Shaw, P.J. and R. Williams, Serum and cerebrospinal fluid biochemical markers of ALS.
Amyotroph Lateral Scler Other Motor Neuron Disord, 2000. 1 Suppl 2: p. S61-7.
448. Jacobsson, J., et al., Superoxide dismutase in CSF from amyotrophic lateral sclerosis
patients with and without CuZn-superoxide dismutase mutations. Brain, 2001. 124(Pt 7):
p. 1461-6.
449. Spreux-Varoquaux, O., et al., Glutamate levels in cerebrospinal fluid in amyotrophic
lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in
a large cohort of patients. J Neurol Sci, 2002. 193(2): p. 73-8.
450. Marcinkiewicz, M., et al., Expression of neuroendocrine secretory protein 7B2 mRNA in
the mouse and rat pituitary gland. Neuroendocrinology, 1993. 58(1): p. 86-93.
451. Marcinkiewicz, M., P. Touraine, and M. Chretien, Pan-neuronal mRNA expression of the
secretory polypeptide 7B2. Neurosci Lett, 1994. 177(1-2): p. 91-4.
260
452. Zhu, X., et al., Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2:
a potential mechanism for its inactivation. Proc Natl Acad Sci U S A, 1996. 93(10): p.
4919-24.
453. Hwang, J.R. and I. Lindberg, Inactivation of the 7B2 inhibitory CT peptide depends on a
functional furin cleavage site. J Neurochem, 2001. 79(2): p. 437-44.
454. Stark, M., et al., Peptide repertoire of human cerebrospinal fluid: novel proteolytic
fragments of neuroendocrine proteins. J Chromatogr B Biomed Sci Appl, 2001. 754(2):
p. 357-67.
455. Chaudhuri, B., et al., The neuroendocrine protein 7B2 acts as a molecular chaperone in
the in vitro folding of human insulin-like growth factor-1 secreted from yeast. Biochem
Biophys Res Commun, 1995. 211(2): p. 417-25.
456. Davidsson, P., R. Ekman, and K. Blennow, A new procedure for detecting brain-specific
proteins in cerebrospinal fluid. J Neural Transm, 1997. 104(6-7): p. 711-20.
457. Coria, F. and I. Rubio, Cerebral amyloid angiopathies. Neuropathol Appl Neurobiol,
1996. 22(3): p. 216-27.
458. Palm, D.E., et al., Cystatin C, a protease inhibitor, in degenerating rat hippocampal
neurons following transient forebrain ischemia. Brain Res, 1995. 691(1-2): p. 1-8.
459. Nishio, C., et al., Involvement of cystatin C in oxidative stress-induced apoptosis of
cultured rat CNS neurons. Brain Res, 2000. 873(2): p. 252-62.
460. Sastre, M., et al., Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro
amyloid fibril formation. Neurobiol Aging, 2004. 25(8): p. 1033-43.
461. Levy, E., et al., Codeposition of cystatin C with amyloid-beta protein in the brain of
Alzheimer disease patients. J Neuropathol Exp Neurol, 2001. 60(1): p. 94-104.
261
462. Kalso, E., Biomarkers for pain. Pain, 2004. 107(3): p. 199-201.
463. Okamoto, K., et al., Bunina bodies in amyotrophic lateral sclerosis immunostained with
rabbit anti-cystatin C serum. Neurosci Lett, 1993. 162(1-2): p. 125-8.
464. Seilhean, D., et al., Amyotrophic lateral sclerosis with neuronal intranuclear protein
inclusions. Acta Neuropathol (Berl), 2004. 108(1): p. 81-7.
465. Schreiber, G., The evolution of transthyretin synthesis in the choroid plexus. Clin Chem
Lab Med, 2002. 40(12): p. 1200-10.
466. Monaco, H.L., The transthyretin-retinol-binding protein complex. Biochim Biophys
Acta, 2000. 1482(1-2): p. 65-72.
467. Power, D.M., et al., Evolution of the thyroid hormone-binding protein, transthyretin. Gen
Comp Endocrinol, 2000. 119(3): p. 241-55.
468. Sockanathan, S. and T.M. Jessell, Motor neuron-derived retinoid signaling specifies the
subtype identity of spinal motor neurons. Cell, 1998. 94(4): p. 503-14.
469. Malaspina, A. and J. de Belleroche, Spinal cord molecular profiling provides a better
understanding of amyotrophic lateral sclerosis pathogenesis. Brain Res Brain Res Rev,
2004. 45(3): p. 213-29.
470. Zheng, W., et al., Transthyretin, thyroxine, and retinol-binding protein in human
cerebrospinal fluid: effect of lead exposure. Toxicol Sci, 2001. 61(1): p. 107-14.
471. Sousa, J.C., et al., Transthyretin is involved in depression-like behaviour and exploratory
activity. J Neurochem, 2004. 88(5): p. 1052-8.
472. Mears, E., Outcomes of continuous process improvement of a nutritional care program
incorporating TTR measurement. Clin Chem Lab Med, 2002. 40(12): p. 1355-9.
262
473. Cohen, J. and G.P. Wilkin, Neural cell culture : a practical approach. Practical approach
series ; 165. 1996, Oxford ; New York: IRL PRess at Oxford University. xx, 248.
474. Khursigara, G., J.R. Orlinick, and M.V. Chao, Association of the p75 neurotrophin
receptor with TRAF6. J Biol Chem, 1999. 274(5): p. 2597-600.
475. Ye, X., et al., TRAF family proteins interact with the common neurotrophin receptor and
modulate apoptosis induction. J Biol Chem, 1999. 274(42): p. 30202-8.
476. Kanekura, K., et al., Alsin, the product of ALS2 gene, suppresses SOD1 mutant
neurotoxicity through RhoGEF domain by interacting with SOD1 mutants. J Biol Chem,
2004. 279(18): p. 19247-56.
477. Tini, M., et al., Association of CBP/p300 acetylase and thymine DNA glycosylase links
DNA repair and transcription. Mol Cell, 2002. 9(2): p. 265-77.
